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EXPLANATION OF DISSERTATION FORMAT 
The following alternate format dissertation consists of a general introduction, 
a review of the literature, two separate manuscripts (Sections I and 11), 
summary and conclusions, literature cited, acknowledgements, and appendices. 
The Ph.D candidate Michael J. McGinley, is the principal investigator and author 
of the work presented here. All experiments were performed by the principal 
investigator with the exception of DNA sequence analysis which was performed 
by Dr. Soren Alexandersen. The references cited in each manuscript are listed 
in LITERATURE CITED at the end of each manuscript. References cited 
elsewhere in the dissertation are listed in the LITERATURE CITED at the end of 
the dissertation. 
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GENERAL INTRODUCTION 
Pseudorabies virus (PRV) is the etiological agent of pseudorabies, an 
economically important disease of swine. An important characteristic of PRV is 
that an acute disease episode is followed by the establishment of latency in 
surviving animals. This characteristic is an important problem for PRV control 
efforts which have centered on vaccination and serological monitoring. 
Vaccines have traditionally been an integral part of control programs. 
There use in the past has been to retard the spread of the virus over large areas 
and to prevent imminent outbreaks of disease within herds. Pigs that have 
received traditional vaccines had to be regarded as potential carriers of the virus 
because although the vaccines prevented disease they did not always prevent 
infection and the subsequent latent state that follows. Consequently, 
traditionally vaccinated pigs had to be considered virus infected and their 
movement in normal trade patterns restricted. 
Recent advances in vaccine technology have led to the use of various 
marker vaccines in control programs. These vaccines are deletion mutant 
vaccines that lack one or more of the envelope glycoproteins gl, gill, or the 
nonstructural glycoprotein gX. As a result, it is now possible to identify 
vaccinated pigs that have been exposed to and possibly infected with the virus. 
One requirement for the effective use of these marker vaccines and their 
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companion diagnostic antigen is tliat accurate and compiete vaccination records 
of individual pigs must be maintained. Furthermore, laboratories must maintain 
the ability to perform all companion tests that are commercially available. A 
universal diagnostic antigen would eliminate the need for extensive record 
keeping and a reliable identification system for individual pigs. Testing would 
also become simpler and less expensive for diagnostic laboratories. 
The future trend in the biologies industry will be to minimize the use of 
live virus vaccines wherever possible. Consequently, PRV live vaccines may be 
replaced with inactivated or recombinant subunit vaccines consisting of 
envelope glycoproteins. Previous work done in our laboratory demonstrates 
that PRV nucleocapsid proteins would be logical candidates as companion 
diagnostic antigens for these vaccines. 
The work described in the following dissertation describes the 
development of an enzyme-linked immunosorbant assay designed to detect 
antibodies to native PRV nucleocapsid proteins. The work also describes the 
cloning and in vitro translation of truncated nucleocapsid protein genes and 
demonstrates that the truncated polypeptides are recognized by PRV infected 
pigs. Efforts to clone the PRV major nucleocapsid protein genes are necessary 
if these proteins are to be used as diagnostic antigens because the production 
of native nucleocapsid protein by traditional methods is not cost effective for 
commercial application. 
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LITERATURE REVIEW 
Introduction 
Pseudorabies or Aujeszky's disease is an economically important disease 
of swine. The etiological agent responsible is pseudorabies virus, a herpesvirus. 
Economic losses attributed to this disease have Increased with the geographical 
spread of the virus. In 1977 total losses in the United States were estimated at 
$25.6 million (35). By 1981 estimated losses to the Iowa swine industry alone 
had reached $33.9 million (11). A recent study estimated the economic loss in 
Iowa to be between $107 to $117 million per year (29). This increasing 
economic impact has underscored the need for effective PRV control programs. 
Vaccines have traditionally been an important component of PRV control 
programs and vaccination has been used to limit the spread of the virus and 
prevent disease outbreaks. Today there is a need for vaccine preparations that 
provide protection from disease and facilitate the identification of vaccinated 
pigs that have been infected with PRV. The method of identification needs to 
be reliable and universal. Unfortunately, the use of traditional modified live and 
killed PRV vaccines do not provide a means of differentiation. Deletion mutant 
PRV vaccines have created a method for differentiation. One or more PRV 
envelope glycoproteins are deleted from the vaccine strain. Pigs vaccinated 
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with modern deletion mutant vaccines do not generate an immune response to 
a deleted glycoprotein gene product and as a result the deleted glycoprotein can 
be used as a companion diagnostic antigen to identify PRV infected pigs. 
Although these vaccines have been shown to be efficacious, recent studies 
have shown that in vivo recombination between live deletion mutant vaccines 
and virulent challenge virus does occur (32,33,38) Therefore, a potential for 
the emergence of virulent marker negative strains of PRV in the field exists. 
These concerns may lead to a future trend to minimize the use of live vaccines 
where possible. If this is the case inactivated or subunit vaccines may be 
preferred. Previous studies in this laboratory have demonstrated that an 
envelope glycoprotein based subunit vaccine is effective in limiting PRV 
mediated disease and that purified PRV nucleocapsid preparations can be used 
as reliable universal diagnostic antigens. 
The work described in this dissertation describes the development of a 
suitable diagnostic test using native nucleocapsid proteins. The work also 
describes the cloning and in vitro translation of truncated major nucleocapsid 
proteins and demonstrates that these expression products are recognized by 
PRV infected pigs. The following review will concentrate on PRV general 
characteristics, PRV genomic organization and gene expression, structural and 
non-structural protein composition, the porcine immune response to PRV 
proteins, and PRV diagnosis, vaccination, and control. 
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General Pseudorabies Virus Characteristics 
Pseudorabies virus (PRV) or Suid herpesvirus I is a member of the family 
Herpesviridea and subfamily alphaherpesvirinae (24,86). The virus is also 
referred to as Aujeszky's disease virus (109). Only one serotype of PRV is 
known (109). As a member of the alphaherpesviridae, pseudorabies virus is 
taxonomically related to herpes simplex virus types I and II, equine herpesvirus 
I, and bovine herpesvirus I (37,41,86). These viruses are classified by four 
general characteristics: 1) wide host range, 2) short replication cycle, 3) rapid 
cytopathic effect leading to cell death, and 4) ability to establish latent 
infections (1,86). This section will expand on these general characteristics. 
Pseudorabies virus svmmetrv and moroholoav 
Pseudorabies virus is a double-stranded DNA virus with an icosohedron 
capsid symmetry of 162 capsomeres and an average diameter of 180 nm as 
measured by negative staining and electron microscopy (8,86). The PRV 
nucleocapsid (capsid and genome) is surrounded by an envelope consisting of a 
double or triple layer lipid membrane rich in glycoprotein that is derived from the 
nuclear or cytoplasmic membrane of infected cells (8). The viral capsid is made 
up of three major proteins and several minor proteins (8,96). The viral envelope 
contains five to seven virus-encoded proteins and glycoproteins (8). 
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Host range 
Pseudorabies virus has a very broad host range. The pig is the only 
known PRV reservoir and appears to serve as a source of infection for other 
susceptible animals. Other domestic animals that have been clinically infected 
with PRV include cattle, sheep, goats, dogs, cats, and furbearing animals (mink 
and fox) (109). Pseudorabies virus infection has also been reported in wild 
pigs, rabbits, skunks, raccoons, foxes, leopards, otters, mice, rats, and deer 
(109). Avian species seem to be refractory to natural infection; however, 
experimental infection can be achieved with large doses injected parenterally 
(109). The susceptibility of laboratory animals to PRV varies. Rabbits and 
suckling mice are the most sensitive (23,56). Mice display an age related 
resistance to PRV, as susceptibility to infection decreases with age (21,23). 
Pseudorabies virus has a wide in vitro tissue culture range. The virus 
replicates in pig kidney and testis cells, Madin-Darby bovine kidney cells, rabbit 
cells, Vero cells, chick embryo fibroblasts, chicken kidney cells, canine kidney 
cells, feline kidney cells, and human cell lines HeLa and HEP-2 (81,95). 
Pseudorabies virus replication cvcle 
The virus replication cycle of all animal viruses can be divided into four 
basic events: 1) attachment, 2) penetration and uncoating, 3) eclipse and 4) 
release. A review of the PRV replication cycle in vitro follows. 
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The attachment of PRV to cells is primarily an electrostatic process 
(20,86). However, the presence of certain electrolytes (i.e.- Ca+^ and Mg^^) is 
required (86). It is also apparent that certain viral envelope glycoproteins 
participate in, but are not absolutely required for, attachment to target cells 
(20,86). 
Virus penetration is an energy-requiring process mediated by the viral 
envelope and its glycoproteins (86). Fusion of the viral envelope and the target 
cell membrane results in expulsion of the nucleocapsid into the cell cytoplasm. 
The nucleocapsid does not penetrate the cell nucleus although structural PRV 
proteins are associated with the nucleus following uncoating and transport of 
the PRV genome into the nucleus (20,86). 
The eclipse period of virus infection is the period of time between the 
disappearance of infecting virions and the appearance of progeny virions within 
the cell. The PRV eclipse period ranges from three to five hours, depending on 
the cell type and virus strain used (86). The PRV-directed biosynthetic events 
occurring during eclipse will be addressed separately. 
Nucleocapsids are assembled in the nucleus and are enveloped by 
budding through the nuclear membrane. Intact enveloped virions are 
transported through the cell cytoplasm in membrane vesicles which fuse with 
the cell plasma membrane and release progeny virions into the extracellular 
environment (20,86). 
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The replication cycle of PRV, defined as the time from virus attachment 
to release of a mature progeny virion, is 6 to 9 hours. The time required for cell 
death and lysis following PRV attachment is 15 to 19 hours. 
Pseudorabies virus pathogenesis 
The severity of PRV infection is determined by the virus strain and the 
age of the animal. Low virulence strains can infect all animals but clinical signs 
are only apparent in animals younger than three weeks of age. In contrast, high 
virulence strains will cause clinical disease in older animals (4). The 
transmission of virus between animals is primarily by aspiration of virus laden 
aerosols or direct contact with PRV infected animals (24,109). Prior to the 
onset of clinical signs, PRV infected animals begin to excrete virus. Infectious 
virus is present in nasal secretions for two to three weeks after natural 
exposure and has been isolated from vaginal secretions, ejaculate, milk and 
urine between two and 12 days after exposure (26). In addition, latent virus 
can be reactivated and transmitted similarly by animals surviving initial PRV 
infection. 
The primary route of PRV infection is the upper respiratory tract. 
Pseudorabies virus initially infects and replicates in epithelial cells of 
nasopharynx, tonsillar crypts, and respiratory tract (56,72,106). Virus drains 
from these primary sites via the lymphatics to the regional lymph nodes where a 
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second round of replication occurs (72). Further dissemination of PRV to 
visceral organs can occur through infected peripheral blood cells. Monocytes, T 
and B lymphocytes, and granulocytes have been shown to support virus 
replication (18,106). 
Following primary replication, PRV invades the central nervous system. 
Progeny virus infects the olfactory and glossopharyngeal nerves which service 
the area of primary replication and virions travel along nerve fibers within the 
axoplasm until reaching the trigeminal ganglia, medulla, and pons (72). Virus 
replication can occur in the medulla and pons and invasion of the cerebrum and 
cerebellum can follow (72). Cells of the central nervous system also serve as 
sites of latency for PRV. The subject of latency will be reviewed separately. 
Virulence 
The variability of PRV virulence within the pig population has been 
investigated by comparing the mortality and morbidity attributed to the virus 
isolates associated with disease outbreaks. Variants range from apathogenic 
for all pigs to highly neurotrophic and pathogenic for all pigs. An example of 
this variation among field virus isolates is the description of four virus strains 
isolated from Northern Ireland. The NIA-1 strain exhibits moderate mortality in 
young pigs and is neurotrophic, NIA-2 exhibits similar mortality but 
is exclusively pneumotropic, NIA-3 causes high mortality in young pigs and 
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moderate mortality In adult pigs, and NIA-4 is apathogenic for all pigs, cattle, 
and sheep (5). It is interesting to note that NIA-4 and another natural avirulent 
PRV strain Bartha K61 carry deletions in the unique short regions of their 
genomes (5). The relationship between genomic deletions and variable 
virulence among field strains continues to be actively studied at this time. 
Similar virulence variants of PRV have been created by tissue culture 
attenuation, chemical mutation, and genetic manipulation. Many of the 
avirulent strains created by these methods have been used in vaccine 
preparations, which will be discussed in a later section. 
Latencv of PRV 
Pseudorabies virus persists in a latent state in pigs that survive initial 
infection (12,16,28,69,88,91,100,108). The establishment of latency appears 
to be unrelated to the state of immunity in affected animals. Virus exposure 
among vaccinated animals and those with circulating maternal antibodies can 
result in the establishment of latent PRV infections (100). Consequently, 
latency must be recognized as an important feature of disease transmission. 
Latent virus can be periodically reactivated resulting in infectious virus excretion 
and spread to uninfected animals regardless of immune status of infected pigs. 
Latent PRV can be detected in cells of the trigeminal ganglion, brain, 
spinal cord, and inner ear (88,89), but the primary site of latency in swine 
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following nasal infection is the trigeminal ganglion (23). Latent virus can be 
detected by virus rescue from tissue by co-cultivation with indicator cell 
monolayers. Virus rescue from the neural tissue of latently infected pigs is 
successful 50-75% of the time (90). Reactivation seems to be dependent on 
the virus strain used for infection and the time post-infection that the isolation 
is attempted (108). The use of PRV nucleic acid probes has greatly enhanced 
detection of latency. These methods have can be used to detect latent virus 
and abortive or non-lytic infections not capable of producing infectious virus. In 
one study, virus-specific nucleic acid was found in 30% of cases where PRV 
was not rescued (88). 
The molecular basis for PRV latency is an active area of research. 
Studies have focused on the detection of PRV genomic DNA and RNA 
transcripts in latently infected tissues in hopes of elucidating the mechanisms 
that govern both the establishment and subsequent reactivation of latent 
infection. In situ hybridization studies show that latent PRV DNA is present in 
less than 1 % of peripheral and central nervous system neurons (85,88). Latent 
PRV genomes exist as linear, non-integrated molecules confined to the infected 
cell nuclei (88). A PRV DNA positive cell nuclei in a latently infected neuron 
contains approximately 30 viral genome copies (88). Increased numbers of PRV 
13 
genomes can be detected in some cases without any evidence of virus 
replication (55,88). This variability may be related to the titer of the infecting 
dose of PRV or to the presence of an abortive or non-lytic infection (55,88). 
The transcriptional activity of latent PRV genomes is important for 
establishing, maintaining, and reactivating latent infections. Viral DNA can be 
found localized in neural tissue of the host; however, gene expression is 
restricted to certain areas of the latent genome (15,45,85). Viral RNA resulting 
from this limited transcription can be detected in neural tissue. Latency 
associated transcripts (LAT's) have been mapped to the 3' end of the 
transactivating immediate-early gene (IE180), in an antlparallel orientation 
relative to the IE180 gene (14,45,78). The IE180 gene is expressed during 
productive infection while LAT expression is limited to latent infection (14,15). 
Recently, Cheung described a single large latency transcript (LLT) of 8.5 
Kb that is transcribed only during latent infection (15). The LLT transverses the 
entire IE180 coding region in an antlparallel orientation (15). Cheung's findings 
are similar to those described for herpes simplex virus where a similar LLT has 
been described (15). It is thought that the previously described smaller LAT's 
may be stable introns of the 8.5 Kb LLT (15). Since the LLT is the only 
transcript expressed during latent infection, it seems likely that the balance 
between productive and latent infection depends on interaction between 
immediate-early and LLT expression and possible cellular factors (15). 
14 
Pseudorabies Virus Genomic Organization and Gene Expression 
The genome of PRV has a coding capacity of 50-100 viral genes (8,109). 
More than 70 PRV-specific RNA species can be detected in infected cells by 
Northern blot analysis (8). The purpose of this section is to review the genomic 
structure and regulated gene expression patterns of PRV. 
PRV genomic structure 
The genome of PRV is a linear, double stranded DNA of 136 kilobase 
pairs (kbp) with an approximate molecular weight of 90x10® and a relatively 
high G + C content of 74 mole% (8). The genome is divided into two main 
regions; a unique short region (Ug) of 9.2kbp, flanked by inverted repeats of 
15.4 kbp and a unique long region (UJ of 105 kbp (8). The presence of the 
inverted repeats allows the Ug to invert itself relative to the UL resulting in two 
isomeric forms the genome (8). Each isomeric form is infectious and present in 
equimolar quantities in progeny virions (8). However, recent studies have 
shown that in at least one PRV vaccine strain (Norden strain), four 
isomeric forms of the PRV genome exist (46,47,110). Sequences normally 
present only at the extreme left end of the PRV genome are translocated, in an 
inverted form, to the junction between the U,. and the inverted repeat of the Ug 
region (46,110). The result of this translocation is the creation of a U^ region 
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capable of inverting relative to the Ug region creating four possible isomeric 
forms. 
Transcription and translation in PRV infected cells 
The PRV genome is transcribed by a cellular RNA polymerase II (8). 
Naked PRV DNA devoid of any viral protein is transcribed in transfected cells 
and there has been no viral RNA polymerase identified in herpesviruses (8). 
Pseudorabies virus transcription requires cellular components. Accordingly, the 
transcription and processing of cellular RNA into mRNA is rapidly reduced (8). 
Similarly, PRV infection results in a rapid inhibition of cellular protein synthesis. 
This inhibition requires transcription and translation of viral sequences and is 
due to viral factors that prevent the association of cellular mRNA with 
ribosomes (8). 
The PRV transcription cascade can be divided into three temporal phases: 
immediate-early, early, and late (109). Immediate-early RNA is synthesized in 
the absence of viral protein synthesis, early RNA is synthesized prior to the 
initiation of viral DNA synthesis, and late RNA is synthesized after viral DNA 
synthesis has begun (8,109). Translated proteins from each phase are required 
for progression to the next phase. As a result, the PRV proteins have been 
organized into classes corresponding to the transcription phases that produce 
their mRNA's. 
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A single transcript, 5.1 kb In size, is transcribed during immediate-early 
transcription (98,109). This transcript is synthesized up to 40 minutes post­
infection in the absence of other virus specific protein synthesis and is rapidly 
transported to the cytoplasm (8). A nonstructural regulatory IE protein (IE180) 
is encoded by this transcript (IE180). The IE 180 protein is required for 
subsequent transcription of other PRV genes (8). 
Early phase genes are transcribed prior to DNA synthesis and are 
maximally produced one to four hours post-infection (109). Approximately 30 
early RNA transcripts have been detected and studies indicate that most areas 
of the PRV genome are being transcribed during this phase (8). The exceptions 
are the IE gene region and a region in the middle of each inverted repeat (17). 
Early phase transcripts are rapidly transported into the cell cytoplasm and are 
relatively stable (8). In general, sequences encoding gene products vital to PRV 
DNA synthesis are transcribed during this phase ( i.e. - DNA polymerase, 
thymidine kinase, and the major DNA binding protein) (73,109). 
Late phase transcription begins after the onset of PRV DNA synthesis. 
The major capsid protein genes are transcribed within this subclass (17). Late 
transcription begins at 2.5 hours post-infection immediately following the onset 
of DNA synthesis and these transcripts accumulate until the end of the 
infectious cycle (8,109). Many of the structural protein genes, including the 
envelope glycoprotein genes, are transcribed during late transcription (8,109). 
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Pseudorabies Virus Proteins 
Pseudorabies virus proteins can be divided into two general categories: 
structural and nonstructural. Structural PRV proteins are those proteins that 
physically make up the mature PRV virion. These include the envelope and 
nucleocapsid components. By contrast the nonstructural proteins are those 
virus or virus induced proteins not incorporated into a mature virion. Viral 
enzymes and regulatory proteins are included in this category. 
Structural PRV alvcooroteins 
The structural glycoproteins of PRV are found localized in the viral 
envelope and the membranes of PRV infected cells. These viral glycoproteins 
are involved directly in PRV infectivity, pathogenesis, and interaction with host 
immune responses. To date, five major envelope glycoproteins have been 
identified: gl, gll, gill, gp50, and gp63. Two minor envelope glycoproteins 
designated gIV and gV have also been described. They are found in a complex 
with gl (31,109). 
Glvcoprotein al: Pseudorabies virus glycoprotein gl has an apparent 
molecular weight of 120 to 130k (31). Mature, membrane bound gl exists as a 
complex with a non-glycosylated 115k molecular weight protein, gp63 and two 
minor glycoproteins gIV and gV (31). Pulse chase experiments show that a 
18 
precursor protein pgl of between 73 and 861c molecular weight is translated and 
processed to mature gl in the Golgi apparatus of infected cells (63,65). The 
gene encoding gl is located in the Ug region of the PRV genome at map units 
0.845 to 0.891 and a gl specific 1.7 kb mRNA has been identified (63). 
Experimental evidence indicates that gl is a multi-functional glycoprotein. 
Restriction mapping and marker rescue of attenuated PRV strains have shown 
that gl is not essential for PRV replication but may be associated with virulence, 
as most attenuated vaccine strains display a 4 kb deletion in the gl coding 
region (46,49,70,79). However, gl has not been found to be absent in any the 
virulent field strains of PRV tested to date (6,7,101). Glycoprotein gl also plays 
a role in the release of progeny virus from infected cells (7,48,66). In addition, 
complement mediated in vitro virus neutralization has been described using gl 
specific monoclonal antibody (50). It must be noted that the gl functional data 
summarized above represents in vitro experimentation. The actual functions of 
gl in vivo have not been elucidated. 
Glvcoorotein all: Glycoprotein gll is the major PRV envelope 
glycoprotein. Structurally, gll exists as a disulfide bonded complex of three 
glycoproteins designated glla, glib, and gllc with molecular weights of 120-
125k, 74-67k, and 58k respectively (31,40,50). Under non-reducing conditions 
glla and gllc remain linked in a complex with an apparent molecular weight of 
155k (31,50). One gll precursor, pgll, with a molecular weight of 110k has 
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been identified (64). This precursor has been shown to be glycosylated and 
cleaved into glib and gllc (50,64,82). A precursor for glla has not been 
identified. The gene encoding gll has been mapped to the left end of the 
genomic region between map units 0.105 and 0.130 (64). A S.Okb mRNA 
for gll is detectable at 8 hours post-infection (82). 
Functional analysis of gll have not been undertaken. However, gll is 
essential to viral replication and all PRV strains studied to date express gll at 
similar levels (109). Researchers have speculated that the gll glycoprotein 
complex plays an essential role in critical aspects of infectivity such as 
adsorption and penetration (6). In vitro virus neutralization studies show that 
gll is a major target for host humoral immune responses in the presence or 
absence of complement (109). 
Glvcoorotein QIII: Pseudorabies virus glycoprotein gill is the only major 
envelope glycoprotein that appears to exist as a uncomplexed monomer (31). 
Reports describing the apparent molecular weight of gill range between 82 and 
98k (31,50,83,108). A non-glycosylated precursor product with a molecular 
weight of 60k has been identified (109). The coding region for gill is located in 
the UL region spanning the BamHI-B and K restriction fragment junction between 
map units 0.390 and 0.420 (84,104). A specific gill mRNA of 1.55 kb is 
synthesized starting at four hours post-infection (83). 
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Glycoprotein gill has been shown to be multifunctional in nature. 
Researchers have shown that gill is involved in virus adsorption, release, and 
thermostability (94,109). These functions cannot be attributed to gill alone. A 
synergistic relationship between gl, gill, and gp63 has been demonstrated in 
these areas (67). The multifunctional nature of gill has led researchers to 
speculate that gill, in conjunction with gl and gp63, plays an important role in 
PRV virulence (109). In vitro experiments with gill specific monoclonal 
antibodies have demonstrated virus neutralization in the presence and absence 
of complement (6,87). Studies in swine have identified gill as a major target of 
serum antibodies (6). These same studies indicate that gill specific serum 
antibodies constitute a major fraction of the swine antibody response to PRV 
infection. 
Glvcoorotein QD50; The PRV envelope glycoprotein gp50 is essential to 
viral replication. Mature gp50 is a 50 to 60k molecular weight protein with O-
linked glycosylation (73,103). The gp50 is a minor glycoprotein that appears to 
be uncomplexed to other envelope glycoproteins. The coding region for gp50 
has been mapped to the Ug region of the PRV genome between map units 
0.845 and 0.891 (73,103). No terminal polyadenylation signal is present in the 
gp50 coding region (73,75). The gp50 transcript appears to be coterminal with 
the adjacent gp63 coding region (44,73,75). In support of this finding, a 2.4 
kb mRNA has been identified which is specific for gp50 and gp63 (44). 
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Functional studies on gp50 are incompiete; however, it has been 
proposed that gp50 is involved in adsorption and release (109). Recent studies 
have shown that gp50 is an important immunogen in the host immune response 
to PRV infection (103). Convalescent immune serum is highly reactive to 
purified gp50 (103). In vitro studies have shown that gp50-specific monoclonal 
antibodies neutralize PRV in the presence and absence of complement 
(19,102,103). Recombinantly expressed gp50 alone has been shown to induce 
protective immunity against PRV challenge in mice and swine (51,52). 
Givcoorotein QD63: The envelope glycoprotein gp63 has an apparent 
molecular weight of 63k and is not required for PRV replication. Glycoprotein 
gp63 exists in a non-covalently bonded membrane complex with gl, a 115k 
non-glycosylated protein, and minor envelope components gIV and gV (31). 
This glycoprotein is encoded within the Ug region of the PRV genome at map 
units 0.845 to 0.891, immediately downstream from the gp50 gene stop codon 
(109). Glycoproteins gp63 and gp50 appear to have a coterminal 3' end with 
one 2.4 kb mRNA transcript encoding both proteins (44,75). 
Functional studies indicate that gp63 and gl play major roles in the 
release of progeny virions from PRV infected cells (62,66,68,74), The host 
immune response to gp63 has not been described to date. 
Glvcoproteins IV and V: Two minor envelope glycoproteins designated 
gIV and gV have been described (31). The apparent molecular weights of 
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glycoproteins gIV and gV are reported to be 98k and 62k respectively (31). 
Studies to date have shown that gIV and gV exist as a complex with gl and a 
115k non-glycosylated protein (31). The genomic locations and transcript sizes 
for gIV and gV have not been determined. 
The functional role(s) of gIV and gV have not been determined. 
However, the glV-gV-gl-gp63-115k protein complex has been implicated in the 
adsorption and penetration events of PRV infection (31). There have been no 
studies to date on gIV and gV interaction with host immune systems. 
Non-Qlvcosvlated structural PRV proteins 
A major class of PRV structural proteins are the proteins of the 
nucleocapsid including the major and minor capsid proteins and a 10k PRV DNA 
binding protein. Several other proteins are associated with PRV nucleocapsids 
(96); however, these are nonstructural and will be discussed separately. 
Capsid proteins of PRV: Three major PRV capsid proteins with molecular 
weights of 142k, 62k, and 32k have been described (8,96). All three of these 
proteins are encoded within the 10 kb BamHI-D genomic restriction fragment 
between map units 0.445 and 0.512. Specific mRNA transcripts of 4.4 kb, 2.1 
kb, and 1.5 kb in size map to this area (8,17,48). In addition, seven minor 
proteins with molecular weights of 112k, 85k, 41k, 38k, 35k, 30k, and 27k 
have been described (96). The 35k protein is a major component of empty 
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capsids (without a DNA genome and associated proteins) but is minor 
component of mature virions (8). It is suspected that the 35k protein is a 
scaffolding protein for capsid formation and is degraded prior to envelopment of 
the mature nucleocapsid (8). A second hypothesis suggests that the 35k 
protein is a precursor that is processed prior to incorporation into a mature 
capsid (8). The possible functional roles of the other minor components have 
not been described. The genomic loci and specific mRNA's for these minor 
proteins have not been identified. 
10k DNA binding protein: The 10k DNA binding protein is one of several 
structural and nonstructural proteins associated with PRV DNA. The 10k 
protein has been found associated with concatameric DNA during replication 
and with genomic DNA packaged into mature virions (8). It has been suggested 
that this protein may function as a topoisomerase (8). 
Nonstructural PRV proteins 
The PRV specific proteins included in this class are those that are not 
incorporated into a mature progeny virion. These include the 180K IE protein, 
DNA binding proteins, an excreted PRV glycoprotein, and various PRV encoded 
enzymes. 
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Immediate-Earlv (IE) protein: The IE 180 protein is a multifunctional 
protein responsible for the regulation of PRV replication and inhibition of cellular 
biosynthesis. This protein has an apparent molecular weight of 180k (8). The 
gene encoding IE180 is located in the inverted repeat regions of the PRV 
genome and specifies a single mRNA of 5.1 kb (17,36). 
The IE180 protein is required for initiating and maintaining the 
coordinated transcription and expression of PRV genes. The protein appears to 
be necessary for the formation of a stable transcription complex with cellular 
RNA polymerases II and III (8,22). However, IE180 is not required for the 
maintenance of this stable transcription complex (8,22). Additionally, IE180 
regulates its own transcription by affecting IE180 mRNA stability and synthesis 
(8). IE180 is also involved in the disruption and inhibition of cellular protein 
synthesis. Experimental evidence suggests that the protein binds to cell 
polysomes (multiple ribosome/cell mRNA complexes engaged in translation) 
disaggregating these complexes and freeing cellular ribosomes for the 
translation of viral transcripts (8,20). 
DNA binding proteins; The 136K DNA binding protein is the major PRV 
DNA binding protein and is encoded in the region of the PRV genome 
between map units 0.140 and 0.180. A specific mRNA transcript of 4.3 kb 
mapping to this region has been identified (17). 
25 
Three functional roles for this protein have been described. The 136K 
DNA binding protein is required for the initial rounds of PRV DNA synthesis 
(8,9). The specific role in this event has not been elucidated. The protein is 
also required for subsequent DNA replication events and concatamer formation 
leading to progeny virus genome production (8,9). Lastly, this protein stabilizes 
unit length progeny virus genomes prior to encapsidation (8,9). 
A second poorly characterized nonstructural 15k DNA binding protein has 
also been described. This late phase protein is found associated with genomic 
concatamers and appears to stabilize these DNA molecules (8). 
Excreted olvcoorotein. aX: This nonstructural PRV glycoprotein is 
produced in large amounts by infected cells. Excreted glycoprotein gX is highly 
sulfated and has a molecular weight ranging from 90-98k (58,80,99). A 
precursor pgX, with a molecular weight of 65k has been identified. Processing 
of pgX produces an intracellular glycoprotein of 110k that is reduced to the 
mature protein molecular weight by proteolytic cleavage (10,71,80,92). The 
structural gX gene is located at map units 0.850 to 0.870 and specifies a 
mRNA of 1.6 kb in size (80). 
A specific functional role for gX has not been described. The protein is 
not required for virus replication (99) and antiserum directed against it does not 
neutralize virus in vitro (52,66,99). However, there have been no naturally 
occurring gX negative PRV strains described, suggesting a hitherto undetected 
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role for gX may exist. The glycoprotein has been used as a diagnostic antigen 
in conjunction with gX deletion mutant vaccines (42) and subunit vaccines 
(58,76,77) to detect PRV infection of vaccinated pigs. 
PRV specified enzvmes: A limited number of PRV enzymes have been 
described to date. These include PRV specific thymidine kinase, ribonucleotide 
reductase, DNase, and DNA polymerase. All of these enzymes have been 
shown to be antigenically distinct from their counterparts in target cells and in 
some cases subtle functional differences have been found (8). 
Pseudorabies virus thymidine kinase (TK) is encoded in the U,. region of 
the genome and is associated with viral neurovirulence (8,30). This enzyme 
generates the DNA precursor deoxythymidilate (dTMP) from free thymidine 
(93). This allows the virus to utilize thymidine and acquire this DNA precursor 
independent of the cellular precursor pathway (93). 
Pseudorabies virus also encodes a ribonucleotide reductase that functions 
to eliminate normal cellular feedback inhibition of DNA synthesis when 
thymidine concentrations are high (8). This enzyme does not require energy in 
the form of ATP and continues to aid in the production of DNA precursors 
without being subject to feedback inhibition by high levels of these precursors. 
A PRV specific DNase exists which appears to modify genomic PRV DNA 
and degrade cell DNA. Specifically, PRV DNase is an exonuclease that releases 
deoxyribonucleoside-5'-monophosphates from the 3' end of DNA molecules (8). 
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Pseudorabies virus also encodes a virus specific DNA polymerase. This 
PRV DNA polymerase Is antigenically different from target cell DNA 
polymerases and HSV-1 and HSV-2 DNA polymerases {30). As a result, PRV 
provides itself with a DNA polymerase that is independent of cellular DNA 
polymerase concentration and function. 
Porcine Immune Responses to Pseudorabies Virus 
Humoral immunitv 
Antibody responses to PRV infection can be categorized as neutralizing or 
non-neutralizing. Descriptions of porcine antibody responses to PRV are 
therefore dependent on the assay system used. Virus neutralization assays 
measure those antibody species that prevent virus replication at some level, 
while assays such as the enzyme-linked immunosorbant assay measure non-
neutralizing as well as neutralizing antibody. Furthermore, most studies 
measure serum antibody levels and attempt to correlate serum antibody with 
protection from disease. As a result, local antibody responses and immune 
mechanisms that affect virus replication at sites inaccessible to serum antibody 
are discounted. 
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Following natural infection, PRV neutralizing antibody is first detected in 
serum at four to six days post-infection (p.i.). Maximal levels of antibody 
occur between 14 and 21 days p.i. (13,56,109). Complement is required for 
early (four to six days p.i.) detection of virus neutralization suggesting IgM and 
complement-requiring IgG subclasses predominate (109). Serum virus 
neutralization without complement is first detectable on day nine p.i., 
corresponding with the peak and decline of IgM between days seven and 11 
p.i. (106). Neutralizing serum IgG peaks at day 14 p.i. while serum IgM is not 
detected after day 14 p.i. (106,109). Enzyme-linked immunosorbent assays, 
which also detect non-neutralizing PRV specific antibody, have demonstrated 
antibody response kinetics similar to those described above. However, 
maximum titers were found from days 24 to 42 p.i. in some cases (2,54,109), 
suggesting that the antibody responses to some non-neutralizing viral epitopes 
are of a later onset. 
Local secretory humoral immunity is thought to be important in PRV 
infection because the predominant route of viral infection is the nasal mucosa. 
However, no data are available regarding the humoral profile of PRV neutralizing 
IgA antibody. It is thought that cell-mediated mechanisms, cytokines, 
lymphokines, and other immune mediators play a primary role in cotrolling local 
infection (109). 
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Passive immunity (maternal antibody) 
There is a significant transfer of neutralizing antibody, immune cells, and 
immune mediators from PRV-infected sows to offspring via colostrum. 
Pseudorabies virus specific colostral antibody can be detected in piglet serum 
for 5 to 17 weeks (57,105). As a result, maternal antibody interference with 
PRV vaccination can be a problem (107). 
Colostral transfer of cell-mediated immunity has also been demonstrated 
(57,105). In a few cases, PRV specific lymphocyte stimulation was detected in 
piglets from PRV vaccinated sows (107). These studies indicate that immune 
cells or soluble immune mediators can be transferred to offspring via colostrum. 
Cell-mediated immunity 
Cell-mediated immunity (CMI) to PRV can be demonstrated in pigs 
following natural infection and vaccination. However, the correlation of in vitro 
demonstrations of CMI with in vivo realities is extremely difficult. Individual, 
group, and temporal variations of CMI are great. Additionally, most 
measurements of CMI are performed with peripheral blood cells which may not 
be representative of events occurring at the site of virus infection and 
replication. Evidence also indicates that PRV is disseminated in circulating 
lymphocytes, monocytes and macrophages. Virus mediated effects on these 
cells may influence measures of CMI. 
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Specific PRV-mediated effects on porcine lymphocytes have been 
observed. These events are usually detected prior to the appearance of 
antibody. Lymphocyte stimulation and lymphocyte-mediated inhibition of 
macrophage migration in PRV-infected pigs can be demonstrated as early as 
four days post-infection (25,53,107). Studies on the cytotoxic activities of T-
lymphocytes have not been reported due to difficulties in establishing an 
isogeneic assay system in pigs. There have been several demonstrations of 
enhanced natural killer cell mediated cytotoxicity using peripheral blood 
lymphocytes from PRV Infected pigs as effector cells and PRV infected Vero 
cells as target cells (53,109). The early onset of CM! suggests a role for CM! 
early in viral infection. 
Measurements of CMI in vaccinated pigs show that the kinetics of 
lymphocyte stimulation and lymphocyte-mediated inhibition of macrophage 
migration were similar to those found in natural infection. However, differences 
were detected when inactivated versus live vaccines were used. The duration 
of stimulation was found to be increased when an inactivated vaccine was 
used; however, the lymphocyte stimulation indices were found to be much 
higher when live vaccines were administered (53,107). 
Antibody-dependent cell-mediated cytotoxicity has also been 
demonstrated in response to PRV infection. This cytotoxicity appears to be 
mediated by macrophages, neutrophils, and lymphocytes (K cells) (108,109). 
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The appearance of this phenomenon correlates with the production and 
detection of PRV-specific neutralizing antibody and persists as long as 
neutralizing antibody persists (108). It is thought that antibody-dependent cell-
mediated cytotoxicity plays an important role in recovery from PRV infection. 
Cvtokines and Ivmohokines 
Few studies have been published regarding the role for cytokines and 
lymphokines In PRV Infection. Studies with porcine interferon-alpha show that 
it evokes a potent antiviral effect and is present in detectable amounts six hours 
post-infection (109). The immunomodulating effects of interleukin-2 in PRV 
infection and vaccination studies have indicated that this lymphokine may be 
useful in upregulating the immune response to PRV (39). 
Pseudorabies Virus Diagnostics, Vaccination, and Control 
Diagnostic procedures in PRV detection 
The diagnostic procedures used for the detection of PRV infection fall 
into three general categories: 1 ) the isolation of virus, 2) the detection of virus 
antigen or nucleic acid in tissues, and 3) the detection of immune responses 
directed against the virus. 
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Isolation of PRV from tissue: Pseudorabies virus can be isolated from a 
variety of tissues and tissue homogenates. Typically, brain, tonsil, lung, lymph 
node, and spleen are tested for the presence of virus (109). Tissue 
homogenates or expiants can be used to inoculate tissue culture cells (56). 
Cytopathic effect indicative of PRV and virus re-isolation from tissue culture 
cells is evidence of virus infection. Virus re-isolation can also be attempted by 
inoculating susceptible laboratory animals with tissue homogenates. Final 
identification must be made electron microscopy or serology. 
Detection of PRV antigen or nucleic acid: Immunofluorescence is the 
primary method used to demonstrate the presence of PRV antigen in tissue 
sections, impression smears, and virus-infected tissue culture cells (109). 
Fluorescein conjugates of PRV positive serum are used to probe and detect 
antigen in fixed cells. Specific immunofluorescence is usually detected in the 
cytoplasm or on the surface of infected cells. 
Pseudorabies virus nucleic acid can be detected in tissue sections or 
infected tissue culture cells using PRV specific nucleic acid probes. These 
extremely sensitive and specific procedures can detect small amounts of PRV 
genomic DNA (88) or transcribed PRV-specific RNA (85) in infected cells. In 
addition to having a big impact on PRV detection, these procedures are playing 
an important role in our understanding of PRV pathogenesis and latency. 
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Detection of PRV-specific immune responses: Serum virus neutralization 
(34), enzyme-linked immunosorbent assays (58,60), latex agglutination (61), 
and radial immunodiffusion (26,27,98) are the most widely used methods for 
detecting serum antibody. Enzyme-linked immunosorbent assays and latex 
agglutination are the most sensitive of these assays (109). In addition, these 
two assays and radial immunodiffusion detect a broad range of PRV antibodies, 
while serum neutralization only detects a neutralizing antibody response. 
Increased sensitivity and specificity can be achieved using western-immunoblot 
and radioimmunoprecipitation techniques (58-60), however, these techniques 
require specialized equipment, facilities and expertise. As a result, widespread 
implementation of these techniques outside of the research laboratory is not 
practical. 
A PRV antigen skin test for eliciting and detecting a delayed-type 
hypersensitivity response has been used as a method for detecting virus 
infection (107,109). This test is not as sensitive as any of the assays 
described above and may be useful only on a herd testing basis. 
Pseudorabies virus vaccines 
Commercially available and experimental PRV vaccines can be organized 
into three categories: 1 ) modified live virus vaccines, 2) genetically engineered 
deletion mutant vaccines, and 3) inactivated virus vaccines. 
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Modified live virus vaccines: Strains of PRV with reduced pathogenicity 
for pigs have been used as live PRV vaccines. Live PRV vaccines can be 
categorized as natural variant strains, biologically modified strains, or chemically 
induced mutant strains. Live genetically engineered deletion mutants will be 
dealt with separately. 
Naturally variant strains of PRV are non-pathogenic field strains of virus 
isolated from pigs or other susceptible hosts. An example of a natural variant 
strain is the K61 Bartha strain (3). This strain has been used as a vaccine 
and has been further adapted to chicken embryo fibroblast and pig kidney cell 
culture (109). The Bartha strain has been used as a commercial modified live 
vaccine manufactured by Boehringer Ingelheim Animal Health Inc. (Bio-Ceutic). 
Biologically modified strains of PRV are characterized as moderately 
pathogenic isolates attenuated by serial passage in embryonated chicken eggs 
and chicken embryo fibroblast cell cultures (109). The Bucharest strains of PRV 
were attenuated in this manner. A commercial modified live vaccine 
manufactured by Smith Kline Beecham Animal Health (PR-Vac) utilizes a strain 
(Norden) derived by biological modification. 
Chemically induced mutant strains of PRV were derived by growing virus 
in the presence of nucleoside analog mutagens such as 5-iodo-deoxyuridine and 
5-bromo-deoxyuridine (109). This treatment selects for thymidine kinase 
negative mutants that will not lethally incorporate the chemical analogs. 
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Reduced neurovirulence has been attributed to PRV strains containing a 
mutated or deleted thymidine kinase gene (43). Thymidine kinase negative 
strains of PRV have served as the basis for some genetically engineered deletion 
mutant vaccines (42,43). 
Genetically engineered deletion mutant vaccines: This family of live PRV 
vaccines are attenuated by the deletion of one or more nonessential viral genes. 
The viral genes selected for deletion are not essential for virus replication but do 
contribute to viral virulence in some way. 
Several PRV deletion mutant vaccines have been developed with 
deletions in one or more of the PRV genes encoding thymidine kinase and the 
envelope glycoproteins gl, gill, gp63, and gX (42,68). The absence of one 
or more of the PRV envelope glycoproteins in these vaccine strains has provided 
a means for differentiating between vaccinated and infected pigs. The deleted 
glycoprotein serves as antigen in a differential companion diagnostic test. 
In general, the deletion mutant vaccines are as efficacious as 
conventional modified live PRV vaccines (109). However, two important 
questions with regard to their use have not been answered. It is not known if 
vaccination with a deletion mutant vaccine can prevent the establishment of 
latency upon exposure to wild-type PRV. Recent studies have also shown that 
in vivo recombination between deletion mutant vaccines and wild-type PRV can 
occur (32,33,38). Recombination between deletion mutant vaccines and field 
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strains of PRV could result in the establishment of virulent marker negative PRV 
strains. The frequency of recombination and factors contributing to its 
occurrence have not been adequately studied. 
Inactivated virus vaccines: Inactivated virus vaccines are defined as 
those vaccines produced by inactivating virulent virus while attempting to retain 
overall immunogenicity (20). included in this category are chemically 
inactivated whole virus preparations, split or subunit vaccines, and 
recombinantly expressed proteins or polypeptides (51,76,109). 
Inactivated vaccines are unable to replicate in the host animal. 
Therefore, efficient inactivation of the parental strain and immunopotentiation of 
the vaccine preparation are important to the safety and efficacy of inactivated 
vaccines. The chemical inactivation of PRV is accomplished by treatment of 
live virus with ethylenimines, glutaraldehyde, or formaldehyde (109). In the 
case of split or subunit vaccines, viable virions are solubilized with non-ionic 
detergents such as Triton X-100 or Nonidet P-40 (76). The immunopotentiation 
of inactivated vaccines is accomplished with a variety of adjuvant formulations. 
The adjuvant formulations used in commercial inactivated PRV vaccines are 
primarily aluminum hydroxide, aluminum oxide, and various oil emulsions (109). 
Experimental inactivated vaccines have been described with adjuvants 
consisting of lauric acid, Freund's complete adjuvant, and Freund's incomplete 
adjuvant (76,109). 
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Efficacious inactivated PRV vaccines did not begin to appear until 1973. 
However, several commercial inactivated PRV vaccines are available at this 
time. In some cases, deletions present in the parental PRV strains can be 
utilized as the basis for a differential diagnostic test. For example, inactivated 
vaccines derived from cell culture adapted Bartha strain contain a large deletion 
in the gl glycoprotein gene. As a result, no gl is expressed by this PRV strain 
and gl based diagnostic tests can be used to differentiate between vaccinated 
and infected pigs (109). 
Inactivated PRV vaccines are very safe. However, the injection of a large 
antigenic mass is required. Primary injection is usually followed by periodic 
booster at 6 months to maintain a protective humoral response. In contrast to 
modified live PRV vaccines, inactivated PRV vaccines are generally ineffective in 
eliciting a specific cell-mediated immune response (109). 
Pseudorabies virus control and eradication 
The control of pseudorabies virus and its eradication from infected swine 
herds is a complex problem. The methods used in attaining these goals are: 1 ) 
depopulation-repopulation, 2) test and removal, and 3) offspring removal 
(97,111). The method used depends on the number of pigs infected and 
individual management and economic conditions. However, sensitive diagnostic 
tests are absolutely required for all control and eradication programs. 
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Depopulation-Repopulation; This method of PRV control and eradication 
requires the removal of all swine from an infected area, extensive disinfection of 
all facilities and equipment, a minimum 30 day waiting period before 
repopulation with certified PRV negative stock, and periodic serological 
monitoring of the new herd (111). Serological verification of the PRV 
seronegative status of new stock is of primary importance. This program is not 
compatible with the preservation of genetic stocks and bloodlines. It is also the 
most expensive of the programs due to stock losses and production downtime 
(111). 
Test and removal: Test and removal programs of PRV control and 
eradication are based on the identification and removal of seropositive animals 
from an infected herd (97,111). Infected herds are serologically tested every 
30 days and positive animals are removed after each testing. This cycle 
continues indefinitely. This program is best suited to herds with a low PRV 
infection rate. Test and removal is the most economic of the three programs. 
Seropositive animals are sold to slaughter, genetic bloodlines can be retained, 
and there is no production downtime. 
Offspring segregation: Offspring segregation is based on the rearing of a 
PRV negative herd to replace infected stock (97,111). Once PRV infection has 
been detected a regular program of vaccination is implemented. Vaccination 
limits the spread of PRV in the herd and induces high levels of colostral 
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antibody in farrowing gilts and sows. Giits are vaccinated at breeding and two 
to four weeks before farrowing. Sows are vaccinated two to four weeks before 
farrowing. Tine offspring from these farrowings are weaned at 2 to 3 weeks of 
age and physically separated from the herd. At 4 months of age offspring are 
serologically tested for PRV antibody. At this time maternal antibody has 
decayed to undetectable levels and seropositive animals are considered PRV 
infected. Segregation is maintained until all seropositive animals have been 
removed and the facilities disinfected. Offspring segregation is an economical 
program and is frequently used because it does not interfere greatly with 
production. 
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SECTION I: DETECTION OF PSEUDORABIES VIRUS INFECTION IN 
SUBUNIT-VACCINATED AND NON-VACCINATED PIGS 
USING A NUCLEOCAPSID BASED 
ENZYME-LINKED IMMUNOSORBANT ASSAY 
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The potential of a pseudorabies virus (PRV) nucleocapsid protein (NC) 
based ELISA as a screening assay for PRV infection in subunit-vaccinated and 
non-vaccinated pigs was studied. The NC-ELISA compared favorably to a 
commercial ELISA for detecting PRV infection in non-vaccinated pigs. Virus 
specific antibody was first detected by the NC-ELISA between day 14 and 21 in 
5 pigs challenged intranasaily with 10^ PFU of virus. Antibody continued to be 
detected in these pigs through day 42 when the experiment was terminated. 
The NC-ELISA also detected antibody in 23 of 24 pigs from PRV infected herds. 
In contrast, the commercial ELISA detected antibody 1 week earlier than the 
NC-ELISA in experimentally infected pigs, but failed to detect antibody in 3 
naturally exposed pigs that were identified by the NC-ELISA. Infection in these 
animals was confirmed by radioimmunoprecipitation analysis. The potential 
usefulness of the NC-ELISA for detecting infection in vaccinated pigs was also 
evaluated. The nucleocapsid specific antibody responses of 10 PRV envelope 
glycoprotein subunit-vaccinated pigs were monitored prior to and following 
nasal exposure to a low dose (10" PFU) of PRV. Serums were collected 
periodically for 113 days after infection. Nucleocapsid specific antibody 
responses measured by the NC-ELISA remained below the positive threshold 
before challenge but increased dramatically following virus exposure. Maximum 
ELISA responses were obtained on day 32 post-challenge (p.c.). Mean ELISA 
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responses decreased thereafter but remained well above the positive threshold 
on day 113 p.c. The results of these studies demonstrate that PRV 
nucleocapsid protein can be used effectively as antigen in the ELISA for 
detecting PRV infection In both non-vaccinated and subunit-vaccinated pigs. 
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INTRODUCTION 
Pseudorabies or Aujeszky's disease virus is an alpiiaherpesvirus which 
causes an economically important disease of swine (3,22). The disease is 
characterized by acute respiratory and neurological involvement followed by the 
establishment of latent infection (3). Mortality following acute infection of 
young pigs (1-4 weeks old) ranges from 50-100% (3). Mortality decreases 
with age; however, morbidity and latency occur following infection of older 
animals (3). Current methods of disease prevention and control are centered on 
vaccination and serological monitoring. Pseudorabies vaccines provide 
protection against acute disease but do not prevent pseudorabies virus (PRV) 
infection and subsequent transmission (5,6,8,14,16,17,21). Current national 
PRV eradication programs underscore the need for reliable, sensitive, and 
specific assays to identify virus infected pigs and differentiate them from 
vaccinated pigs. 
Earlier work in this laboratory demonstrated that it was possible to 
differentiate between wild type virus infected and non-infected pigs vaccinated 
with a PRV envelope glycoprotein based subunit vaccine using a differential 
diagnostic test based on an early excreted PRV glycoprotein, gX (10,13). This 
concept is in part, the basis of some current PRV deletion mutant vaccines. 
The virus strains used in these vaccines are characterized by 
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deletions in one or more of the genes encoding thymidine kinase and 
glycoproteins gl, gp63, gill, and gX (1,8,17,19). The deleted proteins are the 
basis of differential diagnostic tests. The presence or absence of antibodies to 
these glycoproteins makes it possible to distinguish wild type virus infection 
from vaccination. 
The variety of deletion-mutant vaccines available pose some problems for 
PRV control programs. Since each deletion-mutant vaccine requires the use of 
a specific diagnostic antigen, accurate vaccination records must be kept to 
permit selection of the appropriate differential diagnostic test. Furthermore, 
pigs that are initially vaccinated with one vaccine cannot be revaccinated with 
another without the possibility of inducing a false positive reaction. These 
problems can be avoided with the use of PRV envelope glycoprotein based 
subunit vaccines and a diagnostic test based on a single antigen preparation as 
demonstrated by recent work in this laboratory using PRV nucleocapsid proteins 
and Western immunoblot analysis to detect virus infection in both subunit-
vaccinated and non-vaccinated pigs (11). In light of concerns with PRV control 
and eradication, the following study was undertaken. The purpose of this study 
was to evaluate the potential of a PRV nucleocapsid (NC) ELISA as a serological 
screening assay for the detection of PRV infection in non-vaccinated pigs and in 
pigs immunized with subunit vaccines. 
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MATERIALS AND METHODS 
Virus and cell culture 
Pseudorabies strain Be (16) was used for all antigen production and virus 
challenge experiments. Madin-Darby bovine kidney (MDBK) cells were used for 
virus propagation. Growth and maintenance medium consisted of Dulbecco's 
modified Eagle's medium (Gibco BRL) supplemented with 10% and 1% heat 
inactivated fetal bovine serum (Hyclone Laboratories) respectively. 
Serum virus neutralization assay 
Serum virus neutralization (SN) was performed on all serum samples as 
previously described (15). Briefly, all sera were heat inactivated at 56°C for 45 
minutes. Two-fold dilutions of sera were made in D-MEM and 50 tj\ aliquots 
were added to wells of microtiter plates (Costar). Virus was diluted to 300 
TCIDgo, 50 ij\ was added to microplate wells, and the mixture was incubated at 
37°C for 45 minutes. A suspension of approximately 2x10* MDBK cells was 
added in 50 //I of growth medium and incubated at 37°C for 48 hours. 
Microplates were fixed in 10% formalin and stained in 1% crystal violet. Titers 
represent the geometric mean titer of 5 wells, rounded to the nearest dilution. 
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Buffers and reagents 
The following buffers were used for the isolation of PRV nucleocapsids. Cell 
lysis (CL) buffer consisted of 150 mM NaCI, 2 nnM MgClj, 10 mM Tris, pH 7.5, 
and 1 % Nbnidet P-40. Nuclei disruption (ND) buffer consisted of CL buffer 
containing 1 % sodium deoxycholate. Protease inhibitor cocktail consisted of 
1 mM 1,10-phenanthroline, 1 mM benzamidine, 50 juM phenylmethylsulfonyl 
fluoride, 50 /JM sodium metabisulfite, 20 //g/ml leupeptin, 50 jjg/m\ ovomucoid 
trypsin inhibitor, 50 //g/ml soybean trypsin inhibitor, and 50 //g/ml aprotinin (all 
Sigma Chemical Co). 
The buffers and reagents used in the ELIS A are as follows. Antigen 
coating (AC) buffer was 100 mM sodium carbonate and 100 mM sodium 
bicarbonate, pH 9.6. Blocking buffer consisted of AC buffer containing 2% 
gelatin. Serum dilution (SD) buffer consisted of 150 mM NaCI, 10 mM EDTA, 
0.05% Tween 20, 50 mM Tris, pH 7.4, and 1% gelatin. Wash buffer was 150 
mM NaCI, 50 mM Tris, pH 7.4, and 0.5% Tween 20. Goat anti-porcine 
lgG(H + L) conjugated with horseradish peroxidase and 2, 2'-azino-di-[3-ethyl-
benzthiazoline sulfonate] (ATBS) (KIrkeegard and Perry) enzyme substrate 
solutions were prepared and used according to manufacturer's directions. 
The following buffers were used in radioimmunoprecipitation and SDS-
PAGE. Radioimmunoprecipitation buffer consisted of 10 mM Tris, pH 7.4, 
containing 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS. 
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Sample preparation buffer for SDS-PAGE consisted of 2% SDS, 
4% 2-mercaptoethanol, 0.05% bromophenol blue, and 50% glycerol in 500 
mM Tris, pH 6.8. 
PRV subunit vaccine preparation 
An envelope glycoprotein-based PRV subunit vaccine was prepared as 
previously described (14). The vaccine consisted of PRV envelope 
glycoproteins that were isolated from Triton X-100 solubilized virus infected 
cells by lectin affinity chromatography using Lens culnaris agglutinin covalently 
linked to agarose beads (E-Y Laboratories). Appropriate protein concentrations 
of affinity purified glycoproteins were emulsified in incomplete Freund's 
adjuvant and used as vaccine. 
PRV nucleocapsid isolation 
Nonenveloped PRV nucleocapsids were isolated using a modification of 
the methods of Gibson and Roizman (2), and Stevely (18) as previously 
described (11). In brief, approximately 10° MDBK cells were infected at a 
multiplicity of 5 with PRV strain Be. Infected cells were harvested at 12 hours 
after infection, lysed by resuspension in CL buffer and incubated for 30 minutes 
in an ice bath. Infected cell nuclei were isolated from the cell lysate by 
centrifugation at 1000 xg, washed twice in CL buffer and lysed in 10 ml of ND 
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buffer. Nuclear lysates were incubated at 37*C with 50 //g/ml DNasel (Sigma 
Chemical Co.) for 2 hours and clarified at 1000 xg. The supernatant was 
layered on a 5-45% glycerol gradient and centrifuged at 100,000 xg for 90 
minutes in a Beckman SW41 rotor. The nucleocapsid pellet was resuspended in 
2 ml of 10 mM Tris, pH 7.5 containing 100 //I of protease inhibitor cocktail. 
This preparation was treated for 30 minutes at 25 ®C with Lens culnaris 
agglutinin covalently linked to agarose beads (E-Y Laboratories) and clarified by 
centrifugation at 1000 xg to eliminate any potential contaminating enveloped 
virus or envelope components. The purity of the nucleocapsids was confirmed 
by electron microscopic examination of 5 negatively stained aliquots of the 
preparation. No enveloped virions or envelope remnants were found. Purified 
nucleocapsids were aliquoted and stored at -70°C. 
Enzyme linked fmmunosorbant assay 
Ninety-six well microplates (Immulon I; Dynatech Laboratories) were 
coated with antigen by adding 100 fj\ of AC buffer containing 2 jjg of 
nucleocapsid antigen/ml and incubated overnight at 4*'C. All wells were 
blocked with 200 //I/well of blocking buffer for 2 hours at 37°C. Test serums 
were diluted 1:50 in SD buffer. Fifty JJ\ of diluted serum was added per test 
well and allowed to react for 20 minutes at 37°C. All wells were washed 5 
times with 200 //I of wash buffer. Two hundred /j\ of optimally diluted goat 
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anti-porcine lgG(H + L} conjugated to horseradish peroxidase was then added to 
each well and allowed to react at 37°C for 45 minutes. All wells were washed 
as above. Enzyme substrate, ABTS, was added and allowed to react for 30 
minutes before reading. The optical density (OD) of the reaction mixtures was 
determined at 405 nm with a kinetic microplate reader (Vmax: Molecular 
Devices, Inc.). Each reported value represents the mean of 4 replications. 
Baseline positive/negative ELISA OD's were determined by testing serums 
collected from 28 certified PRV negative pigs. The mean OD of these sera was 
0.048 +/- 0.025. The range of negative values was 0.010 to 0.110. 
Accordingly, the minimum positive threshold was set at 0.200. The maximum 
negative value was set at 0.110 and all values in between were considered 
suspect. The commercially available PRV screening ELISA was used according 
to the manufacturer's directions (Herdchek: Idexx Corp.). 
Radioimmunoprecipitation and SOS-PAGE 
Purified nucleocapsid protein was labelled with "^l-sodium iodide using a 
commercially available kit (lodobead: Pierce Chemical Co.). Radioimmuno­
precipitation and SDS-PAGE were performed as previously described (4,20). 
Briefly, approximately 5x10^ cpm of labelled nucleocapsid in a volume of 100 fj\ 
was combined with 25 JJ\ of test serum diluted 1:50 in 10 mM Tris, pH 7.4, 
vortexed and incubated overnight at 4°C. Antigen-antibody complexes were 
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precipitated with 25 //I of a 40% (v/v) solution of Sepharose CL4B-protein A 
(Pharmacia LKB Biotechnology), and incubated at 4°C for 1 hour. The protein 
A-immune complexes were pelleted by microcentrifugation for 2 minutes and 
washed 6 times in radioimmunoprecipitated buffer. Washed 
immunoprecipitates were boiled for 4 minutes in sample preparation buffer and 
separated on 10% polyacrylamide gels at a constant current of 35 mA. 
Electrophoresed gels were dried under vacuum and exposed to film (XOMAT: 
Eastman Kodak) at -70°C overnight. 
Evaluation of the nucleocapsid protein based ELISA 
The efficacy of the NC-ELISA was evaluated by comparing its ability to 
detect PRV infection in experimentally and naturally infected pigs to that of a 
commercially available ELISA. A total of 28 serums were collected over a 7 
week period from 5 non-vaccinated pigs that were experimentally infected 
intranasally challenged with 10^ FPU of virus. Twenty-four field serums were 
collected through the Iowa State University Veterinary Diagnostic Lab from pigs 
of herds in which PRV was circulating. The PRV vaccination histories of these 
pigs are not available. Twenty of these serums had SN titers ranging from 1:2 
to 1:64. Four of these field serums did not have detectable SN antibodies. 
The potential usefulness of the NC-ELISA for detecting infection in 
subunit-vaccinated pigs was also evaluated. Ten weanling pigs were 
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vaccinated with 3 subcutaneous doses of subunit vaccine (1 x 100 //g and 2 x 
50 tiq of vaccine protein) in Freund's incomplete adjuvant at 21 days intervals. 
Serum neutralizing titers in these pigs ranged from 1:4 to 1:32 immediately 
prior to virus challenge. All pigs were challenged intranasally with 10" PFU of 
virus 3 weeks after the last vaccine dose and monitored for PRV nucleocapsid 
protein specific antibody periodically for 113 days. 
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RESULTS 
Detection of PRV antibody In experimentally infected pigs 
Tlie PRV specific antibody response of ali experimentally infected pigs 
was monitored by the commercial ELISA and NC-ELISA periodically throughout 
the 42 day test period. Following virus challenge all pigs showed clinical signs 
indicative of PRV infection. Antibody was first detected between days 7 and 
14 post-challenge (p.c.) by the commercial ELISA and between days 14 and 21 
by the NC-ELISA (Table 1). Thereafter PRV specific antibody was detected by 
both ELISA's through the end of the experiment. 
These results indicated that the NC-ELISA was not as sensitive as the 
commercial ELISA in detecting early antibody responses to experimental PRV 
infection of non-vaccinated pigs. However, the NC-ELISA was as sensitive as 
the commercial ELISA after day 14 p.c. 
Detection of PRV antibody in naturally infected pigs 
Serums were collected from 24 pigs from PRV infected herds. Each 
serum was analyzed by the SN test, the commercial ELISA and the NC-ELISA 
for PRV specific antibody. Pseudorabies-specific antibody was detected in 20 
pigs by all 3 assays and in 3 pigs by the NC-ELISA (Table 2). No antibody was 
detected in 1 of the 24 pigs. 
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Table 1. Comparison of the ability of the NC-ELISA and the commercial ELISA 
to detect experimental pseudorabies infection in non-vaccinated pigs 
Days After 
Virus Challenge 0 7 14 21 35 42 
NC-ELISA 0/5" 0/5 0/5 5/5 4/4= 4/4 
Commercial ELISA 0/5" 1/5 5/5 5/5 4/4= 4/4 
"Number of pigs NC-ELISA positive/total number of animals. A positive value is 
an OD of 0.200 or greater (See Materials and Methods). 
•"Number of pigs commercial ELISA positive/total number of pigs. A positive 
value is determined using manufacturer protocols. 
"One pig died of causes unrelated to PRV infection. 
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Table 2. Comparison of the ability of the NC and commercial ELISA to detect 
natural pseudorabies infection in non-vaccinated pigs 
SN titer No.pigs No.Positive" No.Positive'' Percent 
tested commercial NC-ELISA Agreement 
ELISA 
0 4 0 3 25 
1:2 3 3 3 100 
1:4 6 6 6 100 
1:8 7 7 7 100 
1:16 1 1 1 100 
1:32 2 2 2 100 
1:64 1 1 1 100 
"A positive value is determined using manufacturer's protocols and varies with 
each test plate. 
*'A positive value is an OD of 0.200 or greater (See Materials and Methods). 
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The reactivity of the 3 serums that tested positive only by the NC-ELISA was 
further analyzed by radioimmunoprecipitation using labeled PRV 
nucleocapsid protein. (Figure 1). The molecular masses of the 
immunoprecipitated proteins were in close agreement with previously reported 
values (5,18). These results provide evidence that an ELISA utilizing 
nucleocapsid protein can detect PRV infection in pigs that are undetected by 
the both the SN test and the commercial ELISA. 
Detection of nucleocapsid protein specific antibody in virus infected 
subunit-vaccinated pigs 
We also tested the feasibility of using nucleocapsid protein to detect 
virus infection in 10 pigs that had been immunized with PRV envelope 
glycoprotein subunit vaccine. The antibody response of the 10 subunit-
vaccinated pigs to nucleocapsid protein is summarized in Figure 2. The mean 
OD values remained below the positive threshold prior to challenge but 
increased dramatically following virus exposure. Antibody levels reached 
maximum levels by day 32 p.c. Antibody levels decreased thereafter but still 
remained well above the positive threshold on day 113 p.c. These results 
demonstrate the compatibility of the NC-ELISA with PRV envelope glycoprotein 
subunit vaccine. 
Figure 1. Analysis of swine serum for PRV nucleocapsid specific antibody by 
radioimmunoprecipitation using labelled antigen. Lanes: A, B 
and C, represent sera with antibody detectable by the NC-ELISA 
but not by the commercial ELISA; D and E, represent sera with 
antibody detectable by both ELISA's; F, PRV positive control 
serum; G, known PRV negative control serum. Molecular mass 
standards in kllodaltons are shown to the far left. 
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Figure 2. Mean NC-ELISA response of 10 subunit-vaccinated pigs prior to and following PRV exposure 
expressed as optical density. Day -63 = first subunit vaccine dose. Day -21 = third subunit 
vaccine dose. Day 0 = PRV exposure with 10" PFU, Positive Threshold = minimum positive 
OD reaction. Negative Threshold = maximum negative OD reaction. 
a»»» 
-63 -21 0 7 14 21 32 53 96 113 
Days Post-PRV Challenge 
(+) Threshold 
(-) Threshold 
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DISCUSSION 
The identification of PRV vaccinated pigs that have been infected with 
field strains of PRV is of paramount importance in controlling the spread of the 
disease pseudorabies. The current approach to vaccination centers on the use 
of avirulent deletion mutant viruses whereby genes encoding one or more viral 
proteins are deleted using recombinant DNA methodology. Although deletion 
mutant vaccines have been shown to be efficacious, recent studies have shown 
that in vivo recombination between modified live deletion mutant vaccines and 
virulent challenge virus does occur (5,6). As a result there is a potential for the 
emergence of virulent marker negative strains of PRV in the field. If the risk of 
in vivo recombination of modified-live deletion mutant vaccines with virulent 
field virus is perceived to pose a threat to national PRV eradication efforts, this 
approach will need to be further evaluated and modified. In this study, we 
evaluated PRV nucleocapsid protein as an ELISA diagnostic antigen. The 
suitability of PRV nucleocapsid protein in an ELISA was first determined by 
comparing its efficacy to that of a standard commercially available PRV 
screening ELISA. Subsequently we evaluated the potential of the NC-ELISA for 
use as a differential diagnostic test for pigs immunized with a PRV envelope 
glycoprotein subunit vaccine. 
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The NC-ELISA was compared to a commercially available ELISA for the 
ability to detect PRV specific antibody in experimentally infected and naturally 
exposed pigs. There was 100% agreement between both ELISA's in both 
groups of pigs with 2 exceptions. Antibody was detected at least 1 week 
earlier by the commercial ELISA in experimentally infected pigs (Table 1). 
However, the SN test and the commercial ELISA failed to detect antibody in 3 
of 24 naturally infected pigs which were positive by the NC-ELISA (Table 2). 
The NC-ELISA reactions of these 3 pigs were verified by 
radioimmunoprecipitation (Figure 1). We recognize the possibility that these 3 
serums may have contained cross-reacting antibody induced by the porcine 
cytomegalovirus. The antigenic cross-relationship of PRV to porcine 
cytomegalovirus is not known and is an area that needs to be clarified (12). 
The earlier detection of antibody by the commercial ELISA may have 
been due to differences in the antigen composition of the 2 assays. The 
antigen of the commercial screening assay is a mixture of PRV proteins, 
including the envelope glycoproteins. In contrast, the antigen of the NC-ELISA 
consists of highly purified non-enveloped solubilized PRV nucleocapsids. Earlier 
detection of antibody by the commercial ELISA may also be a reflection of the 
kinetics of the porcine immune response to different PRV proteins. Several 
investigators have demonstrated the SN antibodies which are specific for 
envelope glycoproteins are usually detectable within the first 7 days after 
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infection (4,9,13). We have likewise shown in previous studies that SN 
antibodies appear between 4 and 7 days after infection (7,10). Earlier studies 
in our laboratory have also demonstrated that antibodies to nucleocapsid 
proteins were not readily detected until day 14 p.c (11). 
The long duration of nucleocapsid specific antibody makes the NC-ELISA 
ideal for detecting PRV infections in PRV control programs. The ability of the 
NC-ELISA to detect PRV infection in the absence of detectable SN antibody 
was illustrated in the current study by the detection of PRV specific antibody in 
the 3 naturally exposed pigs. 
The potential of the NC-ELISA as a differential diagnostic test was 
demonstrated in 10 pigs immunized with a lectin purified glycoprotein subunit 
vaccine. Nucleocapsid specific antibody was first detected in all pigs between 
7 and 21 days following nasal challenge with a low dose (10" PFU) of virulent 
PRV. Antibody continued to be detected through day 113 p.c. when the 
experiment was terminated (Figure 2). These results are particularly meaningful 
because the antibody response of vaccinated pigs to a low challenge dose of 
virus is more difficult to detect than the response to a high virus dose (10). 
The low virus challenge dose is also a better reflection of natural exposure 
among vaccinated pigs since immunized pigs shed less virus than non-
immunized pigs (20). 
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In this study, the mean NC-ELISA OD rose slightly following subunit 
vaccine administration. In our estimation, this slight rise was not due to 
contamination of the nucleocapsid antigen with envelope glycoprotein or 
contamination of the subunit vaccine with nucleocapsid protein. If either 
preparation were significantly contaminated with the other, the administration 
of 3 vaccine doses over a 63 day period would have resulted in a more 
dramatic rise in NC-ELISA OD. Additionally, the NC-ELISA appeared to be 
detecting a primary response to nucleocapsid antigen following virus challenge 
with a rise to peak OD occurring between 7 and 21 days p.c. 
This study has demonstrated that the NC-ELISA can be used for the 
detection of PRV infection in vaccinated and non-vaccinated pigs. A major 
advantage of the NC-ELISA is its ability to identify infected pigs that may go 
undetected if tested with ELISAs based predominantly on glycoprotein antigens. 
A potential disadvantage of the NC-ELISA is its apparent inability to consistently 
detect PRV infections during the first 2 weeks after exposure. Furthermore, a 
PRV nucleocapsid based ELISA such as the one described here may be a 
significant tool in the ongoing national eradication program. It appears that the 
NC-ELISA may also be valuable for the long-term herd monitoring that will 
follow a successful eradication effort. 
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SECTION II; PRODUCTION AND EVALUATION OF RECOMBINANT 
POLYPEPTIDES DERIVED FROM THE BamHI-D FRAGMENT 
OF THE PSEUDORABIES VIRUS GENOME FOR USE AS 
DIAGNOSTIC ANTIGENS 
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The potential of two in vitro translation products representing truncated 
pseudorabies virus (PRV) major nucleocapsid proteins was studied. Two cDNA 
clones designated p462A and p462D, containing 0.8 and 1.0 kb cDNAs 
respectively were isolated by hybridization with ^^P-labelled BamHI-D fragment 
of the PRV genome. The BamHI-D restriction enzyme fragment encodes the 
major nucleocapsid proteins of PRV (B. Lomniczi, S. Watanabe, T. Ben-Porat, 
and A.S. Kaplan, J.Virol.61:796-801,1987.). Northern blot analysis showed 
that ^^P-labelled insert cDNA probes 462A and 462D hybridized to 1.5 and 4.4 
kb RNAs respectively in total RNA from PRV infected IVIDBK cells. Restriction 
enzyme analysis and sequence comparison of cDNA 462D with the published 
PRV 142k major capsid protein gene sequence (MCP) (S. Yamada, T. Imada, W. 
Watanabe, Y. Honda, S. Nakajima-lijima, Y. Shimizo, and K. Sekikawa, Virology 
185:56-66,1991.) shows that cDNA 462D encodes the carboxy terminal 215 
amino acids of the PRV 142K MCP. In vitro transcription and translation of 
cDNA 462A yielded a polypeptide doublet with a molecular weight of 19 and 
21k. Similarly, cDNA 462D produced a single polypeptide with a molecular 
weight of 24 k. Pseudorabies virus infection was detected by 
radioimmunoprecipitation in 21 of 23 pigs when reactions with both in vitro 
translation products were considered. Sera from 15 of 23 PRV infected pigs 
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immunoprecipitated the 462A polypeptide doublet, while sera from 16 of 23 
pigs immunoprecipitated the 462D polypeptide. In addition, sera from 4 of 4 
PRV low dose challenged (10^ PFU) pigs immunoprecipitated both translation 
products beginning at day 14 p.i. and continuing to the last day tested, day 60 
PALL* 
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INTRODUCTION 
Pseudorabies virus (PRV) is a member of the family Herpesviridae, sub 
family alphaherpesvirinae, and is the etiological agent of the disease 
pseudorabies (9). An important characteristic of PRV is its ability to persist in 
the host in a latent state. As a consequence, the reactivation and subsequent 
dissemination of latent PRV has a tremendous impact on efforts to control the 
spread of this economically important disease. 
Vaccines have traditionally been an integral part of PRV control programs 
(18). They have been used to retard the spread of the virus and to prevent 
imminent outbreaks of disease within herds. Pigs that have received traditional 
vaccines are to be regarded as potential carriers of the virus because, although 
the vaccines prevent disease, they do not prevent infection and the latent state 
that follows. As a result, these PRV vaccinated pigs are considered virus 
infected and their movement in normal trade patterns is restricted. 
Recent advances in vaccine technology have led to the use of various 
marker vaccines in control programs (15). These vaccines are deletion mutant 
vaccines that lack one or more of the envelope glycoproteins gl, gill, or the 
nonstructural glycoprotein gX. It is now possible to identify vaccinated pigs 
that have been exposed to and possibly infected with virulent PRV. One 
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requirement associated with the use of marker vaccines and their companion 
diagnostic antigens is that complete vaccination records of individual pigs must 
be maintained and diagnostic laboratories must maintain the ability to perform 
all commercially available companion tests. The availability of a universal 
diagnostic antigen would make PRV testing simpler and less expensive. 
Although marker vaccines have been shown to be efficacious, recent 
studies have shown that in vivo recombination between live deletion mutant 
vaccines and virulent challenge virus does occur (11,12,14). Therefore, a 
potential for the emergence of virulent marker negative strains of PRV in the 
field exists. These concerns may lead to a future trend minimizing the use of 
live vaccines wherever possible. Consequently, PRV live vaccines may be 
replaced with inactivated or recombinant subunit vaccines consisting of 
envelope glycoproteins. Previous work done in our laboratory demonstrates 
that PRV nucleocapsid proteins would be logical candidates as companion 
diagnostic antigens for subunit vaccines (19,20). 
The studies presented here describe the cloning and in vitro translation of 
truncated nucleocapsid protein genes and demonstrates that the truncated 
polypeptides are recognized by PRV infected pigs. Earlier work by Lomniczi, et 
al. demonstrated that the 3 major nucleocapsid proteins of PRV are encoded 
within the BamHI-D fragment of the PRV genome (16). In the present study we 
describe the use of the BamHI-D fragment to identify cDNAs representing these 
75 
coding sequences. Two BamHI-D positive cDNA clones were selected for in 
vitro transcription and translation experiments. The immunoreactivity of the 
translation products was determined using radioimmunoprecipitaion and SDS-
PAGE with nucleocapsid specific polyclonal rabbit antiserum and PRV positive 
pig serum from experimentally infected and field exposed animals. 
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MATERIALS AND METHODS 
Virus and cell culture 
Pseudorabies strain Be (22) was used for antigen production, viral 
DNA/RNA isolation, and virus challenge. Madin-Darby bovine kidney (MDBK) 
cells were used for these purposes. Growth and maintenance medium was 
Duibecco's modified Eagle's medium (Gibco-BRL) supplemented with 10% and 
1 % heat inactivated fetal bovine serum (Hyclone Laboratories) respectively. 
Serum virus neutralization assay 
Serum virus neutralization (SN) was performed on all serum samples as 
previously described (21). 
PRV nucleocapsid Isolation 
Nonenveloped PRV nucleocapsids were isolated using a modification of 
the methods of Gibson and Roizman (7), and Stevely (24) as previously 
described (3,19). 
Enzyme-linked Immunosorbant assay (ELISA) 
An indirect nucleocapsid ELISA (NC-ELISA) was used as previously 
described (3). Baseline ELISA OD's were determined using sera from 28 
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certified PRV negative pigs. Negative values ranged from 0.010 to 0.110. 
Accordingly, the maximum negative value was set at 0.110 and a minimum 
positive threshold was set at 0.200. Values in between were considered 
suspect and were retested. Reported reactions are based on these criteria and 
represent 4 separate experiment replications. The commercial PRV screening 
ELISA (Herdcheck; Idexx, Corp.) was used according to the manufacturer's 
directions. 
Enzymes, buffers, and standards 
All enzymes, reaction buffers, and molecular size standards were 
obtained from Bethesda Research Laboratories unless otherwise noted. All 
enzymes were used as directed by the supplier. 
RNA preparation 
Total cellular RNA was obtained using a standardized RNA extraction 
system (Amersham). Briefly, PRV infected or mock infected MDBK cells were 
harvested at 6 h post-infection (p.i.) and disrupted by sonication (Sonifier Cell 
Disrupter 350; Branson Sonic Power Co.) in the presence of gaunidinium 
thiocyanate (5). Total RNA was separated from DNA by lithium chloride 
precipitation and purified by phenol extraction and ethanol precipitation (4). 
Poly (A)^ RNAs were selected by oligo-dT cellulose column chromatography (1). 
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cDNA synthesis and plasmid library construction 
A cDNA library was constructed from PRV infected cell poly (A)+ RNA 
harvested at 6 h p.i. using a commercially available integrated kit (Librarian II; 
Invitrogen). cDNA synthesis was performed using the method of Gubler and 
Hoffman (8) with oligo-dT priming. cDNAs were fitted with non-palindromic 
BstXI linkers and size selected by gel electrophoresis and electroelution for 
species ^ 500bp. Size selected cDNAs were ligated into the BstXI site of a 
plasmid vector pcDNAII (Invitrogen). Vector constructs were used to transform 
competent E coU strain INVa' by the method of Hanahan (10). Ampicillin 
resistant, B-galactosidase negative colonies were retained for colony-blot 
hybridization screening. 
PRV BamHI-D fragment probe preparation 
A BamHI-D fragment probe was generated from PRV BamHI restriction 
enzyme digested genomic DNA (Figure 1). Genomic PRV DNA was purified by 
Hirt extraction (13) and digested to completion with BamHI. Restriction 
digested genomic DNA was electrophoresed in a 0.7% agarose gel (Sea Kem 
GTG; FMC BioProducts) overnight at 25V in Tris acetate EDTA. The BamHI-D 
fragment was visualized by ethidium bromide staining, excised from the gel, 
and electoeluted by standard methods (17). Purified BamHI-D fragment was 
cloned into BamHI digested pUC19 and used to transform competent E. coli 
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Figure 1. Organization of the pseudorabies virus (PRV) genome and genomic 
restriction fragment BamHI-D. (A): Schematic representation of 
the PRV genome and BamHI restriction enzyme map, (B): 
Restriction enzyme map of the BamHI-D fragment of the PRV 
genome. Restriction enzyme abbreviations: Bg = Bgl II, 
Bm= BamHI, Nc= Ncol. The Ncol restriction enzyme fragments 
are lettered according to kilobase size ( a = largest fragment, 
g= smallest fragment). 
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strain DH5a. A bacterial clone containing a BamHI-D fragment construct was 
identified by restriction enzyme analysis with BamHI and was designated 
pN111D. To obtain the entire BamHI-D fragment DNA free of vector 
contamination, pN111D was digested with EcoRi and Bglll to obtain the 4.4 kb 
Bglll subfragment of BamHI-D (the EcoRI site of the pUC19 multiple cloning site 
was used). Similarly, pN111D was digested with Hindlll and Bglll to obtain the 
5.6 kb Bglll subfragment of BamHI-D. Both BamHI-D subfragments were 
purified by electroelution from agarose gels and labelled with [a-]®^P-dCTP by 
random hexamer priming. Subsequent cDNA insert probes were also purified 
and labelled in this way. 
Colony-blot screening of cDNA libraries 
Bacterial colonies were transferred from agar plates to nylon filter disks 
(Hybond-N; Amersham) by colony lift. Bacterial DNA was fixed, denatured, and 
neutralized by placing filters for 5 minutes each on Whatman 3MM sheets 
soaked with 10% sodium dodecyl sulfate (SDS), 1.5M NaCI - 0.5M NaOH, and 
1.5M Tris, pH 8.0 respectively. Filters were air dried for 30 minutes and baked 
in a vacuum oven at 80°C for 90 minutes. Colony-blots were prehybridized for 
4 hours at 65°C in hybridization buffer consisting of 3X SSPE (IX SSPE is 
150mM NaCI, lOmM sodium phosphate, and 1.0 mM EDTA, pH 7.4), 5X 
Denhardt's (IX Denhardt's is 0.02% each bovine serum albumin, Ficoll, and 
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polyvinylpyrrolidone), and 100 //g / ml denatured salmon sperm DNA. 
Hybridization was carried out overnight at 65°C in fresh hybridization buffer 
with 10® cpm of boiled ®^P-labelled BamHI-D probe DNA (Figure 1). Filters were 
washed once with 2X SSPE, 0.1% SDS for 30 minutes and twice with 0.1X 
SSPE, 0.1 % SDS for 30 minutes at 68°C and exposed to X-ray film (Kodak 
XOMAT) at -70®C with intensifying screens. 
Characterization of cDNA clones 462A and 462D 
Genomic PRV DNA digests (10//g), purified PRV BamHI-D fragment (2//g), 
and purified cDNA inserts (2//g) were electrophoresed on 1 % agarose gels. 
Southern blot analysis of these gels was performed as follows. Separated DNA 
fragments were denatured in 1.5M NaCI - 0.5M NaOH for 45 minutes and 
neutralized in 1.5 M NaCI - 1.5M Tris, pH 8.0 for 45 minutes. DNA fragments 
were transferred in 20X SSPE overnight to a nylon membrane (Hybond-N; 
Amersham), rinsed briefly in 2X SSPE, air dried 30 minutes, and baked in a 
vacuum oven at 80°C for 90 minutes. The membranes were hybridized and 
exposed to film as described above. Southern blot hybridization was performed 
with probes having a minimum specific activity of 50 x 10® dpm ///g DNA. 
Northern blot analysis was performed as follows. Total (15//g) RNA 
samples from mock and PRV infected IVIDBK cells were denatured by heating to 
75°C for 15 minutes in RNA sample buffer consisting of 50% formamide, 2.2M 
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formaldehyde, ImM EDTA, 1 mg/ml ethidium bromide and lOmM sodium 
phosphate pH 7.4. Denatured RNAs were electrophoresed through 1 % agarose 
gels containing 2.2M formaldehyde in 10 mM sodium phosphate running buffer, 
pH 7.4. Separated RNAs were transferred directly in 20X SSPE overnight to 
nylon membranes. Hybridization was performed as described for Southern blot 
analysis except that RNA hybridization buffer consisting of 50 % formamide, 
6X SSPE, 5X Denhardt's, and 100//g / ml each of denatured salmon sperm DNA 
and tRNA and a hybridization temperature of 50°C was used. 
Limited sequence analysis of the cDNA clones in the plasmid vector 
pcDNAII was performed by the dideoxy chain termination method (23) with Taq 
DNA polymerase, [a-]®®S-dATP, and Sp6 and T7 specific primers (Promega). 
Dried sequencing gels were exposed to X-ray film overnight at -70®C. Each 
sequence determination was repeated 3 times. 
In vitro transcription and translation 
RNA transcription in vitro was performed using Sp6 and T7 RNA 
polymerases and the Geminii core system (Promega). Selected cDNA clones 
were linearized with Xhol or Hindi!! for generation of Sp6 or T7 directed 
transcripts respectively. Approximately 5-10//g of capped RNA's were 
produced from 1//g of linearized DNA template using supplier protocols. 
Template DNA was degraded with RNase-free DNase and the reaction mixtures 
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were extracted with phenol and ethanol precipitated. Transcript sizes and 
quantities were estimated by 1 % agarose, 2.2M formaldehyde gel 
electrophoresis with RNA standards. 
RNA transcripts were translated in vitro in a rabbit reticulocyte lysate in 
vitro translation system (Promega). RNAs were heated at 65°C for 15 minutes 
prior to translation to minimize secondary structure. Reaction mixes containing 
SOOng of RNA, 0.8 mCi/ml of ®®S-methionine (1000 Ci/mmole; Amersham) and 
amino acids minus methionine were incubated at 30°C for 2 hours. Translation 
products were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and fluorography as described below. 
Radioimmunoprecipitation and SDS-PAGE 
Radioimmunoprecipitation and SDS-PAGE were performed as previously 
described (20). Briefly, approximately 10® cpm of pre-cleared labelled antigen 
was combined with 25 fj\ of test serum diluted 1:10 in 
radioimmunoprecipitation (RIP) buffer consisting of 10 mM Tris, pH 7.4, 
containing 1% Triton X-100, 1% sodium deoxycholate, and 0.1 % SDS. The 
mixture was adjusted to a total volume of 150 //I with RIP buffer and incubated 
overnight at 4°C. Antigen-antibody complexes were precipitated with 50 //I of 
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a 30% (v/v) solution of Sepharose CL4B-protein G (Pharmacia), and incubated 
at room temperature with mixing for 2 hours. The immune complexes were 
pelleted by microcentrifugation for 2 minutes and washed 6 times in RIP buffer. 
Washed immunoprecipitates were boiled for 4 minutes in sample preparation 
buffer (2% SDS, 4% 2-mercaptoethanol, 0.05% bromophenol blue, and 50% 
glycerol in 500 mM Tris, pH 6.8) and separated on 15% polyacrylamide gels at 
a constant current of 35 mA. Electrophoresed gels were fixed in 40% 
methanol/10% acetic acid/ 50% water, enhanced for fluorography (ENTENSIFY; 
DuPont/New England Nuclear), dried, and exposed to film at -70°C for 48 
hours. 
Evaluation of the Immunoreactivity of translated polypeptides 
The immunoreactivity of in vitro translation products was evaluated by 
radioimmunoprecipitation with rabbit antiserum prepared against purified PRV 
nucleocapsids and antisera from experimentally and naturally infected pigs. 
Pseudorabies virus nucleocapsid specific serum was prepared in New 
Zealand white rabbits. Purified nucleocapsids were emulsified in Freund's 
incomplete antigen at a concentration of 500 ng of nucleocapsid protein per 
dose. Each rabbit was boosted four times over a 6 month period. Normal 
rabbit serum was obtained prior to the first antigen injection. 
85 
Experimentally infected antiserum was prepared in 10 week old PRV-
negative crossbreed pigs. Four pigs were intranasally challenged with 10^ PFU 
of virus and serum was collected prior to challenge and periodically for 60 days 
after challenge. The appearance of a serum-virus neutralizing titer after 
challenge was used to indicate virus infection. 
Antisera from naturally infected pigs was obtained from the Iowa State 
University Veterinary Diagnostic Lab. All samples were had detectable serum-
virus neutralization titers and were positive by a commercially available PRV 
screening ELISA. The PRV vaccination histories of these pigs were not 
available. A total of 23 samples were analyzed. 
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RESULTS 
Analysis of plasmid cDNA library 
A cDNA library containing approximately 10^ ampicillin resistant bacterial 
colonies was screened by colony-blot hybridization with ^^P-labelled PRV 
BamHI-D fragment. Two stable hybridization positive clones containing 
plasmids designated p462A and p462D were retained for further study. 
Plasmids p462A and p462D contained cDNA inserts of 800 and 910 kbp 
respectively as determined by agarose gel electrophoresis with Hindlll digested 
lambda bacteriophage, 1 kb ladder, and 123bp ladder DNA standards. 
Characterization of cDNAs 462A and 462D 
The results of colony-blot hybridization were confirmed by Southern blot 
hybridization between ^^P-labelled PRV BamHI-D fragment and cDNA inserts 
462A and 462D (Lanes 3 and 4, Figure 2B). These experiments show a cross-
hybridization between cDNAs 462A and 462D (Lanes 3 and 4, Figure 2C and 
2D). However, a stronger homologous hybridization signal is evident. Cross-
hybridization was eliminated in subsequent experiments (Figure 3) by using 
more stringent washing conditions. A Southern blot analysis of BamHI digested 
PRV genomic DNA, cloned PRV BamHI-D fragment, and cDNA inserts 462A and 
462D with ^'P-labelled PRV BamHI-D fragment was performed (Figure 2). 
Figure 2. Southern blot analysis of cDNA clones 462A and 462D. Panel (A): 
Etidium bromide stained agarose gel of BamHi digested PRV genomic 
DNA (Lane 1), purified BamHI-D fragment digested with Bglll 
(Lane 2), purified cDNA insert 462A (Lane 3), and purified cDNA 
insert 462D (Lane 4). Panel (B): the same samples transferred to 
nylon membranes and hybridized with "P-labelled BamHI-D. Panel 
(C): the same samples transferred to nylon membranes and 
hybridized with ®^P-labelled cDNA 462A. Panel (D): the same 
samples transferred to nylon membranes and hybridized with 
^^P-labelled cDNA 462D. Lane Kb: kilobase size markers. 
(*): denotes the location of the BamHI-D fragment. 
88 
AM 
89 
These experiments show that cDNAs 462A and 462D hybridize exclusively to 
the BamHI-D fragment of PRV genomic digests (Lane 1, Figure 2C and 2D). 
Furthermore, both 462A and 462D hybridize to the 4.1 kb Bglll subfragment of 
PRV BamHI-D (Lane 2, Figure 2C and 2D), indicating the RNA transcripts 
represented in these cDNAs are encoded in this subfragment of BamHI-D. 
In order to further map the location of cDNAs 462A and 462D within the 
4.1kb Bglll subfragment of BamHI-D, Ncol digestion of BamHI-D and Southern 
blot hybridization was performed using ®^P-labelled cDNAs 462A and 462D as 
probes (Figure 3). cDNA clones 462A and 462D both hybridize to a 1.7 kb 
Ncol fragment of the 4.1 kb Bglll subfragment of BamHI-D (Lanes 1 and 2, 
Figure 3C and 3D). 
Previous restriction enzyme mapping of the BamHI-D fragment and each 
Bglll subfragment has shown that the 4.1 kb Bglll subfragment of BamHI-D 
contains two adjacent co-migrating 1.7 kb Ncol fragments (Figure IB, 
fragments c and d). In order to determine which Ncol fragment each cDNA 
derived from, sequence comparison and restriction enzyme analysis of each 
cDNA relative to the published sequence for Ncol fragment c (fragment c 
encodes the 3' end of the PRV 142K major capsid protein (MCP) gene (25)) 
was performed. We were unable to demonstrate any shared sequence between 
Ncol fragment c and cDNA clone 462A. The sequence and hybridization data 
indicates that cDNA 462A derives from the co-migrating Ncol fragment d. 
Figure 3. Mapping of cDNA clones 462A and 462D within the PRV BamHI-D 
fragment. Restriction enzyme digestion was performed on PRV 
BamHI-D cloned in pUC19 (pN111D). Panel (A) is an ethidium 
bromide stained agarose gel of pN111D digested with Ncol, BamHI 
and Ncol, and Bglll (Lanes 1-3 respectively). Lanes 4 and 5 
contain purified cDNA inserts 462A and 462D respectively. 
Panels (B), (C), and (D) represent the same samples transferred to 
nylon membrane and hybridized with ^^P-labelled BamHI-D, 462A, 
and 462D respectively. Lane (Kb): kilobase size standards. 
(*): denotes the position of the pUC19 plasmid vector. The Ncol 
subfragments of BamHI-D are labelled by size a through g. 
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Conversely, the limited amount of sequence obtained from cDNA clone 462D is 
homologous with 3' end of PRV 142K MOP contained In Ncol fragment c. 
Furthermore, a restriction enzyme pattern predicted from the PRV 142K MOP 
sequence using the four single site enzymes Aval, Sad, Sail, and Tthi 111 was 
duplicated in cDNA 462D. 
Radiolabelled cDNA inserts from p462A and p462D and PRV BamHI-D 
were hybridized to total RNAs extracted from mock and PRV-infected tissue 
culture cells at 4 to 10 hours p.i. (Figure 4). These experiments showed that 
PRV BamHI-D probe hybridized to RNA species of approximately 4.4, 2.2, and 
1.5 kb in size. These results are similar to those described previously by 
Lomniczi, etal (16). cDNA probe 462A hybridizes to a 1.5 kb RNA species in 
total infected cell RNA. No hybridization between 462A and mock infected 
RNA was observed. cDNA probe 462D hybridizes to a 4.4 kb RNA species in 
total infected cell RNA. No hybridization between 462D and mock infected 
RNA was observed. 
Limited dideoxy chain termination sequence analysis of both strands of 
cDNAs 462A and 462D was done using Sp6 and T7 primers and primer 
sequences present in the cloning vector pcDNAII. The correct transcription 
orientation for each cDNA was also determined. cDNA 462A was sequenced 
for 144 and 108 bp from the Sp6 and T7 primers respectively. A poly(A)* 
track was located adjacent to the T7 primer site, but no ATG-Met translation 
Figure 4. Northern blot analysis of PRV and mock infected total RNA isolated from 4 to 10 hours after 
infection. In each panel. Lane 1 is total RNA from mock infected MDBK cells. Lanes 2 through 5 
represent total RNA isolated from PRV-infected MDBK cells at 4, 6, 8, and 10 hours after infection 
respectively. Panels (A), (B), and (C) were hybridized with ^^P-labelled PRV BamHI-D fragment, 
cDNA 462A, and cDNA 462D respectively. Lane (Kb): positions of RNA molecular size standards. 
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start site was found in the region sequenced. Similarly, cDNA 462D was 
sequenced for 143 and 83 bp from the Sp6 and T7 primers respectively. A 
poly(A)+ track was located adjacent to the T7 primer site and an ATG-Met 
translation start site was found adjacent to the Sp6 primer site. The G + C 
content of cDNAs 462A and 462D were 67 and 71% respectively compared to 
the overall PRV value of 73% (2). 
In vitro transcription and translation 
Linearized plasmids p462A and p462D containing cDNA inserts 462A 
and 462D respectively, were prepared for both Sp6 and T7 directed 
transcription (see Materials and Methods). The translation products from each 
RNA transcript were analyzed by SDS-PAGE (Figure 5). The 462A Sp6 
transcript was translated into a polypeptide doublet with molecular weights of 
19 and 21 k and the 462D Sp6 transcript was translated into a polypeptide 
with a molecular weight of 24 k. No translation products were produced from 
the T7 transcripts of 462A or 462D. 
Detection of antibodies to in vitro translation products 
The immunoreactivity of in vitro translation products with specific PRV 
and nucleocapsid positive antisera was evaluated by radioimmunoprecipitation. 
Specific rabbit anti-PRV nucleocapsid serum immunoprecipitated a 19 and 21 k 
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Figure 5. SDS-PAGE analysis of in vitro translation products from cDNA 462A 
and 462D Sp6 and T7 RNA transcripts. ®®S-methionine labelled 
translation products were analyzed by SDS-PAGE and fluorography. 
Lane (MW): positions of protein molecular weight markers. 
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polypeptide doublet from the 462A translation and a 24 k polypeptide from the 
462D translation mix (Figure 6). Normal rabbit serum obtained from the same 
rabbits prior to the preparation of anti-PRV nucleocapsid serum mix did not 
immunoprecipitate any polypeptides from either translation mix. 
The immunoreactivity of the cDNA translation products with PRV positive 
pig serum was evaluated using sera collected from 23 naturally infected pigs. 
These results are summarized in Table 1. All sera were found to have 
detectable antibody to native PRV nucleocapsid protein by the NC-ELISA. A 
representative immunoprecipitation of in vitro translation products 462A and 
462D with pig serum is shown in Figure 6. Sera from 15 of 23 naturally 
infected pigs immunoprecipitated the 19 and 21 k 462A polypeptide doublet. 
Similarly, sera from 16 of 23 naturally infected pigs immunoprecipitated the 
24k 462D polypeptide. Sera from 10 of 23 pigs immunoprecipitated both 
cDNA translation products, while sera from 2 of 23 pigs did not 
immunoprecipitate either product. 
Lastly, the antibody response of low dose experimentally infected pigs to 
the cDNA translation products over time was investigated. Sera was collected 
from 4 pigs intranasally challenged with 10^ PFU of PRV Be on day 0, 14, 30, 
and 60 p.i.. The results of this experiment are summarized in Table 2. Sera 
from all 4 pigs were found to have detectable antibody to native PRV 
nucleocapsid protein by the NC-ELISA from day 14 to 60 p.i.. All four pigs also 
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Figure 6. Immunoprecipitation of radiolabelled in vitro translation products 
encoded by cDNAs 462A and 462D. Normal rabbit serum (NRS), 
rabbit anti-PRV nucleocapsid serum (NC + ), PRV positive pig serum 
(PRV + ), and normal pig serum (NPS) was reacted with 
^^S-methionine labelled 462A and 462D in vitro translation 
products and analyzed by SDS-PAGE. 
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Table 1. Summary of the antibody responses of pseudorabies positive field 
exposed pigs to native and recombinant nucleocapsid polypeptides 
Pig SN ELISA resDonses RIP resDonses" 
# titer PrV-S" NC= 462A 462[ 
23 1 128 ( + ) ( + ) { + ) neg. 
13 1 256 { + ) ( + ) { + ) ( + ) 
152 1 64 { + ) ( + ) ( + ) neg. 
311 1 2 { + ) { + ) { + ) neg. 
1822 1 32 { + ) ( + ) ( + ) { + ) 
231 1 32 ( + ) ( + ) neg. neg. 
3424 1 256 ( + ) ( + ) ( + ) neg. 
24111 1 4 ( + ) ( + ) neg. { + ) 
773 1 256 ( + ) ( + ) ( + ) ( + ) 
775 1 32 ( + ) ( + ) ( + ) neg. 
7715 1 32 ( + ) ( + ) neg. ( + ) 
7722 1 16 ( + ) ( + ) { + ) ( + ) 
7726 1 16 ( + ) { + ) { + ) ( + ) 
781 1 16 ( + ) { + ) { + ) ( + ) 
782 1 32 ( + ) { + ) { + ) ( + ) 
7822 1 8 ( + ) { + ) neg. ( + ) 
7824 1 32 ( + ) { + ) ( + ) ( + ) 
7827 1 16 ( + ) { + ) neg. neg. 
952 1 4 ( + ) { + ) neg. { + ) 
954 1 8 ( + ) { + ) neg. { + ) 
956 1 4 ( + ) { + ) ( + ) { + ) 
958 1 4 { + ) { + ) neg. { + ) 
9510 1 8 { + ) ( + ) ( + ) ( + ) 
"Radioimmunoprecipitation of ®®S-methionine labelled in vitro translation 
products. ( + ) = presence of a detectable signal on X-ray film, (neg.) = 
absence of a detectable signal on X-ray film. 
''Commercial ELISA responses (Herdchek: Idexx Corp.). ( + )= variable 
with each test as determined by manufacturer protocols. 
°NC-ELISA responses. ( + )= OD greater than 0.200 (see Materials and 
Methods) 
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Table 2. Summary of the antibody responses of experimentally infected pigs 
to native and recombinant nucleocapsid polypeptides following 
virus challenge of 10^ ° plaque-forming units of virulent pseudorabies 
virus strain Be. 
Pig days SN ELISA resDonses RIP responses" 
# p.c. titer PrV-S" NC 462A 462D 
1 0 neg. neg. neg. neg. neg. 
14 1:16 { + ) ( + ) { + ) { + ) 
30 1:32 ( + ) { + ) { + ) { + ) 
60 1:64 ( + ) ( + ) { + ) { + ) 
2 0 neg. neg. neg. neg. neg. 
14 1:16 ( + ) ( + ) ( + ) { + ) 
30 1:128 ( + ) ( + ) ( + ) { + ) 
60 1:64 ( + ) ( + ) (4 . )  { + ) 
3 0 neg. neg. neg. neg. neg. 
14 1:32 ( + ) ( + ) ( + ) { + ) 
30 1:64 ( + ) { + ) { + ) ( + ) 
60 1:32 { + ) { + ) { + ) ( + ) 
4 0 neg. neg. neg. neg. neg. 
14 1:16 ( + ) { + ) { + ) ( + ) 
30 1:64 ( + ) { + ) { + ) ( + ) 
60 1:32 ( + ) { + ) ( + ) ( + ) 
'Radioimmunoprecipitation of ^^S-methionine labelled in vitro translation 
products. ( + ) = presence of a detectable signal on X-ray film, (neg.) = 
absence of a detectable signal on X-ray film. 
•"Commercial ELISA responses {Herdchek: Idexx Corp.). { + )= variable 
with each test as determined by manufacturer protocols. 
°NC-ELISA responses. ( + )= OD greater than 0.200 (see Materials and 
Methods) 
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immunoprecipitated the translation products from 462A and 462D from day 14 
to 60 p.i. No immunoprecipitation was detected in any serum collected on day 
0. 
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DISCUSSION 
The results presented in this study show that two in vitro translation 
products encoded by cDNA clones, 462A and 462D, are recognized by antisera 
from PRV infected pigs. Our studies further indicate that these two 
polypeptides are truncated nucleocapsid proteins. This assertion is supported 
by our experimental evidence and the work of others. We have shown that 
cDNAs 462A and 462D hybridize exclusively with the BamHI-D fragment of 
PRV genomic DNA digestions (Figure 2). Others have shown that only four 
mRNAs are transcribed from the PRV BamHI-D fragment (5.5, 4.4, 2.1, and 
1.5kb transcripts) and they encode the three major nucleocapsid proteins 
(142k, 62k, and 32k molecular weight) (6,16,25). In addition, our Northern 
blot experiments show that cDNAs 462A and 462D hybridize to RNAs of 
approximately 1.5 and 4.4kb from PRV infected cell RNA isolated at 4 to 10 
hours p.i. when the major nucleocapsid protein transcripts are abundantly 
expressed (Figure 4). Lastly, the polypeptides translated from cDNAs 462A and 
462D are immunoprecipitated by PRV nucleocapsid specific rabbit serum and 
PRV infected pig serum (Figure 6). 
These studies also addressed the question of which native PRV 
nucleocapsid protein are in part represented by the truncated in vitro translation 
products. At the nucleic acid level, restriction enzyme analysis, sequence 
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comparison , and hybridization studies showed that cDNA clone 462D 
represents the 3' end of the PRV 142k MCP gene, encoding the carboxy 
terminal 215 amino acids of this capsid protein. The same experimental 
protocol has shown that cDNA clone 462A derives from the 1.7 kb Ncol (c) 
fragment of PRV BamHI-D and represents a portion of a 1.5 kb RNA transcript 
from PRV infected cells. This evidence indicates that cDNA 462A may 
represent a portion of the 32k MCP gene. Alternatively, 462A may represent a 
portion of a hitherto undescribed 1.5 kb transcript from the BamHI-D fragment 
of the PRV genome. 
The most important aspects of our study were those directed at 
ascertaining if antibody from PRV infected pigs would recognize the in vitro 
translation products we generated. Demonstrations of in vitro translation 
products immunoreactivity with sera collected from PRV infected pigs would 
indicate that recombinant polypeptides representing PRV nucleocapsid proteins 
could be used as diagnostic antigens. Our study detected PRV antibody in 21 
of 23 (91 %) naturally infected pigs using both translation products indicating 
that recombinant PRV nucleocapsid polypeptide combinations can be used to 
reliably detect PRV infection. 
The fact that all pigs did not have serum antibody capable of 
immunoprecipitating the in vitro translation products was not unexpected. The 
in vitro translation products described here are truncated polypeptides 
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containing a limited number of the epitopes present in the native protein. 
Furthermore, certain epitope confirmations may differ between the truncated 
and native forms of the protein. As a result, antibodies from some pigs may be 
incapable of reacting with epitopes or epitope confirmations present on the in 
vitro translation products. In addition, it has been demonstrated that antibody 
responses directed against the PRV 142k MCP are more variable than those 
directed against other PRV nucleocapsid proteins and envelope glycoproteins 
(19,25). 
Our studies have also demonstrated that PRV antibody in experimentally 
infected pigs could be detected by day 14 p.i. with either translation product. 
Most importantly these experiments showed that low dose PRV exposure (10^ 
PFU), could be detected using these in vitro translation products. This is 
important because a low dose PRV challenge has been shown to be harder to 
detect and it is a better reflection of natural exposure levels among vaccinated 
pigs (18). 
Overall these studies demonstrated that truncated PRV nucleocapsid 
polypeptides could be used to detect PRV infection in naturally and 
experimentally infected pigs. However, these studies also showed that a 
combination of these products were required to achieve a 91 % detection rate. 
These findings are in agreement with our previous studies using PRV native 
nucleocapsid proteins to detect infection (19). In those studies, consideration 
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of antibody responses to a combination of native nucieocapsid proteins 
enlianced detection efficiency. It is therefore not surprising that a combination 
of recombinant polypeptides may be required for reliable detection of PRV 
infection. 
Attempts to express cDNAs 462A and 462D in a high-level eukaryotic 
expression system are underway. Greater yields of both recombinant 
polypeptides will facilitate future studies to specifically design diagnostic assays 
such as the ELISA for large-scale detection of PRV infection. In addition, it is 
anticipated that cDNAs 462A and 462D will be as probes to identify larger or 
full length cDNA clones. 
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SUMMARY AND CONCLUSIONS 
Pseudorabies virus (PRV) is tlie etiological agent of pseudorabies, a swine 
disease with economically devastating potential. Acute disease episodes are 
followed by the establishment of latency in surviving animals. Efforts to control 
this disease have centered on vaccination and serological monitoring. However, 
pigs that received traditional vaccines had to be regarded as potential carriers of 
the virus because although the vaccines prevented disease they did not 
routinely prevent infection and the establishment of latency. 
Today's deletion mutant vaccines make it possible to identify vaccinated 
pigs that have been exposed to and possibly infected with the virus. However, 
individual vaccines require specific companion diagnostic tests. Consequently, 
extensive recordkeeping is required when using these vaccines in order to avoid 
false test reactions. These concerns and recently reported vaccine virus and 
field virus recombination events may lead to the elimination of live virus 
vaccines. It is likely that live vaccines will be replaced with inactivated or 
recombinant subunit vaccines consisting of envelope glycoproteins. Previous 
work done in our laboratory demonstrates that PRV nucleocapsid proteins 
would be logical candidates as companion diagnostic antigens with glycoprotein 
based subunit vaccines (59). In view of this, the studies contained in this 
dissertation were undertaken to: 1 ) develop and evaluate a test format for a 
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PRV nucleocapsid-based diagnostic antigen, and 2) attempt to isolate and 
express a major nucleocapsid protein or a truncated thereof for use as a 
diagnostic antigen. 
In the first study, the efficacy of a PRV nucleocapsid protein based ELISA 
(NC-ELISA) for detecting PRV infection was evaluated. In doing so, the NC-
ELISA was compared to a standard commercially available PRV screening ELISA 
for the ability to detect natural and experimental PRV infection. Lastly, the NC-
ELISA was evaluated for use with an envelope glycoprotein subunit vaccine to 
detect PRV infection of vaccinated pigs. 
Five PRV negative pigs were experimentally infected by intranasal 
challenge with virulent PRV. Sera obtained by periodic sampling was tested for 
PRV specific antibody using the NC-ELISA and the commercial screening ELISA. 
The NC-ELISA detected PRV nucleocapsid specific antibody between 14 and 21 
days after challenge. The commercial ELISA detected PRV antibody 1 week 
earlier. The earlier detection of the commercial ELISA is likely a reflection of 
the antigen composition of the assay and the kinetics of the porcine antibody 
response to PRV proteins. The commercial ELISA antigen is largely composed 
of PRV envelope glycoprotein and antibody responses to these proteins have 
been shown to be detected as early as 4 to 7 days after PRV exposure (109). 
By contrast, the NC-ELISA antigen is composed of highly purified unenveloped 
113 
PRV nucleocapsids. The antibody response of pigs to these proteins has been 
shown to arise much later after PRV infection (59). 
The ability of the two ELISAs to detect natural PRV infection was also 
evaluated. The NC-ELISA detected PRV antibody in 23 of 24 naturally infected 
pigs. The commercial ELISA failed to detect antibody in 3 pigs identified as 
PRV infected by the NC-ELISA. Serum from all three pigs immunoprecipitated 
radiolabelled PRV protein while negative control pig serum did not which 
confirmed the results of the NC-ELISA. It is possible that these pigs had been 
infected an extended period of time and antibody to the envelope glycoproteins 
may have declined below detectable levels. The response of the 3 pigs to the 
nucleocapsid proteins suggests that these proteins may be more effective in 
detecting antibody to long standing infection. 
The ability of the NC-ELISA to function as a differential diagnostic test in 
conjunction with a PRV envelope glycoprotein subunit vaccine was also 
demonstrated. Ten pigs were immunized with subunit vaccine and then 
challenged with a low dose of virulent PRV (10" PFU). Nucleocapsid specific 
antibody was detected in all pigs by day 21 after challenge and was still 
detectable at 113 days after challenge. These results are particularly important 
because the NC-ELISA was able to detect low dose PRV infection which 
represents more closely the natural exposure doses that vaccinated pigs 
encounter in the field. 
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Overall, this first study showed that the NC-ELISA can function as a 
differential companion diagnostic test with an PRV envelope glycoprotein 
subunit vaccine. This work has also shown that the NC-ELISA may be useful in 
detecting PRV infections after levels of SN or envelope glycoprotein antibody 
have decayed below detectable levels. However, the apparent inability of the 
NC-ELISA to detect early PRV infection is a potential disadvantage. 
The second study contained in this dissertation describes the cloning and 
in vitro translation of truncated major nucleocapsid proteins and demonstrates 
that these expression products are recognized by PRV infected pigs. Efforts to 
clone the PRV major nucleocapsid protein genes were undertaken because the 
production of native nucleocapsid protein by traditional methods is not cost 
effective for widespread application. 
The results of this study show that two in vitro translation products 
encoded by cDNA clones, 462A and 462D, are recognized by antisera from 
PRV infected pigs. This study further suggests that these two polypeptides are 
truncated nucleocapsid proteins. This possibility is supported by the 
experimental evidence presented in this study and the previous studies of other 
researchers. 
The two cDNAs 462A and 462D hybridize exclusively with the BamHI-D 
fragment of PRV genomic DNA digestions. Previous studies have shown that 
only four mRNAs are transcribed from the PRV BamHI-D fragment and they 
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encode the three major nucleocapsid proteins (142k, 62k, and 32k molecular 
weight) (17,48). These findings strongly indicate that cDNAs 462A and 462D 
represent portions of major PRV nucleocapsid protein genes. 
The results of Northern blot analysis show that cDNAs 462A and 462D 
hybridize to RNAs of approximately 1.5 and 4.4kb from PRV infected cell RNA 
isolated at 4-10 hours p.i. when the major nucleocapsid protein transcripts are 
abundantly expressed. These two RNA transcript sizes match two of the major 
nucleocapsid protein transcripts from the BamHI-D fragment (17,48). 
Additionally, sequence comparison and restriction enzyme analysis show that 
cDNA 462D represents the 3' end of the PRV 142K major capsid protein gene, 
encoding the carboxy terminal 215 amino acids of this capsid protein. In the 
case of cDNA 462A, Northern blot data indicates that this clone may represent 
a portion of the PRV 32K major capsid protein or a portion of a hitherto 
undescribed 1.5 kb RNA transcript originating from the BamHI-D fragment of 
the PRV genome. 
Lastly, when the in vitro RNA transcripts transcribed from cDNAs 462A 
and 462D are translated in vitro, 462A produces a polypeptide doublet with a 
molecular weight of 19 and 21 k and 462D produces a polypeptide with a 
molecular weight of 24 k. Both polypeptides are immunoprecipitated with 
serum from PRV infected pigs indicating that they represent PRV proteins. In 
addition, both polypeptides are immunoprecipitated by rabbit serum prepared 
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against purified PRV nucleocapsids. This indicates a specificity for PRV 
nucleocapsid protein. 
The immunoreactivity of cDNA in vitro translation products with sera 
collected from PRV infected pigs demonstrates that recombinant polypeptides 
representing PRV nucleocapsid proteins can be used as diagnostic antigens. 
This study showed that PRV antibody was detected in 21 of 23 (91 %) naturally 
infected pigs using both translation products. It is important to note that 
consideration of antibody responses to both translation products was required 
to achieve a 91 % detection rate. These findings are in agreement with 
previous studies from this laboratory using PRV native nucleocapsid proteins to 
detect infection (59). In those studies, antibody responses to a combination of 
native nucleocapsid proteins enhanced detection efficiency. Also, since these 
polypeptides represent truncated proteins, the fact that all pigs did not respond 
to them was not unexpected. The truncated forms contain a limited number of 
epitopes and individual pigs may not respond to some epitopes. 
These immunoreactivity studies also showed that low dose PRV exposure 
(10^ PFU), could be detected using these in vitro translation products. This is 
an important consideration because the low dose challenge has been shown to 
be harder to detect and it is a better reflection of natural exposure doses that 
occur in the field (58). All diagnostic tests for PRV must be sensitive enough to 
reliably detect a low dose virus infection. 
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An on going effort in this laboratory will attempt to express cDNAs 
462A and 462D in a high-level eukaryotic expression system. It is anticipated 
that greater amounts of both recombinant polypeptides will be produced. 
Greater amounts of both truncated polypetides will facilitate future studies to 
determine if combinations of recombinant PRV nucleocapsid proteins can be 
used in various diagnostic assay formats. However, the work described in this 
dissertation has set the stage for the use of recombinant nucleocapsid proteins 
as diagnostic antigens in conjunction with PRV glycoprotein subunit vaccines. 
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APPENDIX A. PROTOCOLS FOR THE ISOLATION, PURIFICATION, AND 
SYNTHESIS OF NUCLEIC ACIDS 
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Small scale olasmid DNA isolation (mini-prep boiling method) 
The following procedure is designed for the rapid preparation of small 
quantities of plasmid DNA from a large number of transformed bacterial 
cultures. A small volume of overnight broth culture will yield 2-25 //g of 
plasmid DNA depending on the size and copy number of the plasmid to be 
isolated. 
Required Equipment: 
- Microcentrifuge 
- Vortex 
- Boiling water bath 
- 1.5ml centrifuge tubes (Eppendorf tubes) 
- Autoclaved and dried toothpicks 
- Vacuum centrifuge or dessicator 
Required Reagents: 
- Luria-Bertani broth with antibiotics (see Appendix D) 
- STET plasmid mini-prep buffer (see Appendix D) 
- Lysozyme (Boehringer Mannheim Biochemicals) 
- Tris, 10 mM, pH 8.0 (see Appendix D) 
- Sodium acetate, 3 M (see Appendix D) 
- Isopropanol 
- DNase-free RNase T1 (Bethesda Research Laboratories) 
133 
- 70% ethanol 
- TE, pH 8.0 (see Appendix D) 
- Chloroform:isoamyl alcoliol (see Appendix D) 
- Tris-saturated phenol (see Appendix D) 
Protocol: 
1. Inoculate 2-5 ml of broth containing the appropriate selective 
antibiotic with a single colony of interest. Incubate overnight at 
37°C with agitation. 
2. Fill a 1.5 ml tube with the overnight culture and pellet the bacteria by 
centrifugation for one minute in a microcentrifuge. 
3. Aspirate the supernatant and resuspend the pellet in 350 //I of STET 
plasmid mini-prep buffer. 
4. Prepare a fresh solution of 10 mg/ml lysozyme in 10 mM Tris pH 
8.0. Add 25 fA of lysozyme to each mini-prep tube. Vortex 
thoroughly. 
5. Place the tubes in a boiling water bath for 45 seconds. 
6. Centrifuge immediately for 10 minutes at room temperature in a 
microcentrifuge. 
134 
7. Remove the white pellet (containing denatured chromosomal DNA 
and bacterial cell components) with a toothpick and discard. 
8. Phenol/chloroform extract the supernatant as outlined below: 
- Mix equal volumes of tris-saturated phenol and 
chloroform/isoamyl alcohol in a volume appropriate for 
sample number. Each sample will require 400 //I of 
phenol/chloroform. 
- Add 400 //I of phenol/chloroform to each sample and mix phases 
by vortexing vigorously. 
- Separate the phases by centrifugation in a microcentrifuge for 2 
minutes. 
- Remove the upper aqueous phase to a new tube. Take care not 
to disturb the material at the interface. 
9. Precipitate the plasmid DNA by adding 30 //! of 3 M sodium acetate 
and 420 /j\ of isopropanol. Mix thoroughly by vortexing and 
freeze at -70°C for 1-4 hours. 
10. Microcentrifuge the samples for 30 minutes at 4°C. Wash the pellet 
with 70% ethanol and dry for 3-5 minutes in a vacuum centrifuge 
or desiccator. 
11. Resuspend the pellet in 25 /j\ of TE containing 100 units of RNaseTI 
and incubate at 37°C for 30 minutes. 
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Larae/medium scale plasmid DNA isolation (Qiaaen method) 
in many cases a large or medium-scale preparation of plasmid DNA is 
desired. The method chosen here utilizes a commercial anion-exchange 
chromatography system called Qiagen. High purity plasmid DNA is obtained 
selective elution with differing NaCI concentrations. Briefly, bacterial lysates 
are adsorbed to the resin, impurities are washed away with a low salt solution 
and plasmid DNA is obtained by elution with a high salt buffer. This is a double 
protocol based on the protocols set forth by Qiagen. For large-scale plasmid 
preparations involving 150-500 ml of bacterial broth culture all volumes are in 
bold type. For medium-scale plasmid preparations involving 30-150 ml of 
bacterial broth culture all volumes appear in normal type. 
Required Equipment: 
- Low speed centrifuge capable of 2,000 x g 
- 50 ml conical polypropylene centrifuge tubes 
- High speed centrifuge capable of 20,000 x g 
- 25 ml and 50 ml Corex glass screwcap tubes 
- Qiagen anion exchange columns, tip 100 or 500 size 
- Ring stand and small diameter ring clamp 
- Vacuum centrifuge or desiccator 
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Required Reagents: 
- 30-500 ml of bacterial broth culture containing the plasmid to be 
Isolated 
- Qiagen buffers: PI, P2, P3, QBT, QC, and QF (see Reagents and 
Solutions section) 
- Isopropanol 
- 70% ethanol 
- TE buffer, pH 8.0 (see Appendix D) 
Protocol: 
1. Spin out the bacterial cells at 2,000 x g in 50 ml conical 
polypropylene tubes. 
2. Combine the pellets from all tubes and resuspend in 4.0 or 10.0 ml 
of PI buffer and transfer to a 25 or 50 ml Co rex tube. 
3. Add 4.0 or 10.0 ml of P2 buffer, mix by gently inverting 10 times, 
and allow to sit 5 minutes at room temperature. 
4. Add 4.0 or 10.0 ml of P3 buffer, mix immediately by gentle 
inversion, and centrifuge at 4®C for 30 minutes at 20,000 x g. 
5. During centrifugation equilibrate a tip-100 or tip-500 column with 
3.0 or 10.0 ml of QBT buffer by gravity flow. 
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6. Following centrifugation, remove the supernatant fluid and apply it to 
the pre-equilibrated Qiagen column. Allow the supernatant to 
enter the column by gravity flow. 
7. Wash the tip-100 with two 5.0 ml aliquots of QC buffer or wash the 
tip-500 with three 15.0 ml aliquots of QC buffer. 
8. Elute the plasmid DNA with 5.0 or 15.0 ml of QF buffer. 
9. Precipitate the plasmid DNA with 0.7 volumes of room temperature 
isopropanol, allow to sit at room temperature 2-4 hours, and pellet 
the DNA by microcentrifugation at 4°C for 30min. 
10. Wash the DNA pellet with 70% ethanol and dry for 3-5 minutes in a 
vacuum centrifuge or desiccator. 
11. Resuspend the pellet in an appropriate volume of TE, pH 8.0 buffer. 
138 
Extraction of viral DNA (Hirt procedure); 
The following is a procedure for isolating viral DNA from total infected cell 
DNA. The protocol is designed for DNA viruses that replicate to high titer in the 
nuclei of infected cells (herpesviruses and adenoviruses). Infected cells are 
disrupted in a high NaCI, SDS, and proteinase K buffer. The cellular and viral 
proteins are degraded by the proteinase K. High molecular weight cellular DNA 
precipitate with the NaCI and SDS at 4°C and is removed by centrifugation. 
Low molecular weight viral DNA remains in solution and can be precipitated 
with ammonium acetate and 95% ethanol. 
Required Equipment: 
- 50 ml glass Corex centrifuge tubes 
- 25 ml glass Corex centrifuge tubes 
- 50 ml conical polypropylene centrifuge tubes 
- 37®C water bath 
- High speed centrifuge (capable of 27,000 x g) 
- Vacuum centrifuge 
Required Reagents: 
- 150 cm^ tissue culture flasks of infected cells 
- Hirt wash buffer (see Appendix D) 
- Hirt disruption buffer (see Appendix D) 
- Proteinase K (100//g/ml in distilled, deionized water) 
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- 5.0 M NaCI 
- 95% ethanol 
- 70% ethanol 
- TE buffer, pH 8.0 (see Appendix D) 
- 0.1 X TE buffer 
- 10 X TE buffer 
- DNase free RNase (100 //g/ml) 
- Phenolrchloroform (see Appendix D) 
- 10 M ammonium acetate (see Appendix D) 
Protocol: 
1. Infect two to four confluent 150 cm^ tissue culture flasks of Madin-
Darby bovine kidney cells at a multiplicity of infection greater than 
3.0 to insure that greater than 90% of the cells are infected. 
Incubate for a period of time appropriate for slightly less than one 
infectious cycle (for alphaherpesviruses one infectious cycle is 10 
to 12 hours). This will insure that virus release and cell lysis has 
not occurred and that viral DNA replication and infectious particle 
assembly is occurring. 
2. Remove the culture supernatant after incubation and wash the 
infected monolayer with 10.0 ml of Hirt wash buffer. Discard the 
wash. 
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3. Add 5.0 ml of HIrt buffer A containing 100 //g/ml proteinase K to 
each flask. Rock gently to cover the entire monolayer and 
incubate at room temperature for 15 minutes. 
4. Pour the contents of each flask into a 50 ml glass Corex tube 
(Do not pipette). Due to the viscosity of the solution it may be 
necessary to prop the flask at a 45° angle and allow the contents 
to gravity drain into the Corex tube for 15 minutes. 
5. Incubate the solution in a 37°C water bath for 2-4 hours. 
6. Add 10 ml of 5.0 M NaCI per 10 ml of original volume and mix by 
inverting the tube 10 times. Incubate on ice for 60 minutes, 
repeat the inversion mixing, and incubate at 4°C overnight. 
7. Centrifuge at 27,000 x g for 90 minutes. A compact white pellet 
should be present with no strands reaching into the supernatent. 
If strands are present respin for 30 minutes at 27,000 x g. 
8. Pour off the supernatent to a clean 50 ml graduated polypropylene 
centrifuge tube and note the total volume. Discard the pellet. 
Combine 10 ml of supernatent with 30 ml of 95% ethanol in a 
new 50 ml glass Corex tube. Incubate overnight at -20°C. 
9. Centrifuge at 15,000 x g for 30 minutes. Decant the supernatent and 
wash the pellet with 70% ethanol. 
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10. Aspirate tlie 70% etiianol and resuspend the pellet in 2-3 ml of 0.1 X 
TE buffer. Vacuum centrifuge for 3 minutes to remove traces of 
ethanol. 
11. Adjust to 5X TE using 10X TE buffer, add DNase free RNase to a 
concentration of 100 //g/ml), and Incubate In a 37°C water bath 
for 1 hour. 
12. Extract the solution with an equal volume of phenohchloroform. 
Remove the aqueous phase to a new 25 ml glass Corex tube. Add 
1/5th volume of 10 M ammonium acetate and 2.5 volumes of 
95% ethanol. Precipitate the DNA overnight at -20°C. 
13. Pellet the precipitate by centrifugation at 15,000 x g for 30 minutes. 
Wash the pellet once each with 95 and 70% ethanol. 
14. Aspirate the ethanol, resuspend the pellet in 500-1000 ti\ of TE 
buffer, pH 8.0, and vacuum centrifuge for 3 minutes to remove 
traces of ethanol. This DNA suspension is now ready for further 
analysis {i.e.-restriction enzyme analysis). 
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Total RNA isolation 
The following is a method for the extraction and purification of total 
eukaryotic RNA. The method described here employs simultaneous disruption 
of tissue and denaturation of cellular RNases and proteins in gaunidinium 
thiocyanate and 2-mercaptoethanol. Lithium chloride precipitation separates 
total RNA from DNA, cell debris and protein residue. Phenol/chloroform 
extraction and ethanol precipitation are then performed to remove any protein 
residue and purify total RNA. Wear gloves at all times. 
Required Equipment: 
- Sonicator 
- 50 ml sterile conical polypropylene centrifuge tubes 
- 50 ml sterile Oakridge centrifuge tubes 
- 30 ml siliconized glass Corex centrifuge tubes 
- 10 ml sterile disposable plastic pipettes 
- Sterile glass Pastuer pipettes 
- Parafilm 
- High-speed centrifuge capable of 10,000 x g 
- Micropipettors and sterile plastic tips 
- 40°C water bath 
- Microcentrifuge tubes 
- Vacuum centrifuge 
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Required Reagents: 
- Amersham RNA extraction Icit or self-prepared solutions as follows: 
- 5.0 M gaunidlnium thiocyanate in 50 mM Tris, pH 7.4 and 25 
mM EDTA 
- 4.0 M lithium chloride 
- 2.0 M lithium chloride, 4.0 M urea 
- 10 mM Tris, 1.0 mM EDTA, and 0.1% SDS, pH 7.4 
- DEPC-treated autoclaved water 
- TBS (see Appendix D) 
- 2-mercaptoethanol 
- 0.2% SDS in DEPC-treated water 
- 95% ethanol 
- 70% ethanol 
- Tris-saturated phenol (see Appendix D) 
- Phenol/chloroform (see Appendix D) 
- 2.0 M sodium acetate, pH 6.0 for RNA (see Appendix D) 
Protocol: 
1. Harvest up to 10^° tissue culture cells into a 50 ml conical 
polypropylene centrifuge tube and wash twice with sterile TBS. 
Place the final cell pellet on ice. 
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2. Pre-chill two 50 ml conical polypropylene centrifuge tubes on ice. 
3. Aliquot 18.4 and 9.2 ml of 5.0 M gaunidinium thiocyanate in 50 mM 
Tris, pH 7.4 and 25 mM EDTA into the two pre-chilled tubes and 
add 1.6 and 0.8 ml of 2-mercaptoethanol respectively to each 
aliquot. 
4. Replace the 20 ml tube on ice and chill for 5 minutes only. 
5. Add the pre-chilled 20 ml aliquot to the pelleted tissue culture cells 
and sonicate on ice using 40 second bursts of 10 watts until the 
solution is a watery consistency. 
6. Transfer this solution to a pre-chilled sterile 50 ml Oakridge 
centrifuge tube and add 0.3 volumes of 95% ethanol at -20°C. 
7. Centrifuge at 10,000 x g for 5 minutes at 0°C. A visible pellet 
should be present at this stage. If there is no pellet, re-sonicate 
and re-centrifuge. 
8. Remove any protein or debris from the top of the tube with a sterile 
Pasteur pipette. Change pipettes and aspirate the supernatant. 
Save this and all supernatants until your RNA has been isolated 
and quanitated. Proceed with the pellet. 
9. Chill the 10 ml aliquot of 5.0 M gaunidinium thiocyanate in 50 mM 
Tris, pH 7.4 and 25 mM EDTA on ice for 5 minutes only. 
10. Add the 10 ml pre-chilled aliquot to the pellet from step 8. 
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11. Resuspend the pellet by gentle agitation and transfer to a 50 ml 
conical polypropylene centrifuge tube. 
12. Repeat the sonication as described in step 5. Transfer the contents 
back to a 50 ml Oakridge centrifuge tube, add 30 ml of 4.0 M 
lithium chloride, and precipitate overnight at 4 C. This precipitate 
can be left at 4°C for up to 3 days. 
13. Pellet the precipitate by centrifugation at 10,000 x g for 90 minutes 
at 4°C. 
14. Remove any protein or debris with a sterile Pasteur pipette. 
15. Remove the supernatant and save. 
16. Resuspend the pellet in 35 ml of 2.0 M lithium chloride, 4.0 M urea. 
This is best accomplished by alternating heating for 5 minutes in a 
40°C water bath with vortexing for 30 seconds. Continue until 
them solution is uniform and absent of large particles. This may 
take 45 minutes to 1 hour to accomplish. 
17. Centrifuge at 10,000 x g for 60 minutes. 
18. Repeat steps 14 and 15. 
19. Add 5 ml of 2.0 M lithium chloride, 4.0 M urea to the pellet, vortex 
for 15 seconds, and freeze at -20°C for 2 hours. Thaw and 
resuspend the remaining pellet as described in step 16. 
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20. Transfer the solution to a 30 ml siliconized glass Corex tube and add 
5 ml of Tris saturated phenol. Vortex for 10 seconds to mix the 
phases. 
21. Mix the phases gently on an orbital shaker for 20 minutes at room 
temperature. 
22. Separate the phases by centrifugation at 8,500 x g for 15 minutes 
at 4=C. 
23. Transfer the aqueous phase to a new 30 ml siliconized glass Corex 
tube and repeat steps 20-22 replacing Tris-saturated phenol with 5 
ml of phenol/chloroform. 
24. Transfer the aqueous phase to a new 30 ml siliconized glass Corex 
tube and add 0.1 volume of 2.0 M sodium acetate, pH 6.0 and 2 
volumes of 95% ethanol. Invert the tube gently a few times to 
insure mixing. 
25. Precipitate the RNA overnight at •20°C. Total RNA can be stored in 
this state for 1 year. 
26. Pellet the RNA precipitate by centrifugation at 8,500 x g for 30 
minutes at 4°C. 
27. Aspirate the supernatant and wash the pellet with 70% ethanol at 
20°C. 
28. Repeat step 26. 
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29. Aspirate the supernatant and vacuum dry the pellet for 2 minutes. 
30. Resuspend the pellet in 1 ml of DEPC-treated water. 
31. Aliquot 50 //I volumes into sterile microcentrifuge tubes. 
32. Store the aliqouts at -70®C. 
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Selection of DOIV A+ mRNA from total RNA 
The following protocol describes a method for purifying poly A* mRNA from 
total RNA for use in cDNA synthesis and direct in vitro translation. The 
selection of poly A+ is dependent on base pairing between the 3' poly A regions 
of mRNA with oligo dT coupled to a solid matrix. Non-poly A^ RNA's are not 
bound and can be washed away. Bound poly A^ RNA can be eluted and 
concentrated in a low salt buffer. 
Required Equipment: 
- 65 ®C water bath 
- Micropipettor and sterile plastic tips 
- Microcentrifuge tubes 
- Microcentrifuge 
- Vacuum centrifuge 
- Sterile plastic 5.0 ml columns (Bio-Rad) 
Required Reaqents: 
- Oligo dT cellulose matrix (Pharmacia) 
- Poly A^ activation buffer (see Appendix D) 
- DEPC-treated water (see Appendix D) 
- Poly A^ loading buffer A (see Appendix D) 
- Poly A^ loading buffer B (see Appendix D) 
- Poly A* elution buffer (see Appendix D) 
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- 2.0 M sodium acetate, pH 6.0 (see Appendix D) 
- 95% and 70% ethanol 
Protocol: 
1. Prepare the oligo dT column as follows: 
- Pour 5.0 ml of oligo dT slurry in poly A"*" loading buffer B into a 
sterile plastic column. This should yield a packed volume of 
0.5 to 1.0 ml of oligo dT. 
- Wash the column with 3.0 ml of poly A^ activation buffer. 
- Wash the column with DEPC-treated water until the pH of the 
eluate is 8.0. 
- Equilibrate the column with 5.0 ml of poly A^ loading buffer A. 
2. Dilute 5-10 mg of total RNA in 500-1000 //I of DEPC-treated water 
and heat at 65°C for 15 minutes. 
3. While heating the RNA pre-warm an aliquot of poly A^ loading 
buffer A to 65°C. 
4. Add 500-1000 //I of warm poly A^ loading buffer A to 500-1000 //I 
of heated RNA solution. Mix and cool to room temperature for 2 
minutes. 
5. Apply the sample to the column and collect the eluate. Reheat the 
eluate to 65°C for 10 minutes and reapply to the column. 
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6. Wash the column with 5.0 ml of poly loading buffer B and discard 
the eluate. 
7. Add 1.5 ml of poly A+ elution buffer and collect 10 drop fractions of 
the eluate in sterile microcentrifuge tubes. 
8. Check each fraction for the presence of RNA (See Estimation of RNA 
quantity protocol). 
9. Pool all RNA containing fractions, add 0.1 volume of 2.0 M sodium 
acetate, pH 6.0 and 2.5 volumes of 95% ethanol, mix thoroughly, 
and freeze at -70°C for 1 hour. 
10. Pellet the RNA by microcentrifugation for 30 minutes at 40°C. 
11. Aspirate the supernatant and wash the pellet with 500 //I of 70% 
ethanol. 
12. Microcentrifuge for 5 minutes at 4°C. 
13. Remove the supernatant and dry the pellet by vacuum centrifugation 
for 3 minutes. 
14. Resuspend the pellet in 50 //I of DEPC-treated water and store at 
70°C. 
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cDNA synthesis and olasmid library construction 
The following protocol is based entirely on a commercially ayailable kit for 
cDNA library construction (Inyitrogen-Librarian 11) and is intended as a guide for 
cDNA synthesis and library construction. Included in the system and outlined 
here are the reagents and materials required for: 1 ) converting single-stranded 
RNA to an RNA-cDNA hybrid using avian myeloblastosis virus reverse 
transcriptase and oligo dT or random priming, 2) converting the RNA-cDNA 
hybrid to double-stranded, blunt-ended cDNA, 3) addition of specific cloning 
linkers, 4) cDNA size selection and excess linker removal, 5) ligation of cDNA 
into a specific plasmid vector, and 6) transformation of cDNA constructs into 
competent E.coli. The efficiency of cDNA synthesis is greatest when the 
quality tested reagents provided by the manufacturer are used. 
Required Equipment: 
- Micropipettor and sterile plastic tips 
- Microcentrifuge 
- Mini-gel agarose electrophoresis unit and power supply 
- Vacuum centrifuge 
- Sterile, baked glass Pasteur pipettes 
- Water bath(s) adjustable to 15, 37, 42, and 70®C. 
- UV transilluminator 
- 37°C shaking water bath or environmental chamber. 
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Required Reagents: 
- Invitrogen Librarian II cDNA library construction system (or a alternate 
comparable system) 
- 95% ethanol 
- 80% ethanol 
- DEPC-treated water (see Appendix D) 
Protocol: First-strand cDNA synthesis 
1. Micropipette 40-120 //I of RNA (total or poly A+ selected RNA) 
containing 10-50 fiq of RNA in DEPC-treated water. 
2. Add 12.5 ij\ of 1.0 M methylmercuryhydroxide. 
3. Mix gently, microcentrifuge briefly, and incubate at room temperature 
for 7 minutes. 
4. Add 20 //I of sterile water and 11 //I of 0.7 M 2-mercaptoethanol. 
Gently mix and incubate at room temperature for 5 minutes. 
5. Place the vial on ice and add the following in order: 
oligo dT primer 1 //I 
Placental RNase inhibitor 2 H \  
5X Reverse transcriptase buffer 50 //I 
25 mM dNTP mix 5 /yl 
AMV reverse transcriptase 6//I 
Add sterile water to a final volume of 250 //I 
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6. Gently mix, microcentrifuge briefly and incubate at 42°C for 60 
minutes. 
7. Remove the reaction vial to ice and add 10 //I of 0.5 M EDTA. 
8. Add 250 //I of phenol, vortex, and microcentrifuge for 2 minutes. 
9. Micropipette the bottom phenol layer and discard, leaving the 
aqueous layer in the same tube. Respin and remove any residual 
phenol. 
10. Add 250 //I of 4.0 M ammonium acetate and 1000 yc/i of 95% 
ethanol at 20°C to the aqueous layer. 
11. Vortex and freeze at 70°C for 20 minutes. 
12. Thaw and microcentrifuge at 4°C for 15 minutes. 
13. Heat a glass Pasteur pipette and draw out the tip in a flame to give a 
very fine tip. 
14. Remove all traces of ethanol with the fine Pasteur pipette. 
15. Resuspend the pellet in 100 //I of sterile water. 
16. Add 100 //I of 4.0 M ammonium acetate and 400 //I of 95% ethanol 
at 20°C. 
17. Vortex and freeze at -70°C for 20 minutes. 
18. Thaw and spin at 4®C for 15 minutes. 
19. Remove all traces of ethanol. 
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20. Add 500 //I of 80% ethanol, rock the tube twice, and 
microcentrifuge at 4°C for 5 minutes. 
Protocol: Second-strand cDNA synthesis 
1. Resuspend the pellet from first-strand synthesis in 33.5 //I of sterile 
water and place on ice. 
2. Add the following in order: 
10X second-strand buffer 5 //I 
I.Omg/mlBSA 2.5 //I 
10 mM B-NAD+ 1 //I 
5.0 mM dNTP mix 2 //I 
RNaseH/E.coli DNA ligase 4 //I 
DNA polymerase I 2 //I 
3. Gently mix and microcentrifuge briefly. 
4. Incubate at 15°C for 15 minutes, followed by incubation at room 
temperature for 60 minutes. 
5. Heat the reaction mix to 70°C for 10 minutes, microcentrifuge 
briefly, let stand at room temperature for 2 minutes, and then chill 
on ice for 3 minutes. 
6. Add 3.5 //I of T4 DNA polymerase, gently mix, microcentrifuge 
briefly, and incubate at 37°C for 10 minutes. 
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7. Stop the reaction by adding 2 fj\ of 0.5 M EDTA. 
8. Add 50 fj\ of phenol and repeat the extraction as described in first-
strand synthesis. 
9. Add 56 fj\ of 4.0 M ammonium acetate and 224 jj\ of 95% ethanol to 
the aqueous and ethanol precipitate as described in first-strand 
synthesis. 
10. Add 500 fj\ of 80% ethanol to the pellet, rock the tube twice and 
microcentrifuge at 4°C for 5 minutes. 
11. Remove all traces of ethanol with a flame drawn Pasteur pipette. 
Protocol; BstXI linker addition 
BstXI linkers are ligated to the blunt-ended cDNA from second-strand 
synthesis. The linker has a CACA 3' overhang which prevents more than one 
linker being ligated per cDNA blunt end. Linker concatmerization is therefore 
not possible. 
1. Resuspend the pellet from second-strand synthesis in 22 //I of sterile 
water. Vortex lightly. 
2. Add the following in order: 
10 X ligation buffer 3 / j \  
BstXI linkers 3  f j \  
T4 DNA ligase 2//I 
3. Vortex and incubate at 15°C overnight. 
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4. Add 2 //I of 0.5 M EDTA and 50 //I of phenol/chloroform. Vortex and 
microcentrifuge for 3 minutes. Remove tine phenol/chloroform as 
described in first-strand synthesis. 
5. Add 35 //I of 4.0 M ammonium acetate and 140 fi\ of 95% ethanol at 
20°C. Ethanol precipitate as described in first-strand synthesis. 
6. Remove all traces of ethanol with a flame drawn Pasteur pipette. 
Protocol: Linker removal and cDNA size selection 
This process involves agarose gel electrophoresis, ethidium bromide 
visualization, and electroelution of cDNA from a gel slice. These procedures are 
described in Appendix B. 
Protocol: Ligation of cDNA into olasmid vector DCDNAII 
The plasmid vector in this system is pre-digested and dephosphorylated. 
Ligation of the cDNA inserts into this vector is performed as described in the 
Ligation section of Appendix B. 
Protocol: Transformation and olatino of cDNA librarv 
Frozen competent cells designated INVaF' are supplied by the manufacturer. 
Transformation proceeds as described in the High efficiency transformation of 
competent E.coli section of Appendix B. 
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Protocol: cDNA library screening 
The ampiciilin resistant colonies resulting from transformation can be blotted 
and probed with specific nucleic acid probes as described in the Colony-blotting 
and Nucleic acid hybridization and Autoradiography sections of this Appendix B. 
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APPENDIX B. PROTOCOLS FOR THE CHARACTERIZATION OF NUCLEIC 
ACIDS 
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Restriction enzvme digestion of DMA 
The specific conditions for restriction enzyme digestion vary with the 
restriction enzymes used and the DNA to be digested. Most enzyme 
manufacturers include a concentrated reaction buffer with each individual 
restriction enzyme. This buffer provides the optimal chemical reaction 
conditions required for that enzyme. In general, 1.0 unit of restriction enzyme 
is defined as the amount of enzyme required to digest one //g of DNA to 
completion at 37°C in 1 hour. To insure complete digestion of a quantified 
preparation of DNA, the use of a two to three-fold excess of enzyme is 
recommended. 
Required Equipment: 
- Micropipettors and sterile plastic tips 
- 1.5 ml microcentrifuge tubes 
- 37°C water bath 
Required Reaqents; 
- Specific restriction enzymes and reaction buffers 
- Sterile distilled, deionized water 
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Protocol: 
1. Combine the following in a sterile 1.5 ml polypropylene tube: 
DNA (0.1 to 5.0//g) 1 to 5 //I 
10 X restriction enzyme buffer 2 IJ\ 
Restriction enzyme 1 jul 
distilled, deionized water 12 to u\ 
20 //I total volume 
2. Incubate the reaction mixture at the specified temperature for 1 to 4 
hours. 
3. Remove a 1 to 2 //I sample for agarose gel electrophoresis to 
check for complete digestion. 
4. While checking for complete digestion add an additional unit of 
restriction enzyme to the reaction mix and continue incubation at 
the specific reaction temperature. 
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Agarose oel electrophoresis and Dhotoaraphv of DNA 
Agarose gel electrophoresis utilizes an agarose matrix to separate 
molecules of DNA on a size basis. The concentration of agarose used will vary 
with the size of the DNA molecules being analyzed. An approximation of 
percentage needed versus fragment size to be resolved is shown below. 
Percent (%) Agarose Fragment size ranoe in kilobase pairs 
0.5% greater than 20 kbp 
1.0% 1.0 kbp to 20 kbp 
1.5% 0.5 kbp to 2.0 kbp 
2.0% less than 0.5 kbp 
Reguired Eguioment: 
- Horizontal gel electrophoresis unit (large gel or mini-gel format 
depending on need, i.e. - BRL H4 or Bio-Rad mini-gel 
electrophoresis unit) 
- Power supply capable of delivering 25 to 150V and 25 to 250mA. 
- Gel former trays and well combs 
- Adhesive tape 
- Micropipettors and sterile plastic tips 
- Staining trays 
- UV transilluminator, Polaroid camera, film, and camera stand 
- UV transparent ruler 
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Required Reagents: 
- Pure to ultra-pure agarose (BRL or Sea-Kern) 
- IX TAE buffer (see Appendix D) 
- 6X OJ sample buffer (see Appendix D) 
- 10 mg/ml Ethidium bromide solution (see Appendix D) 
- DNA samples 
- DNA size standard (i.e.- Hind III digested lambda bacteriophage DNA) 
- 18 % sodium sulfite 
Protocol; 
1. Weigh out the appropriate amount of agarose and volume of TAE 
buffer required for the percentage, size, and thickness of your 
gel(s). For example, a single 1.0% gel approximately 6mm thick to 
be run in the BRL H4 gel apparatus will require 100ml of IX TAE 
and 1.0 gm of dry agarose. 
2. Combine agarose and TAE In a glass bottle and melt in the 
microwave 2 to 5 minutes at high power. Alternatively, melted 
agarose can be prepared by autoclaving for 5 minutes. Cool 
agarose for 30 minutes in a 56°C water bath. 
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3. Seal the ends of the gel tray with adhesive tape, pour agarose cooled 
to 56®C, Insert the well comb, and allow the gel to cool 45 
minutes to 1 hour or until the gel turns from clear to opaque. 
4. Remove the well comb and the end tape and place the gel In the 
electrophoresis unit filled with IX TAE. 
5. Add 1.0 //I of 6X OJ sample buffer per 5 //I of DNA sample and DNA 
size standard, mix , and load the sample into a well. 
6. Connect power cords to the power supply making certain the 
negative electrode is nearest the sample wells. For overnight runs 
using a large gel apparatus set at 25V, for shorter 3 to 4 hour runs 
set at 75V. 
7. Disconnect power unit and place gel into an ethidium bromide 
staining solution of 25 //I of lOmg/ml ethidium bromide in 1.0 liter 
water. Stain gel for 30 minutes to 1 hour and destain in water for 
30 minutes. 
8. Place gel on a UV transilluminator and photograph by exposing 
Polaroid Type 665 positive/negative film at f-stop 4.5 for 1 to 2 
minutes with an orange filter. Place a UV transparent ruler next to 
the gel for standard curve determination. Develop for 15 seconds 
and immediately coat the positive using the manufacturers 
treatment provided with the film cassette. 
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9. The negative can be preserved by immersion in an 18% sodium 
sulfite bath for 1 minute followed by a 5 minute wash in running 
water and air drying. The gel can now be used for electroelution 
or southern blotting if required. 
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Estimation of RNA or DNA quantity 
The following is a quick, reliable and reproducible method of estimating 
the quantity of RNA or DNA in a preparation. The RNA or DNA is diluted and a 
small amount is placed on an agarose plating containing ethidium bromide along 
with serial dilutions of an RNA or DNA standard of known quantity. 
Visualization and photograph is performed using a UV light source. 
Quantitation is based on fluorescence comparisons between the unknowns and 
the serially diluted standards. The photograph provides a permanent record of 
the estimate. 
Required Equipment: 
- Micropipettors and sterile plastic tips 
- Disposable plastic petri dishes 
- UV transilluminator 
- Polaroid camera and camera stand and film 
- Polaroid Type 665 positive/negative film 
Required Reagents: 
- DEPC-treated water (see Appendix D) 
- TE buffer, pH 8.0 (see Appendix D) 
- Agarose, electrophoresis grade 
- 10 mg/ml ethidium bromide (see Appendix D) 
- RNA or DNA standard (Bethesda Research Laboratories) 
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Protocol: 
1. Prepare agarose-ethidium bromide plates as follows: 
- Melt 4.0 g of agarose in 40 ml of TE, pH 8.0 
- Cool to 60°C and add 4jul of 10 mg/ml ethidium bromide 
- Pour into a petri dish and allow to harden at room temperature 
2. Prepare serial dilutions of a RNA or DNA standard in DEPC-treated 
water. 
3. Prepare undiluted, 1:10, and 1:100 dilutions of sample RNA or DNA. 
4. Spot 2 fj\ of each dilution (standards and samples) onto the hardened 
agarose-ethidium bromide plate. Allow 20 minutes for the samples 
to diffuse into the agarose. 
5. Place on a UV transilluminator and photograph. 
6. Estimate RNA or DNA quantity by comparison with the standards. If 
a scanning densitometer is available, the photographic negative 
could be scanned for a more accurate estimation of quantity. 
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Electroelution of DNA fragments from agarose gels. 
In many cases, It is necessary to isolate a particular restriction enzyme 
fragment for the purposes of subcloning or use as a specific probe. In general, 
a piece of agarose containing a specific DNA fragment is excised from a gel, 
placed in a dialysis bag containing electrophoresis buffer and electrophoresed 
until the fragment migrates out of the agarose into the dialysis bag buffer. 
Fragments isolated in this manner are suitable for subcloning or probe 
preparation: however, an agarose of extremely high purity should be selected if 
subcloning of the isolated fragment is required. Lower grade agarose may 
contain compounds that inhibit ligation of the isolated fragment with vector 
DNA. Labelling reactions for probe preparation do not appear to be inhibited by 
such compounds. 
Required Eouioment: 
- Horizontal gel electrophoresis unit (BRL H4 electrophoresis unit) 
- Power supply capable of delivering 25 to 150V and 25 to 250mA 
- Gel former trays 
- UV transilluminator 
- Micropippetors and sterile plastic tips 
- Razor blade 
- Sterile 1.5 ml microcentrifuge tubes 
- Dialysis bag clips 
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Required Reagents: 
- Sterile filtered IX TAE buffer (see Appendix D) 
- Sterile dialysis tubing (see Appendix D) 
- Tris saturated phenol (see Appendix D) 
- 24:1 Chloroform / isoamyl alcohol (see Appendix D) 
- 10 M ammonium acetate (see Appendix D) 
- 95% ethanol 
- TE, pH 8.0 buffer (see Appendix D) 
Protocol: 
1. Place the ethidium bromide stained gel on the UV transilluminator and 
cut out the desired band. Use a new razor blade for each fragment 
to be excised. Minimize the DNA exposure to UV light in the 
presence of ethidium bromide as this will introduce nicks in the 
DNA. 
2. Clip one end of the sterile dialysis tubing shut and wash the inside of 
the tubing with sterile water. Place the gel fragment into the bag, 
add 1.0 ml of sterile IX TAE, squeeze any air bubbles out of the 
bag, and clip the bag shut. This should leave 500 to 750 //I of IX 
TAE in the bag. 
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3. Place the dialysis bag in the horizontal electrophoresis unit making 
certain the entire bag is covered with electrophoresis buffer. 
Orient the bag perpendicular to the current flow between the 
electrodes. 
4. Electroelute at 100-125 V for 3 to 5 hours. 
5. Remove the gel fragment and vigorously massage the entire dialysis 
bag with the fluid in it. Remove the fluid from the bag with a 
micropippetor to a sterile 1.5 ml polypropylene tube, noting the 
volume removed. Add 200 - 500 jj\ of sterile deionized, distilled 
water to the bag and massage. Combine the two volumes and 
microcentrifuge for 1 minute to remove small pieces of agarose. 
6. Combine equal volumes of Tris saturated phenol and chloroform : 
isoamyl alcohol and vortex well to mix. Add an equal volume of 
the phenol/chloroform to the electroelutant and vortex to mix the 
phases. Microcentrifuge for 2 minutes to separate the phases. 
7. Remove the aqueous layer (top layer) containing the electroeluted 
DNA to a new tube. Take care not to remove any phenol or 
material at the interface. Back extract the phenol phase by adding 
an equal volume of sterile deionized, distilled water to the phenol, 
followed by vortexing a microcentrifuging for 2 minutes. Combine 
the two aqueous layers. 
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8. Add 0.25 volumes of 10 M ammonium acetate and 2.5 volumes of 
95% ethanol to the aqueous and precipitate the electroeluted DNA 
at - 70°C for 2 hours to overnight. 
9. Spin out the DNA precipitate by microfcentrifuging at 4°C for 30 
minutes. Resuspend the DNA in 20 to 50 /A of TE buffer. 
10. Remove a 5 to 10 % aliquot for mini-gel electrophoresis to estimate 
the efficiency of fragment recovery. 
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Formaldehyde oel electrophoresis of RNA: 
Formaldehyde gel electrophoresis is a form of agarose gel electrophoresis 
with formaldehyde and formamide used to keep the RNA in a denatured state 
thereby facilitating electrophoretic separation without interference from RNA 
secondary structure. Great care must be taken throughout this procedure to 
eliminate RNase contamination . All glassware must be rinsed with DEPC-
treated water and baked overnight at a minimum of 200°C. Electrophoresis gel 
units, trays, and combs should be washed in T% SDS, rinsed in DEPC water, 
and air dried before use. All buffers and solutions should be prepared with 
DEPC-treated water. Most importantly, gloves must be worn at all times during 
the procedure and while preparing equipment and reagents. 
Required Equipment: 
- Horizontal gel electrophoresis unit (BRL H4) 
- Power supply capable of delivering 75V and 100mA 
- Gel former trays and well combs 
- Adhesive tape 
- Micropipettors and sterile plastic tips 
- UV transilluminator, UV ruler, Polaroid camera, and camera stand 
- Polaroid type 665 positive/negative film 
- Fume hood 
- Heating block capable of attaining 85°C 
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Required Reagents: 
- Ultra-pure agarose 
- 13.3M Formaldehyde 
- BOX "E" buffer (see Appendix D) 
- deionized 99% Formamide (see Appendix D) 
- DEPC-treated water (see Appendix D) 
- 0.5M EDTA, pH 8.0 (see Appendix D) 
- 10 mg/ml ethidium bromide (see Appendix D) 
- 6X OJ sample buffer (see Appendix D) 
- RNA standard (Bethesda Research Laboratories, RNA ladder) 
Protocol: 
1. Melt 1.0 gm of agarose in 100ml of DEPC water and cool to 65 C in 
a water bath. 
2. Tape the ends of a gel tray as described for agarose gel 
electrophoresis. 
3. In a fume hood, add 16.6ml of 13.3M formaldehyde and 2.0ml of 
50X "E" buffer to the melted, cooled agarose. 
4. Pour the formaldehyde agarose into the gel tray, position the well 
combs, and allow the gel to harden for 45 minutes to 1 hour. 
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5. Dilute or dry down RNA samples to contain 10 to 15 //g of total 
RNA or 1 to 2 //g of poly A+ mRNA for each well to be run in a 
total volume of 2 to 5 //I. 
6. Prepare fresh RNA sample buffer before each run by combining : 
50X "E" buffer 20 fj\ 
deionized 99% formamide 505 //I 
13.3M formaldehyde 165 //I 
0.5M EDTA 1 //I 
DEPC water 209 jj\ 
7. Prepare 1 mg/ml ethidium bromide from lOmg/ml ethidium bromide 
stock. 
8. Add 20 jj\ of fresh RNA sample buffer and 1 //I of diluted ethidium 
bromide solution to each sample and standard. 
9. Heat samples at 85°C in a heat block for 10 minutes. 
10. Prepare the gel running buffer to fill the gel unit : 
13.3M formaldehyde 167 ml 
50X "E" buffer 20 ml 
DEPC water to a total volume of 1000 ml 
11. Add 5 fj\ of 6X OJ to RNA samples, mix, and load wells. 
12. Run the gel in the fume hood at 70 to 75V for 3 to 4 hours. 
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13. The formaldehyde gel can be photographed directly as described in 
agarose gel electrophoresis. The gel contents can also be 
transferred directly to a solid support as described in the Northern 
blot protocol. 
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Southern blot transfer of DNA from agarose gels. 
Southern blotting is a technique used to transfer DNA fragments from an 
agarose gel to a solid support like nitrocellulose or nylon filters. The DNA in the 
gel is denatured to single strands, neutralized, and transferred in a high salt 
solution by capillary action to the filter. The singled-stranded DNA binds the 
filter and is permanently affixed by vacuum baking. The baked filter can then 
be used in hybridization experiments with labelled probes. 
Required Eouioment: 
- Plastic boxes or glass dishes (Pyrex) 
- Gel tray from BRL H4 electrophoresis unit 
- Whatman 3MM filter paper 
- Nitrocellulose or nylon filter cut to gel size (BRL H4 gel = 11x14 cm) 
- BRL blotting pads (6-8) or paper towels 
- Glass plate 
- 500 gm weight (500ml bottle containing 300ml water) 
- Vacuum drying oven 
- Plastic sealable bags 
- Plastic bag sealer 
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Required Reagents: 
- Southern I solution (see Appendix D) 
- Southern II solution (see Appendix D) 
- 20X SSPE (see Appendix D) 
Protocol: 
1. Place agarose gel in a plastic box or glass dish containing 
approximately 500 ml of Southern I solution. Rotate slowly on an 
orbital shaker for 30 minutes. Replace with a fresh 500 ml of 
Southern I and shake an additional 30 minutes. This step 
denatures the DNA to single strands. 
2. Remove the Southern I solution and replace with 500 ml of Southern 
II and shake slowly for 30 minutes. Repeat as described above. 
This step neutralizes the gel to aid in transfer. 
3. Place approximately 500 ml of 20X SSPE in the bottom of a glass 
dish. Cut a wick from Whatman 3MM paper 12 cm wide x 40-50 
cm long and wet in 20X SSPE. Place a BRL gel tray upside down 
in the middle of the glass dish. Lay the wick over the gel tray with 
the ends in the 20X SSPE. Smooth the wick with a disposable 
pipette to remove any trapped air bubbles. 
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4. Nick the corner of the gel representing lane number 1, carefully lift it 
and place it on the wick assembly with the wells facing down. 
Smooth the gel and remove any air bubbles trapped between the 
wick and the gel as described above. 
5. Prewet the nitrocellulose or nylon filter in water. Place it on the gel. 
Do not reposition the filter once it has contacted the gel. Smooth 
the filter as described above to remove trapped air bubbles. 
6. Place a stack of BRL blotting pads (if available) directly on top of the 
filter, place a glass plate on top of the pads, and a 500 gm weight 
on top of the glass plate. Allow to transfer by capillary action 
overnight. 
7. If BRL blotting pads are not available, cut 2 sheets of Whatman 3MM 
paper to the size of the filter, soak one in 20X SSPE and place on 
top of the filter, smooth out the air bubbles, place the second on 
top of the first, and smooth to remove the air bubbles. Cut paper 
toweling to the gel size and place a stack of 10 to 20 on top of the 
filter paper. Place the glass plate and the weight on top of the 
paper towels and allow to transfer overnight. 
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8. Remove the weight, glass plate and pads or towels. Cut off the wick 
ends and flip the gel and filter over onto a sheet of Whatman 3MM 
paper. Notch the filter in the same corner as the gel and mark the 
wells using a permanent marker or lead pencil. 
9. Remove the gel and photograph with UV light to determine the 
efficiency of transfer. 
10. Rinse the filter briefly in 2X SSPE, place between 2 sheets of 
Whatman 3MM paper, tape the edges, and dry in a vacuum oven 
at 80°C and 10 to 15 mm Hg of vacuum for 2 hours to bake DNA 
onto the filter. 
11. Begin hybridization immediately or store between Whatman 3MM 
paper in a sealed bag until ready for hybridization. 
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Northern blot transfer of RNA from formaldehyde aels. 
Northern blotting is a technique very similar to Southern blotting. 
Northern blotting is the capillary transfer of RNA in a high salt buffer to a solid 
support. Since the RNA is in a single-strand form with secondary structure 
minimized by the gel conditions, it can be transferred without the denaturation 
and neutralization steps required in DNA transfer. However, great care must be 
taken to avoid the introduction of RNases. 
Required Equipment: 
- Plastic boxes or glass dishes (Pyrex) 
- Gel tray from BRL H4 electrophoresis unit 
- Whatman 3MM filter paper 
- Nitrocellulose or nylon filter cut to gel size (BRL H4 gel = 11x14 cm) 
- BRL blotting pads (6-8) or paper towels 
- Glass plate 
- 500 gm weight (500ml bottle containing ~ 300ml water) 
- Vacuum drying oven 
- Plastic sealable bags 
- Plastic bag sealer 
Required Reagents; 
- 20X SSPE (see Appendix D) 
- 2X SSPE (in DEPC-treated water). 
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Protocol: 
1. The RNA in the formaldehyde gel can be transferred directly without 
soaking the gel to denature and neutralize. Briefly rinse the 
formaldehyde gel in 2X SSPE. 
2. Place approximately 500 ml of 20X SSPE in the bottom of a glass 
dish. Cut a wick from Whatman 3MM paper 12 cm wide x 40-50 
cm long and wet in 20X SSPE. Place a BRL gel tray upside down 
in the middle of the glass dish. Lay the wick over the gel tray with 
the ends in the 20X SSPE. Smooth the wick with a disposable 
pipette to remove any trapped air bubbles. 
3. Nick the corner of the gel representing lane number 1, carefully lift it 
and place it on the wick assembly with the wells facing down. 
Smooth the gel and remove any air bubbles trapped between the 
wick and the gel as described above. 
4. Prewet the nitrocellulose or nylon filter in water. Place it on the gel . 
Do not reposition the filter once it has contacted the gel. Smooth 
the filter as described above to remove trapped air bubbles. 
5. Place a stack of BRL blotting pads (if available) directly on top of the 
filter, place a glass plate on top of the pads, and a 500 gm 
weight on top of the glass plate. Allow to transfer by capillary 
action overnight. 
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6. If BRL blotting pads are not available, cut 2 sheets of Whatman 3MM 
paper to the size of the filter, soak one in 20X SSPE and place on 
top of the filter, smooth out the air bubbles, place the second on 
top of the first, and smooth to remove the air bubbles. Cut paper 
toweling to the gel size and place a stack of 10 to 20 on top of the 
filter paper. Place the glass plate and the weight on top of the 
paper towels and allow to transfer overnight. 
7. Remove the weight, glass plate and pads or towels. Cut off the wick 
ends and flip the gel and filter over onto a sheet of Whatman 3MM 
paper. Notch the filter in the same corner as the gel and mark the 
wells using a permanent marker or lead pencil. 
8. Remove the gel and photograph with UV light to determine the 
efficiency of transfer. 
9. Rinse the filter briefly in 2X SSPE, place between 2 sheets of 
Whatman 3MM paper, tape the edges, and dry in a vacuum oven 
at 80°C and 10 to 15 mm Hg of vacuum for 2 hours to bake DNA 
onto the filter. 
10. Begin hybridization immediately or store between two sheets of 
Whatman 3MM paper in a sealed bag until ready for hybridization. 
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Dephosphorvlation of olasmid DMA 
This procedure is used to remove 5' phosphate group from restriction 
enzyme digested plasmid DNA molecules for use in ligation experiments. 
Dephosphorylation prevents the ends of a restriction enzyme digested plasmid 
vector from religating. As a result, the ends of the vector can only ligate to a 
5' phosphorylated insert end. This procedure drastically reduces vector 
background in subsequent transformation experiments. 
Required Equipment: 
- Micropipettor and sterile plastic tips 
- Microcentrifuge 
37°C water bath 
- 65 ®C water bath 
- Vacuum centrifuge 
Required Reagents: 
- Calf intestine alkaline phosphatase (Boehinger Mannheim Biochemicals) 
- Phosphatase storage buffer (see Appendix D) 
- Restriction enzyme digested plasmid DNA 
- Phenol/chloroform (see Appendix D) 
- Glycogen carrier (Boehinger Mannheim Biochemicals) 
- 3.0 M sodium acetate (see Appendix D) 
- 95% ethanol 
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- 70% ethanol 
- TE buffer, pH 8.0 (see Appendix D) 
Protocol: 
1. Dilute the calf intestine alkaline phosphatase to 1.0 unit///l in 
phosphatase storage buffer. 
2. Add 1.0 unit of enzyme directly to the restriction enzyme digest 
containing vector DNA. Incubate at 37°C for 30 minutes. 
3. Add a second 1.0 unit aliquot of enzyme and incubate at 37*0 for 
an additional 30 minutes. 
4. Move the reaction mix to a 65®C water bath for 45 minutes. 
5. Extract the mix twice with an equal volume of phenol/chloroform. 
Back extract each time with TE buffer, pH 8.0. 
6. Combine the extraction and back extraction aqueous phases and 
precipitate the dephosphorylated vector with 0.1 volume of 3.0 M 
sodium acetate 20 //g of glycogen carrier, and 2.5 volumes of 
95% ethanol. Incubate at 70°C for 1 hour. 
7. Pellet the DNA by microcentrifugation at 4 C for 30 minutes. 
8. Wash the pellet with 70% ethanol and microcentrifuge at 4®C for 10 
minutes. 
9. Dry the pellet for 5 minutes in a vacuum centrifuge. 
10. Resuspend the pellet in 20 //I of TE buffer, pH 8.0. 
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Ligation of DNA molecules: 
Ligation is defined as tlie joining of two DNA molecules between a free 
5' phosphate and 3'hydroxyl end using a specific DNA ligase. This reaction is 
crucial to the creation of recombinant DNA molecules. Ligation can occur 
between cohesive (2 to 6 base complimentary sequences generated by 
restriction enzyme digestion) or blunt ends, although the former occurs with 
much greater efficiency. Two protocols are outlined below for cohesive and 
blunt end ligation respectively. 
Required equipment: 
- Microcentrifuge tubes 
- Micropipettors and sterile plastic tips 
- Refrigerated water bath capable of maintaining 24 and 14°C 
Required Reagents: 
- Dephosphorylated vector DNA (approximately 100 ng///l) 
- Purified insert DNA (50-100 ng///l) 
- T4 DNA ligase (1.0 unit///l) 
- 5X ligase buffer (supplied by the manufacturer or see Appendix D) 
- Sterile distilled, deionized water 
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Protocol: 
1. Determine the molar concentration of ends of the insert and vector 
DNA as follows: 
- Calculate nanomoles of ends of DNA 
= (2 ends)(10'^ ng/g) + (bp)(660 Da/bp) 
- When nanomoles of ends have been calculated for both 
insert and vector, normalize the two values relative to 
each other. 
Normalization = Nanomoles insert + Nanomoles vector 
- In the ligation experiment, ng of vector DNA will be 
constant at 100 ng. 
- A 3:1 insert to vector ratio is recommended in most ligation 
experiments, therefore the ng of insert DNA required 
= (100 ng vector DNA){3) (Normalization factor) 
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- For example: If vector plasmid puC19 = 2686 bp 
and Insert DNA = 1500 bp 
A) Nanomoles of vector = 1.1 x 10'^® nanomoles 
(2 ends)(10® ng/g pUC19) + (2686 bp)(660 Da/bp) 
B) Nanomoles of insert = 2.0 x 10 " nanomoles 
(2 ends){10"® ng/g insert) + (1500 bp)(660 Da/bp) 
C) Normalization factor = 1.8 
2.0 X 10-" + 1.1 X 10'" 
D) ng of insert DNA required for a 3:1 molar end 
insert to vector ratio with 100 ng of vector 
DNA = 167 ng = (100 ng vector)(3) + 1.8 
Combine the following on ice: 
Dephosphorylated vector (100 ng) 1 //I ' 
Insert DNA (3X molar end excess) 2-5 /j\ 
5X ligation buffer 4 //I 
T4 DNA ligase (0.1 unit) 1 JJ\ 
Sterile distilled, deionized water 9-12 fj\ 
Total volume 20 //I 
Mix gently by tapping and microcentrifuge briefly. 
Incubate at 24®C for 4 hours. 
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Dilute 1:4 with sterile distilled, deionized water prior to 
transformation. 
Note: For blunt end ligation the protocol is identical to cohesive 
end ligation except that: 
-1.0 unit of T4 DNA ligase is used 
- The ligation mix is incubated at 14°C for 16-24 hours. 
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High efficiency transformation of competent E.coli 
Tlie following is a procedure for: 1 ) the preparation of competent E.coli 
and 2) the efficient introduction of plasmid DNA into competent E.coli. Efficient 
transformation is dependent upon: 1) growth of the bacteria at elevated Mg^"^ 
levels, 2) combining DNA and E.coli in the presence of l\/ln++, Ca++, Rb+, K+, 
dimethylsulfoxide, dithiothreitol, and hexamine cobalt (III) chloride at low 
temperature, and 3) a heat pulse to initiate DNA uptake. Adherence to these 
conditions aid in achieving reproducible and efficient transformation of E.coli 
with plasmid DNA constructs. 
Required Equipment: 
- 37®C shaking water bath or environmental chamber 
- Low speed centrifuge capable of 2,000 x g 
- 4-2°C water bath 
- 37°C incubator 
- Falcon 2059 polypropylene tubes 
Required Reaqents: 
- LB broth without antibiotics (see Appendix D) 
- SOB broth (see Appendix D) 
- 1.0 M MgS04 (see Appendix D) 
- 1.0 M MgClj (see Appendix D) 
- Transformation buffer (TFB) (see Appendix D) 
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- 2.0 M glucose (see Appendix D) 
- LB agar plates + ampicillin (see Appendix D) 
- Dimethylformamide 
- 2-mercaptoethanol 
Protocol: 
1. Inoculate 10 ml of LB broth with a single colony of host bacteria 
(i.e.- JM109 or DH5). Incubate overnight in a 37®C shaking water 
bath or environmental chamber. 
2. The next day, prepare SOB + IVIg++ by adding 1 ml each of 1.0 M 
MgS04 and 1.0 M IVIgClg to 98 ml of SOB. Warm to 37°C. 
3. Inoculate 30 ml of SOB + Mg^"^ with 1.5 ml of overnight culture. 
Shake vigorously at 37®C until the O.D.ggo is between 0.45-0.55 
(usually takes 1.5 to 2.5 hours). 
4. Chill the culture on ice for 2 minutes, then pellet the cells by 
centrifugation at 1500 x g for 10 minutes at 4°C. 
5. Resuspend the pellet in 8 ml of TFB and place on ice for 15 minutes. 
6. Pellet the cells by centrifugation at 1500 x g for 10 minutes at 4°C. 
7. Resuspend the pellet in 2 ml of TFB (can be stored on ice for 1-2 
hours). 
8. Add 70 /yl of DMF, swirl to mix, and incubate on ice for 5 minutes. 
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9. Add 4 tj\ of 2-mercaptoethanol, swirl to mix, and incubate on ice for 
10 minutes. 
10. Repeat step 8. The cells are now competent. 
11. Pre-chill 10 Falcon 2059 polypropylene tubes on ice. Dispense 210 
//I of competent cells per tube. 
12. Add 2-4 //I of plasmid DNA, ligation mixture dilution, or control 
preparations containing 10-100 ng of DNA. Incubate on ice for 30 
minutes. 
13. During the 30 minute incubation, prepare 10 ml of SOC media by 
adding 100 //I of 2.0 M glucose to 9.9 ml of SOB + Mg^^ for a 
final glucose concentration of 20 mM. 
14. Heat shock the transformation mixes by immersing the tubes in a 
42®C water bath for 90 seconds. Cool on ice for 2 minutes. 
15. Add 800 ij\ of SOC per tube and incubate with shaking at 37°C for 
1 hour. 
16. Plate out empirically determined dilutions of the transformation onto 
LB agar plates + specific antibiotic. Spread the mix evenly over 
the surface of the plate with a bent glass rod. Incubate overnight 
at 37"C. 
17. The resultant colonies can be analyzed by mini-prep DNA isolation or 
colony-blot hybridization. 
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Colonv-blottina of olasmid DNA 
The following is a method for identifying bacterial colonies transformed by 
recombinant plasmids containing an insert of interest. Nitrocellulose or nylon 
filters are used to remove a portion of a bacterial colony from the media plate. 
The bacterial cells adhering to the filters are lysed and the DNA is denatured to 
single-stranded DNA, neutralized, and baked onto the filter for hybridization. 
Required Equipment: 
- 37®C incubator 
- Nitrocellulose or nylon filter disks to fit 90 or 150 mm^ petri dishes 
- Four large plastic boxes 
- Whatman 3MM paper 
- Vacuum drying oven 
- Plastic sealable bags 
- Plastic bag sealer 
Required Reagents: 
- Luria-Bertani antibiotic agar plates (see Appendix D) 
- 10% sodium dodecyl sulfate (see Appendix D) 
- Southern I solution (see Appendix D) 
- Southern II solution (see Appendix D) 
- Tris, pH 8.0, 2M (see Appendix D) 
- 2X SSPE (see Appendix D) 
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Protocol: 
1. Plate bacterial cultures transformed with the plasmid construct of 
interest. Attempt to achieve colony counts of 200-500 per 90 
mm^ petri plate or 5,000-10,000 per 150 mm^ petri plate. 
Incubate inverted at 37°C for 8-16 hours. 
2. Place a dry nitrocellulose or nylon filter (prenumbered with a soft lead 
pencil for identification) on the bacterial plate. This is most easily 
done by grasping opposite edges of the filter between the thumb 
and forefinger making the filter a closed U-shape. Place the 
bottom portion of the U onto the center of the bacterial plate and 
allow the edges to fall to the sides of the plate. Allow the filter to 
wet completely (approximately one minute). 
3. Mark the filter and the plate for orientation by punching holes 
through the filter and the underlying agar near the plate edges with 
an 18 gauge needle. The marking should be done in an 
asymmetric manner to facilitate alignment later. 
4. Remove the filter with a pair of blunt forceps and reincubate the 
plates for 8-12 hours at 37°C to regrow the colonies. 
5. Place two sheets of Whatman 3MM paper into each of four large 
plastic boxes. Tape label the boxes SDS, Southern I, Southern II, 
and Tris respectively. Soak the paper and pour off the excess. 
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6. Place the filters on the SDS saturated paper for 5 minutes. Briefly 
blot off excess SDS on a paper towel. 
7. Transfer the filters to the Southern I saturated paper for 5 minutes. 
Blot briefly as above. 
8. Transfer the filters to the Southern II saturated paper for 5 minutes. 
Blot briefly as above. 
9. Transfer the filters to the Tris saturated paper for 10 minutes. 
10. Air dry the filters on Whatman 3MM paper for 30 minutes. 
11. Place the filters between two sheets of Whatman 3MM paper and 
dry in a vacuum oven at 80 C under 10-15 mm Hg vacuum for 2 
hours. 
12. Begin hybridization immediately or store between two sheets of 
Whatman 3MM paper in a sealed bag until ready for hybridization. 
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Random primed DNA labelling: 
The labelling of DNA molecules for use as specific probes is necessary for a 
variety of procedures including library screening, Southern blotting and Northern 
blotting. The random hexamer priming method is based on the presence of all 
possible random hexanucleotides in the reaction mixture being available to 
hybridize with the DNA to be labelled. The DNA to be labelled is denatured to 
single strands by boiling and the random hexamers are allowed to hybridize to 
complementary sequences on the single stranded sequences. A complementary 
strand of DNA is synthesized using the 3'OH termini of the random hexamer 
and the Klenow portion of DNA polymerase. Modified deoxynucleoside 
triphosphates (^^P-labelled) are incorporated into the newly synthesized DNA. 
Theoretically, since all possible hexamer combinations are present, the primer 
binds the template in a statistical manner and therefore the probe DNA is 
labelled equally along its entire length. 
Required Equipment: 
- 37®C water bath 
- 1.5 ml microcentrifuge tubes 
- iVIicropippettors and sterile plastic tips 
- Geiger counter 
- Liquid scintillation counter with a channel 
- Microcentrifuge 
195 
Required Reagents; 
- Boehringer Mannheim Random primed DNA labelling kit (Cat. No. 1004 
760) 
- alpha -®^P-dCTP (NEN Research products) 
- 0.5M EDTA, pH 8.0 (see Appendix D) 
- Deionized, double distilled water 
- Whatman De81 filter paper 
- 0.35M phosphate buffer (see Appendix D) 
Protocol: 
1. Thaw kit components and ^^P-dCTP and place on ice. Use the ®^P 
decay chart to determine the volume needed to provide 25 //Ci of 
32p.dCTP for the reaction (100% activity = 10 //Ci / //I). 
2. Calculate the component volumes needed for a total volume of 20 //I. 
a) DNA for labelling (25-1 OOng) X/yl 
b) 10X reaction buffer 2 /j\ 
c) dATP 1 fj\ 
d) dGTP 1 fj\ 
e) dTTP 1 fj\ 
f) ^^P-dCTP (25 //Ci) Y//I 
g) Klenow enzyme 1 //I 
h) deionized double-distilled water Z //I to 20 //I 
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3. Combine a), b), and h) in a 1.5ml polypropylene tube and boil for 10 
minutes, quench on ice for 2 minutes. 
4. Add c), d), and e) and microcentrifuge briefly. 
5. Using good radioactive technique in a specified radioactive woric area, 
carefully add f) and microcentrifuge briefly. 
6. Add g) mix gently, microcentrifuge briefly and incubate at 37®C for 
30 minutes to 2 hours. 
7. Stop the reaction with 1 //I of 0.5M EDTA and dilute to 200 //I with 
deionized, distilled water. 
8. Determine percent incorporation of ^^P-CTP : 
- Spot a 1 /yl aliquot of probe onto 2-De81 filter disks labelled 
"Total" and "Washed" with a lead pencil. Label a third 
DeBI disk "Background". 
- Place the "Background" and "Washed" disks into a small beaker 
with 50-100 ml of 0.35M phosphate buffer and wash with 
periodic gentle agitation for 3-5 minutes. Repeat the wash 
twice more with fresh phosphate buffer. 
- Place the disks directly into scintillation vials without scintillant 
and count on the ®'P channel for 1 minute. 
- Calculate percent incorporation: 
cpm "Total" + cpm "Washed" x 100 = % incorporation 
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9. Calculate the specific activity of your probe. The recommended 
specific activity for detection of hybridization Is dependent on the 
type of hybridization experiment being attempted. The minimum 
specific activity for detecting nucleic acid following Southern or 
Northern blot transfer is 50 x 10° dpm / //g of probe. In these 
experiments, limiting amounts of the target nucleic acid may be 
present. By contrast, colony-blots and plaque lifts involving large 
numbers of E.coli or bacteriophage and their nucleic acids, 
detection can be accomplished using probes with specific activities 
less than 50 X 10® dpm///g of probe. 
Specific activity ISA) = 
{% incorp.)(/yCi used)(2.2 x 10® dpm / ^Ci) / {//g of probe DNA) 
10. The probe can be stored at 20°C until needed, keeping in mind that 
the half-life of "P is 14.3 days. 
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Nucleic acid hybridization and autoradiography 
The following protocol is a general procedure to be used for DNA-DNA, RNA-
RNA, or DNA-RNA hybridizations with minor modification. The protocol can be 
used with Southern, Northern, or colony-blotted nucleic acid that has been 
immobilized and bound to a nylon or nitrocellulose support. When RNA is used 
as a probe or is being probed, RNA hybridization buffer should be used for pre-
hybridization and hybridization. For DNA-DNA hybridizations DNA hybridization 
buffer should be used. 
Required Equipment: 
- Hot plate 
- Sealable plastic bags 
- Plastic bag sealer 
- 65 °C shaking water bath 
- Autoradiography cassettes with intensifying screens 
Required Reagents: 
- ^^P-labelled RNA or DNA probe 
- DNA hybridization buffer (see Appendix D) 
- RNA hybridization buffer (see Appendix D) 
- 2X SSPE, 0.1% SDS (see Appendix D) 
- 0.1X SSPE, 0.1% SDS (see Appendix D) 
- Vacuum baked nitrocellulose or nylon filter containing the DNA or RNA 
199 
Protocol: 
1. Cut a plastic bag to fit the filter to be probed, rinse with 2X SSPE, 
0.1% SDS and drain completely. Slide the filter into the bag, add 
25 ml of DNA or RNA hybridization buffer. Make sure the filter is 
wetted completely, express excess air bubbles from the bag and 
seal the bag. 
2. Prehybridize the filter at a suitable temperature (65°C for aqueous 
DNA hybridization buffer and 42-50°C for 50% formamide RNA 
hybridization buffer) in a shaking water bath for 2-8 hours. The 
filters should be prehybridized at the same temperature to be used 
for hybridization. 
3. If your probe is double-stranded DNA boil it for 10 minutes and 
quench on ice for 2 minutes. This denaturation is not necessary 
for RNA or single-stranded RNA probes. 
4. Cut one corner of the bag and pour off the prehybridization buffer. 
5. Pre-heat 10 ml of hybridization buffer in a 15 ml polypropylene tube. 
6. Add 5 ng of probe/ml containing at least 10®-10® cpm to the pre­
heated tube, mix the contents and pipette into the bag with the 
prehybridized filter. 
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7. Hybridize at the determined temperature for 6-24 hours. A good 
estimate of the required hybridization time can be made by 
determining the Cot1/2 time for the probe you are using. Cot1/2 is 
defined as the time required for 50% reassociation of 
complimentary DNA. A period of time equal to 1-5X Cotl/2 has 
been established as a suitable length of time for probe association 
with the nucleic acid being probed. Cot1/2 can be determined 
using the following equation: 
N = {1/X)(Y/5)(Z/10)|2) 
N = hours required for C^tl /2 
X = //g of probe added 
Y = probe length in kb 
Z = volume of hybridization buffer 
- Multiply the value obtained for N by the number of Cot1/2 
periods you require. 
8. Following hybridization, remove the buffer to a 15 ml tube. 
9. Rinse the filter briefly with 2X SSPE, 0.1 % SDS. Place this rinse 
directly into a liquid radioactive waste container. 
10. Add 50-100ml of 2X SSPE, 0.1 % SDS, re-seal the bag and wash at 
the hybridization temperature for 30 minutes. Repeat. 
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11. Discard the wash solution and replace it with 0.1X SSPE, 0.1 % 
SDS. Wash for 30 minutes and repeat. 
12. Rinse briefly with 2X SSPE, 0.1% SDS. 
13. Remove the filter from the wash bag and place it in a new plastic 
bag wetted with 2X SSPE, 0.1% SDS. Express excess air and 
buffer from the bag and seal. 
14. Scan the filter with a hand-held Geiger counter to estimate activity. 
Expose the filters to X-ray film using a film cassette with 
intensifying screens at -70°C for an estimated period of time. Re-
expose if necessary. 
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RNA transcription in vitro: 
RNA transcription in vitro is a versatile procedure with multiple specific 
applications. There are many commercially available plasmid vectors which 
contain promoters specific for a particular RNA polymerase. In most cases, two 
distinct promoters flank a multiple cloning site on opposite strands of the 
plasmid DMA molecule making it possible to transcribe RNA from either strand 
of insert DNA. This type of system makes it possible to synthesize sense 
specific single-stranded RNA probes and large quantities of defined transcripts 
from cloned DNA for use in vitro translation experiments. If the transcribed 
RNA is to be used as a template for in vitro translation experiments it must 
have a 5' methylgaunosine cap structure in place to be efficiently translated. 
For our specific applications, a core system which included all standardized 
buffers, polymerases and ribonucleotides was purchased from Promega, Two 
general protocols for generating capped RNA will be described below and they 
are based on the protocols set forth by Promega. 
Required Eouioment; 
- Microcentrifuge tubes 
- 37 ®C water bath 
- Vacuum centrifuge 
- Micropipettors and sterile plastic tips 
- Microcentrifuge 
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Required Reagents: 
- Plasmid with insert of interest and RNA polymerase promotor sites 
- Specific restriction endonucleases for DNA template preparation 
- RNase-free DNase 
- Promega Gemini core system or other equivalents of the following: 
- Sp6 and/or T7 RNA polymerase 
- 5X transcription buffer 
200 mM Tris, pH 7.5 
30 mM MgClg 
10 mM spermadine 
50 mM NaCI 
- 100 mM Dithiothreitol (see Appendix D) 
- RNase inhibitor (i.e.- Promega RNasin) 
- 10 mM ATP, CTP, GTP and UTP in DEPC treated water, pH 7.0 
- DEPC-treated water 
-1.0 mg/ml acetylated bovine serum albumin solution 
- 5 mM 7-methylguanosine 5'-triphosphate {m'Gppp(5')G) 
- Phenol:ch!oroform (see Appendix D) 
- 95% ethanol 
- 20 mg/ml glycogen carrier (Boehinger Mannheim Biochemicals) 
- 3 M Sodium acetate (see Appendix D) 
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Protocol: 
1. The plasmid containing the insert of interest should be linearized to 
produce run-off transcripts. This insures that the synthesized RNA 
transcripts will contain a minimum of plasmid sequences. Choose 
the appropriate restriction enzyme and RNA polymerase promoter 
combination in your plasmid to produce the run-off in the correct 
direction relative to the RNA polymerase promoter site. 
2. Following restriction enzyme digestion, phenohchloroform extract and 
ethanol precipitate the DNA template. Resuspend the template in 
a volume of TE buffer to achieve an approximate DNA 
concentration of 1 mg/ml. 
3. Combine the following in order in a microcentrifuge tube. 
5X transcription buffer 10 //I 
0.1M Dithiothreitol 5 jj\ 
1.0 mg/ml acetylated BSA 5 fj\ 
RNase inhibitor (RNasin) 50 units 
5 mM ATP, CTP, UTP, 0.5 mM GTP 5 fj\ 
5 mM (m'Gppp(5')G) 5 fj\ 
Linearized DNA template (1 mg/ml) 5 fj\ 
Sp6 or T7 RNA polymerase 40 units 
Sterile DEPC-treated water to a 50 fj\ final volume 
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5. Mix by gentle tapping, microcentrifuge briefiy, and incubate at 37°C 
for one hour. 
6. After one hour, add an additional 40 units of RNA polymerase and 
incubate for an additional hour for increased RNA yield. 
7. Following transcription, degrade the DNA template by adding RNase-
free DNase at a concentration of 1 unit/ //g of template DNA. 
Incubate at 37®C for 30 minutes. 
8. Extract the transcription mix twice with an equal volume of 
phenolxhioroform. 
9. Precipitate the RNA with 0.1 volume of 3M sodium acetate, 20 jt/g of 
glycogen carrier and 2.5 volumes of 95% ethanol. Freeze at -
70°C for two to four hours. Pellet the RNA by microcentrifugation 
at 4°C for 30 minutes. Carefully wash the pellet in 70% ethanol 
and vacuum dry for three minutes. 
10. Resuspend in TE buffer and store at 70°C until further analysis or 
manipulation is required. 
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Translation of RNA in vitro: 
Cell-free protein synthesis can be used for the translation of mRNA 
isolated by a variety of methods. Translation in vitro can proceed from RNA 
templates isolated in vivo (i.e.-poly A^ RNA selected from virus infected tissue 
culture cell or tissue) or RNA synthesized from plasmid vectors in vitro. The 
rabbit reticulocyte system (Promega) utilized in this laboratory contains all the 
cellular components necessary for protein synthesis (tRNA, rRNA, and amino 
acids as well as the initiation, elongation and termination factors). The system 
has been optimized for translation of user specific mRNA's by the: destruction 
of endogenous (rabbit reticulocyte) mRNA; inclusion of a phosphocreatine 
kinase / phosphocreatine energy generating system; addition of hemin to 
prevent initiation inhibition; and the expansion of tRNA, potassium acetate and 
magnesium acetate levels. Systems of this type have greatly enhanced the 
ability to analyze the polypeptide products synthesized from individual mRNA's 
and complex mRNA populations with minimal background. 
Required Equipment: 
- Microcentrifuge tubes 
- Micropipettors and sterile plastic tips 
- Microcentrifuge 
- 75°C heat block 
- 30°C water bath 
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Required Reagents: 
- Rabbit reticulocyte in vitro translation system (Promega) containing the 
following: 
- Nuclease treated rabbit reticulocyte lysate 
- 1 mM amino acid mix without methionine 
- DEPC-treated water 
- RNase inhibitor 
- RNA template resuspended in DEPC-treated water 
- Concentration dependent on RNA population: 
Total cytoplasmic RNA 200 ng///t per reaction 
Purified viral RNA 20 ng///l per reaction 
Poly A+ selected mRNA 20 ng///l per reaction 
RNA transcribed in vitro 10 ng//yl per reaction 
- ^®S-methionine (minimum specific activity of 1000 Ci/mmole) at a 
concentration of 10 //Ci///I 
Protocol: 
1. Remove the rabbit reticulocyte lysate components and the sample 
RNA substrate from storage and thaw on ice. 
2. Dilute the RNA template to the appropriate concentration (see above) 
in DEPC-treated water and heat at 75 °C for 10 minutes to reduce 
RNA secondary structure. Immediately cool on ice. 
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3. Add the following to a 1.5 ml microcentrifuge tube in the order listed 
below. Gently to mix after each component has been added: 
Rabbit reticulocyte lysate 35 //I 
DEPC treated sterile water 7 //I 
RNase inhibitor (RNasin) 1 //I 
1 mM amino acid mix 1 fj\ 
Prepared RNA substrate 2 JJI 
®®S-methionine at 10 JJC\//J\ 4 yt/l 
Total volume of 50 jt/l 
Notes; 
(1) As the ®®S-methionine decays, a greater volume is 
required to achieve the appropriate concentration and 
specific activity. The volume of water added to the 
system can be adjusted accordingly. 
(2) The manufacturer recommends setting up that a control 
reaction containing no sample RNA. This control will 
indicate background levels of amino acid incorporation 
within the system. 
4. Incubate the reactions tubes at 30°C for 2 hours. Freeze at 70°C 
until the translation products can be analyzed by SDS-PAGE. 
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APPENDIX C. PROTOCOLS FOR THE ANALYSIS OF PROTEINS 
AND POLYPEPTIDES 
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Discontinous sodium dodecvl sulfate Dolvacrvlamide oel electrophoresis (SDS-
PAGE) 
Discontinous sodium dodecyl sulfate polyacrylamide gel electrophoresis is a 
method of separating denaturated proteins. The proteins to be analyzed are 
dissociated into their individual polypeptide subunits by boiling in the presence 
of sodium dodecyl sulfate (SDS) and 2-mercaptoethanol. Polypeptides bind 
SDS in a constant ratio of 1.4 gm SDS per gm protein. As a result all 
polypeptides acquire the same net negative charge and migrate in the 
polyacrylamide gel solely according to size. The molecular weight of sample 
polypeptides can be determined by comparison with similarly prepared 
molecular weight standards. The discontinous component of this system refers 
to differences in buffer composition and pH between the polyacrylamide gel and 
the electrode buffer. In this system, proteins are concentrated in a large pore 
stacking gel by virtue of a moving glycine/chloride boundary established by the 
pH and composition differences between the stacking gel and the electrode 
buffer. Due to the large pore size of the stacking gel no size separation occurs. 
The concentrated proteins are now separated by size In the separating gel. The 
protocol outline here is designed for use with the Bio-Rad Protean II vertical 
electrophoresis system. Other systems may necessitate minor modifications. 
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Required Eouioment: 
- Vertical gel electrophoresis unit (i.e.- Bio-Rad Protean II) 
- Gel casting stand and silicon rubber gaskets 
- Glass plates 
- Teflon spacers 
- Gel assembly clamps 
- 15 well combs 
- Vacuum pump 
- 150 ml sidearm Erienmeyer flask 
- No. 8 Rubber stopper 
- Refrigerated circulating water bath and hoses 
- Protean II cooling core 
- Hot plate and boiling dish 
- Microcentrifuge tubes 
- Waterproof marker 
- Buffer dam 
- Microcentrifuge 
- Micropipettors and sterile plastic gel loading tips 
- Power unit to deliver a constant current of up to 100 mA 
- Plastic boxes for staining and destaining 
- Rocking platform 
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Required Reagents: 
- Glassware detergent 
- Acetone 
- Acrylamide/Bis (30%) (see Appendix D) 
- 1.5 M Tris, pH 8.8 (see Appendix D) 
- 0.5 M Tris, pH 6.8 (see Appendix D) 
- 10% SDS (see Appendix D) 
- Protein sample buffer (see Appendix D) 
- 5X Electrode buffer (see Appendix D) 
- Ammonium persulfate, solid 
- TEMED 
- Protein molecular weight markers (Bethesda Research Laboratories) 
- Commassie blue gel stain (see Appendix D) 
- Commassie blue gel destain (see Appendix D) 
Protocol: 
1. Before beginning gel assembly inspect all the needed components 
and clean with a solution of glassware detergent and water. Rinse 
everything with tap distilled water and air dry. 
2. Lay one long and one short glass plate on clean adsorbent paper. 
Clean the glass plate surface that will contact the gel with 
acetone. 
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3. Place a teflon spacer along each side of the long glass plate and 
place the short plate on top. 
4. Place a gel assembly clamp along each side and tighten lightly. 
Move this gel sandwich to the alignment slot in the gel casting 
stand and loosen the gel assembly clamps. Allow the glass plate 
and teflon spacer bottoms to align by gravity. 
5. Tighten the gel assembly clamps and check to see that both gel 
plates and the teflon spacer on each side are all flush to each 
other. If this is not the case repeat step 4 and recheck. 
6. Level the casting stand on the bench top and place a clean silicon 
rubber gasket in the casting slot. Cut a piece of Parafilm to fit 
over the rubber gasket. 
7. Place the assembled and aligned gel assembly into the casting stand, 
aligned edge contacting the gasket. Push in the two knobs on the 
casting stand in and turn them away from you simultaneously. 
This should bring the gel assembly into tight contact with the 
rubber gasket. 
8. Prepare a fresh volume of 10% ammonium persulfate 
(weight/volume). 
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9. Select a gel percentage suitable for your needs and mix the gel 
components as described below (the volumes listed are for 2 gels): 
5.0% 7.5% 10% 15% 
Distilled water 56.8 ml 48.5 ml 40.2 ml 23.5 ml 
1.5 M Tris 25.0 ml 25.0 ml 25.0 ml 25.0 ml 
10% SDS 1.0 ml 1.0 ml 1.0 ml 1.0 ml 
Acrylamide/Bis 16.7 ml 25.0 ml 33.3 ml 50.0 ml 
10% Ammonium 
persulfate 0.5 ml 0.5 ml 0.5 ml 0.5 ml 
TEMED 50 lA 50 jul 50 u\ 50 //I 
- Mix all components except TEMED in a 150 ml sidearm 
Erienmeyer flask and degas with a vacuum pump for 20 
minutes. 
10. Add the TEMED, swirl the flask gently, and slowly pipette 45 ml of 
the gel mix between the glass plates. 
11. Overlay the gel with 5.0 ml of distilled, deionized water slowly 
pipetted down the side of one teflon spacer. Avoid excessive 
turbulence and gel mixing. 
12. Allow the gel to polymerize 1-2 hours and replace the water with 5.0 
ml of 0.375 M Tris, pH 8.8 (Dilute one part 1.5 M Tris, pH 8.8 
with three parts distilled deionized water) for standing overnight. 
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13. Mix the stacking gel components as follows: 
Distilled water 12.2 ml 
0.5 M Tris, pH 6.8 5.0 ml 
10% SDS 200 ^\ 
Acrylamide/Bis 2.6 ml 
10% Ammonium persulfate 100//I 
TEMED 20 u\ 
- Mix all components except TEMED in a 150 ml sidearm 
Erienmeyer flask and degas with a vacuum pump for 20 
minutes. 
15. Place the comb in the gel slot at a slight angle. Pipette the stacking 
gel until it contacts the bottom of the comb. Push the comb in 
completely and align it. Continue to pipette with stacker until full. 
16. Number the wells on the glass plate with a waterproof marker and 
allow the gel to polymerize (approximately 1 hour). 
17. While the stacking gel is polymerizing: 1) attach the Protean II 
cooling core to the refrigerated circulating water bath, 2) dilute the 
300 ml of 5X electrode buffer with 1200 ml of distilled, deionized 
water and pour 1000 ml into the lower buffer chamber of the 
electrophoresis unit, 3) place a boiling dish with water on a hot 
plate and begin heating to a boil. 
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18. Thaw your protein samples and molecular weight standards and 
combine with an equal volume of sample buffer in a tube. 
19. When the stacking gel has polymerized remove the comb from the 
polymerized stacking gel and remove the gel from the casting 
stand. Wet the gaskets on the cooling core with a small volume of 
water snap the gel onto the cooling core. 
20. If two gels are being run repeat step 19 with the second gel. If one 
gel is being run assemble a buffer dam using two gel clamps and 
the plexiglass buffer dam, and repeat step 19. 
21. Add the remaining IX electrode buffer to the upper buffer chamber 
formed by the plate assemblies or buffer dam. 
22. Boil the protein samples for 5 minutes, microcentrifuge briefly and 
cool at room temperature for 2 minutes. 
23. Load the samples into the appropriate wells using a micropipettor 
and special long gel loading plastic tips. 
24. Place the cooling core with the loaded plate assemblies into the 
lower buffer chamber taking care not to trap air bubbles under the 
glass plate bottoms. 
25. Connect the power leads to the power supply and electrophorese 
the samples at 25 mA constant current per gel until the dye front 
traverses the stacking gel interface. 
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26. When the dye front has entered the separating gel increase the 
current to 35 mA per gel. Continue until the dye front reaches the 
end of the gel. 
27. Disassemble the electrophoresis unit and separate the plates. 
Remove the corner of the separating gel corresponding to lane 1 
for orientation. 
28. Place the gel in a plastic tray containing approximately 200 ml of 
Commassie blue stain. Stain the gel for 1-4 hours on a rocking 
platform. 
29. Remove the stain and rinse away any excess with a small volume of 
water. 
30. Add 500 ml of Commassie blue destain and place on rocking 
platform until the gel is clear and stained bands can be easily 
visualized. This step can be enhanced by replacing the destain 
after 2-4 hours. 
31. At this point the gel can be dried and/or prepared for 
autoradiography or fluorography as described in the SDS-PAGE gel 
drying and fluorography section of this appendix. 
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RadioimmunoDreclDitation 
The following protocol describes the use of specific antiserum to identify 
immunoreactive radiolabelled proteins. Radiolabelled proteins are combined 
with sample serum at low temperature. Specific antigen-antibody immune 
complexes are isolated by introducing S. aureus protein A or a recombinant 
subunit of protein A designated protein G coupled to a cellulose bead. The 
specific antibody portions of the immune complexes are bound by protein A or 
G at the antibody Fc region and the Immune complexes are harvested by 
centrifugation. The specific immunoprecipitated protein is identified by SDS-
PAGE and autoradiography or fluorography. 
Required Equipment: 
- Micropipettor and sterile plastic tips 
- Rocking platform 
- Microcentrifuge 
- Microcentrifuge tubes 
Required Reagents: 
- Protein A or G - Sepharose (Pharmacia) 
- Radloimmunoprecipitation buffer (RIP) (See Appendix D) 
- Normal and sample antisera 
- Protein sample buffer (see Appendix D) 
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Protocol: 
1. Prepare a 30% weight/volume solution of Protein A or G - Sepharose 
in RIP buffer. Wash twice with fresh RIP buffer and store at 4®C. 
2. Pre-clear antigen preparations of non-specific reactions by adding 2 //I 
of normal serum per 100 //I of radiolabelled antigen. Incubate at 
4®C for 30 minutes. Add 50 //I of 30% Protein A or G -Sepharose 
and rock gently at 4 C for 30 minutes. Separate the supernatant 
by microcentrifugation for 1 minute. Discard the pellet and label 
the supernatant as pre-cleared antigen. 
3. Dilute normal negative serum and sample serum to a pre-established 
dilution with RIP buffer. 
4. Combine approximately 10^ cpm of radiolabelled antigen and 25 fj\ of 
diluted serum in a microcentrifuge tube. 
5. Mix the tube contents gently, microcentrifuge briefly, and incubate 
overnight at 4®C. 
6. Add 50 /yl of well mixed 30% Protein A or G - Sepharose to each 
tube and incubate at room temperature with gentle rocking for 90 
minutes. 
7. Pellet the immune complexes by microcentrifugation for 1 minute. 
8. Discard the supernatant, resuspend the pellet in 200 //I of RIP 
buffer, and microcentrifuge for 1 minute. 
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9. Repeat step 8 at least 3 times. 
10. Discard the supernatant after the final wash, resuspend the pellet in 
40 jj\ of protein sample buffer, and boil for 5 minutes. 
11. Separate the immunoprecipitated proteins by SDS-PAGE as 
described in the Discontinous sodium dodecyl sulfate 
polyacrylamide electrophoresis section of this appendix. 
12. SDS-PAGE gels be enhanced, dried, and exposed to X-ray film as 
described in the Gel drying and fluorography section of this 
appendix. 
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Polvacrvlamide ael dvino and fluoroaraphv: 
The following is a general procedure for preparing a polyacrylamide gel 
containing radiolabelled polypeptides for exposure to X-ray film. Polypeptides 
labelled with a high energy beta or gamma emitter (i.e.- "P or "®l) may be 
identified by the direct exposure of dried gels to X-ray film (autoradiography). 
Visualization of polypeptides labelled with low to medium energy beta emitters 
(i.e.- ^H, or ®®S) can be enhanced by incorporating a fluor in the gel matrix 
prior to drying, converting low energy radioactive emissions into photons of 
light (fluorography). The X-ray film is exposed by radioactive emissions directly 
in autoradiography and by light in fluorography. The following protocol 
describes gel drying and flourography; however, it can be modified for 
autoradiography by omitting the initial fluor incorporation steps. 
Required Equipment: 
- Gel dryer, condenser unit, and vacuum pump 
- Plastic boxes or trays 
- Whatman SIVIM paper 
- Saran-Wrap 
- X-Ray cassettes with intensifying screens 
- Kodak XOMAT X-ray film 
Required Reagents: 
- Fluorography reagent (i.e.-ENTENSIFY, NEN Radiochemicals) 
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Protocol; 
1. Place a destained SDS-PAGE gel in a plastic tray and add 100 ml of 
ENTENSIPK' solution A. Make certain the volume is sufficient for 
the gel to remain free-floating. Incubate at room temperature on a 
rocking platform for 45 minutes. 
2. Remove the gel from solution A and place it into a plastic dish 
containing 100 ml of ENTENSIFY solution B. Incubate at room 
temperature on a rocking platform for 45 minutes. 
3. Rinse the gel briefly in water and place on a sheet of Whatman 3MM 
paper. 
4. Cover the gel surface with a sheet of Saran-Wrap and smooth out 
wrinkles and air bubbles. 
5. Assemble the gel dryer as follows; 
- Place a sheet of Whatman 3MM paper on the gel dryer screen 
- Place the Saran-Wrap covered gel on the paper covered screen 
- Cover the gel with the rigid plastic cover 
- Cover the gel dryer with the soft rubber sheet 
6. Apply vacuum to the gel dyer making certain the rubber cover seals 
the top of the unit completely. 
7. Turn the gel dryer heater on and set the timer for 90 minutes. 
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Rub your hand over the gel dryer top after 90 minutes checking to 
see that the gel thickness has been completely reduced. 
Release the vacuum, turn off the heater and condenser, and 
disassemble the gel dryer. 
Mark the gel orientation using radioactive or fluorescent markers and 
expose the gel to Kodak XOMAT X-ray film at 70°C overnight. 
Develop the film and adjust the exposure time if necessary. 
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APPENDIX D. REAGENTS AND SOLUTIONS SECTION 
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1. Acrylamide/Bis (30%) 
- Wear gloves at all times while preparing acrylamide solutions. 
Acrylamide is a potent neurotoxin. 
- Dissolve 146.0 gm of electrophoresis grade acrylamide and 4.0 gm of 
bis-acrylamide in 500 ml of distilled, deionized water. 
- Sterile filter through a 0.45 micron Nalgene filter unit. 
- Store in an amber bottle at 4®C. 
- Use within 30 days or discard. 
2. Ammonium acetate, 10M : 
- Dissolve 385.4 gm of ammonium acetate in 150 ml deionized, distilled 
water. 
- When dissolved add water to 500 ml. 
- Sterile filter through a 0.2 micron Nalgene unit rinsed with 20 ml 
deionized, distilled water. 
- Store at room temperature. 
3. Bromophenol blue stock, 10% : 
- Dissolve 5.0 gm in 50 ml sterile deionized, distilled water. 
- Store at room temperature. 
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4. CaClg, 1.0 M : 
- Dissolve 147.0 gm of CaClj ' 2H2O in 1 liter of deionized, distilled 
water. 
- Sterilize by autoclaving. 
- Store at room temperature. 
5. Chloroform / isoamyl alcohol : 
- Combine chloroform and isoamyl alcohol at a 24 to 1 ratio for use in 
extractions. 
- In many protocols involving nucleic acid extraction, this preparation will 
be referred to as chloroform alone. 
6. Denhardt's solution, 50X : 
- Combine 5 gm polyvinylpyrrolidone, 5 gm bovine serum albumin 
fraction V, and 5 gm Ficoll 400. Add deionized, distilled water to 
a total volume of 500 ml. 
- Stir until completely dissolved. 
- Sterile filter through a 0.2 micron Nalgene unit rinsed with 20 ml 
deionized,distilled water. 
- Store at -20°C. 
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7. Dialysis tubing (sterile for electroelution) : 
- Cut tubing into 4 inch lengths and place in a beaker or Erienmeyer flask. 
- Boil in 2% sodium bicarbonate, 1mM EDTA for 5 minutes. 
- Rinse with deionized, distilled water. 
- Boil 10 minutes in 1 mM EDTA. 
- Replace 1 mM EDTA with deionized, distilled water and autoclave 10 
minutes. 
- Store at 4°C. 
8. Diethylpyrocarbonate (DEPC) treated water, 0.02% : 
- Wear gloves throughout this procedure. 
- Place 5.0 liters of deionized water in a baked glass vessel. 
- Add 1.0 ml of DEPC and mix well on a stir plate. 
- Cover and allow to stand 2 to 4 hours. 
- Aliquot into baked 100 and 500 ml bottles and autoclave. 
9. Dithiothreltol (DTT), 1.0 M : 
- Dissolve 7.73 gm of DTT in 50 ml deionized, distilled water. 
- Sterile filter through a 0.2 micron Nalgene unit rinsed with 20 ml 
deionized,distilled water. 
- Aliquot 100 /j\ into 1.5 ml polypropylene tubes and freeze at -20°C. 
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10. "E" buffer for RNA gels, 50X : 
- Prepare 0.5 M NaHgPO^ HjO by dissolving 34.5 gm of NaH^PO^ HgO in 
500 ml DEPC of water. Designate this Phosphate component (1). 
- Prepare 0.5 M NagHPO^ (anhydrous) by dissolving 35.5 gm of 
anhydrous NagHPO^ in 500ml of DEPC water. Designate this 
Phosphate component (2). 
- Combine 400ml of component (2) with 78 ml of component (1) for a 
pH of 7.4. 
- Sterile filter through a 0.2 micron Nalgene unit rinsed with 20 ml of 
deionized, distilled water. 
11. Ethylenediamine tetraacetic acid, disodium salt (EDTA), 0.5 M : 
- Dissolve 93.05 gm EDTA-Naj ^HjO in 300 ml of distilled water. 
- Begin to mix and add 16 N NaOH to pH 8.0. 
- Add water to 500ml when the EDTA is completely dissolved. 
- Sterile filter through a 0.2 micron Nalgene unit rinsed with 20 ml 
deionized,distilled water. 
- Store at room temperature. 
12. Ethidlum bromide (EtBr), 10 mg/ml : 
- Wear gloves when handling ethidlum bromide. 
- Dissolve 0.5 gm of ethidlum bromide in 50 ml of deionized, distilled 
water. Store at room temperature in a brown bottle. 
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13. Formamide, deionized (99.9%) : 
- Combine 100 ml of formamide with 10 gm of Bio-Rad AG 501-X8 
mixed-bed resin. 
- Stir gently at 4°C for 2 to 4 hours. 
- Filter twice through Whatman 1 filter paper. 
- Aliquot and store at -20°C. 
14. Hirt extraction buffer: 
- Combine stock solutions as follows for final concentrations of: 
lOmM Tris, pH 7.4 0.5 ml of 2M stock 
10mM EDTA, pH 8.0 2.0 ml of 0.5M stock 
0.6% sodium dodecyl sulfate 3.3 ml of 10% stock 
distilled, deionized water 94.2 ml 
- Add 5.0 /yl of 20 mg/ml proteinase K per ml of Hirt extraction buffer to 
be used immediately prior. 
15. Hirt wash buffer: 
- Combine stock solutions as follows for final concentrations of: 
lOmM Tris, pH 8.0 0.5 ml of 2.0 M stock 
0.15M NaCI 3.3 ml of 5.0 M stock 
distilled, deionized water 96.2 ml 
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16. Hybridization buffer-DNA : 
- Combine the following ingredients: 
20X SSPE 7.5 ml 
50X Denhardt's solution + 1% SDS 5.0 ml 
2.5 mg/ml salmon sperm DNA 2.0 ml 
(boiled 10 nriinutes) 
deionized, distilled water 35.5 ml 
- Prepare and use immediately. 
- Heat to hybridization temperature in a water bath. 
17. Hybridization buffer-RNA : 
- Combine the following ingredients in order : 
2.5 mg/ml salmon sperm DNA 4.0 ml 
(boiled 10 minutes) 
DEPC water 10.5 ml 
deionized formamide 50.0 ml 
20X SSPE 30.0 ml 
50X Denhardt's solution + 1 % SDS 5.0 ml 
tRNA (20 mg/ml) 0.5 ml 
- Aliquot 20 ml per 50ml polypropylene tube and freeze at -20®C. 
- Heat to hybridization temperature in a water bath. 
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18. Isopropyl-B-D-thiogalactopyranoside (IPTG), 100 mM : 
- Dissolve 0.24 gm of IPTG in 10 ml deionized, distilled water. 
- Aliquot in 500 fi\ fractions and store frozen at -20°C. 
19. Luria-Bertani (LB) agar : 
- Combine 10.0 gm bacto-tyrptone, 5.0 gm bacto-yeast extract, and 
10.0 gm NaCI in 1000 ml of deionized distilled water. 
- Adjust the pH to 7.4 with 16 N NaOH. 
- Add 15 gm agar (8 gm for top agar). 
- Autoclave and cool to 50°C and incorporate antibiotics if desired. 
- Pour into petri dishes and allow to harden at room temperature. 
- Invert plates and dry overnight at 37°C then store inverted at 4®C. 
20. Luria-Bertani (LB) broth : 
- Combine 10.0 gm bacto-tyrptone, 5.0 gm bacto-yeast extract, and 
10.0 gm NaCI in 1000 ml of deionized distilled water. 
- Adjust the pH to 7.4 with 16 N NaOH. 
- Aliquot into suitable bottles and autoclave to sterilize. 
- Store at room temperature. 
21. MgCI^, 1.0 M : 
- Dissolve 101.5 gm MgCla eHjO in 500 ml deionized, distilled water. 
- Autoclave to sterilize. 
- Store at room temperature. 
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22. MgS04, 1.0 M : 
- Dissolve 123.0 gm of IVIgSO^ VHgO in 500 ml deionized, distilled water. 
- Autoclave to sterilize. 
- Store at room temperature. 
23. 3-[N-Morpholino]propanesulfonic acid (MOPS), 1.0 M: 
- Dissolve 21.0 g of MOPS in 100 ml of distilled, deionized water. 
- Sterile filter through a 0.2 micron Nalgene unit rinsed with 20 ml 
deionized,distilled water. 
- Store at room temperature. 
24. O.J. electrophoresis sample buffer, 6X : 
- Combine the following: 
Glycerol 15 gm 
Orange G 0.2 gm 
1.0 M Tris, pH 8.0 0.5 ml 
0.5 M EDTA 10.0 ml 
deionized, distilled water to a 50 ml volume 
- Aliquot in 15 ml polypropylene tubes and store at 4°C. 
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25. Phenol preparation (water saturated) : 
- Remove 1-100 gm bottle of phenol from the -20°C freezer and place in 
a 56°C water bath to melt the crystallized phenol. 
- Fill the bottle to the bottom of the rim with deionized, distilled water. 
- Add 250 mg 8-hydroxyquinoline (anti-oxidant). 
- Shake vigorously to mix the phases. 
- Place at 4°C and allow the phases to separate overnight. 
- Water saturated phenol can be stored a 4°C for 8 - 12 months. 
26. Phosphate buffer, 0.35 M : 
- Dissolve 49.6 gm NagHPO^ per liter of distilled tap water with stirring. 
- Store at room temperature. 
27. Poly Activation buffer: 
- Wear gloves when preparing this reagent. 
- Combine stock solutions to achieve buffer concentrations as follows: 
0.1 M NaOH 1 ml of 10.0 M stock 
5.0 mM EDTA 1 ml of 0.5 M stock 
DEPC-treated water 98 ml 
- Sterile filter and store at room temperature. 
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28. Poly Elutlon buffer: 
- Wear gloves when preparing this reagent. 
- Combine stock solutions to achieve buffer concentrations as follows: 
10 mM Tris, pH 7.4 500 //I of 2.0 M stock 
1.0 mM EDTA 200 fA of 0.5 M stock 
DEPC-treated water 99.3 ml 
- Autoclave to sterilize 
- Add 500 ii\ of 10% SDS stock for a final concentration of 0.05% SDS. 
29. Poly A* Loading buffer A: 
- Wear gloves when preparing this reagent. 
- Combine stock solutions to achieve buffer concentrations as follows: 
40 mM Tris, pH 7.4 2.0 ml of 2.0 M stock 
1.0 M NaCI 20.0 ml of 5.0 M stock 
1.0 mM EDTA 200 //I of 0.5 M stock 
DEPC-treated water 77.8 ml 
- Autoclave to sterilize 
- Add 1 ml of 10% SDS stock for a final concentration of 0.1 % SDS. 
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30. Poly A* Loading buffer B: 
- Wear gloves when preparing this reagent. 
- Combine stock solutions to achieve buffer concentrations as follows: 
20 mM Tris, pH 7.4 1.0 ml of 2.0 M stock 
0.1 M NaCI 2.0 ml of 5.0 M stock 
1 mM EDTA 200 lA of 0.5 M stock 
DEPC-treated water 96.8 ml 
- Autoclave to sterilize 
- Add 1 ml of 10% SDS stock for a final concentration of 0.1 % SDS. 
31. 5X protein electrophoresis buffer, pH 8.3: 
- Combine the following: 
Tris base 45.0 gm 
Glycine 216.0 gm 
Sodium dodecyl sulfate 15.0 gm 
Distilled, deionized water to 3000 ml 
- DO NOT adjust the pHI The combination of Tris and glycine will 
achieve a pH of 8.3. 
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32. Protein gel Commassie blue stain: 
- Combine the following: 
Commassie blue R-250 
Methanol 
Glacial acetic acid 
Distilled, delonized water 
33. Protein gel destain: 
- Combine the following: 
Methanol 
Glacial acetic acid 
Distilled, delonized water 
34. Protein sample buffer (for SDS-PAGE): 
- Combine the following in a 50 ml polypropylene centrifuge tube: 
Distilled, delonized water 5.0 ml 
0.5 M Tris, pH 6.8 12.5 ml 
Glycerol 20.0 ml 
Sodium dodecyl sulfate 2.0 gm 
2-mercaptoethanol 2.5 ml 
0.05% bromophenol blue 10.0 ml 
- Keep tightly sealed between uses. After 30 days supplement with 1.0 
ml of 2-mercaptoethanol. 
1.0 gm 
400 ml 
100 ml 
500 ml 
400 ml 
100 ml 
500 ml 
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35. Qiagen plasmid isolation buffer series: 
- Combine stock solutions to achieve buffer concentrations as follows: 
PI: 50 mM Tris, pH 8.0 
10 mM EDTA 
RNaseA (400 fjg) 
deionized water 
5 ml of 1.0 IVI stock 
2 ml of 0.5 M stock 
25 mg 
93 ml 
P2: 0.2 M NaOH 
1.0% SDS 
deionized water 
10 ml of 2.0 M stock 
10 ml of 10% stock 
80 ml 
P3: 2.55 M potassium acetate, pH 4.8 21 g 
deionized water 100 ml 
QBT: 750 mM NaCI 
50 mM MOPS 
15% ethanol 
0.15% Triton X-100 
deionized water 
15.5 ml of 5.0 M stock 
5 ml of 1.0 M stock 
15.8 ml of 95% stock 
1.5 ml of 10% stock 
62.2 ml 
(pH to 7.0 with a few drops of 16 N NaOH) 
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OC: 1000 mM NaCI 20 ml of 5.0 M stock 
50 mM MOPS 5 ml of 1.0 M stock 
15% ethanol 15.8 ml of 95% stock 
delonized water 59.2 ml 
(pH to 7.0 with a few drops of 16 N NaOH) 
OF: 1250 mM NaCI 25 ml of 5.0 M stock 
50 mM MOPS 5 ml of 1.0 M stock 
15% ethanol 15.8 ml of 95% stock 
deionized water 54.2 ml 
(pH to 7.0 with a few drops of 16 N NaOH) 
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36. Radioimmunoprecipitation buffer: 
- Combine stocic solutions to achieve buffer concentrations as follows: 
50 mM Tris, pH 8.0 
150 mM NaCI 
1.0 mM EDTA 
0.5% sodium deoxycholate 
0.1% SDS 
1.0% Nonidet-P40 
0.1% sodium azide 
0.1% gelatin 
0.1% aprotinin 
25.0 ml of 2.0 M stock 
30.0 ml of 5.0 M stock 
4.0 ml of 0.5 M stock 
5.0 gm 
10 ml of 10% stock 
10 ml of 100% stock 
1.0 gm 
10 ml of 10% stock 
1.0 ml of 100% stock 
875 ml Distilled, deionized water 
- Adjust the pH to 8.0 with 10 M NaOH. 
- Sterile filter, aliquot into 50 ml centrifuge tubes, and store at 4®C. 
37. Salmon sperm DNA, 2.5 mg/ml : 
- Cut and weigh 10 gm of solid DNA. 
I 
- Place in 4.0 ml of deionized, distilled water and the DNA once through a 
20 gauge needle and repeatedly through a 18 gauge needle. 
- When a thick consistency is reached , boil the solution 10 minutes and 
store at -20°C. 
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38. Sodium acetate, 3.0 M : 
- Dissolve 40.8 gm of sodium acetate ^HjO in 75 ml of distilled water. 
- Adjust pH to 7.0 with acetic acid. 
- Add deionized, distilled water to a final volume of 100 ml. 
- Sterile filter and store at room temperature. 
39. Sodium acetate, 2.0 iVI for RNA: 
- Wear gloves when preparing this reagent. 
- Dissolve 27.2 gm of sodium acetate ^HjO in 75 ml of DEPC-treated 
water. 
- Adjust pH to 6.0 with acetic acid. 
- Add DEPC-treated water to a final volume of 100 ml. 
- Sterile filter and store at room temperature. 
40. Sodium chloride, 5.0 M : 
- Dissolve 292.2 gm of NaCI in 1 liter of deionized, distilled water. 
- Autoclave to sterilize and store at room temperature. 
41. Sodium dodecyl sulfate (SOS), 10% : 
- To avoid breathing SDS wear a mask. 
- Dissolve 100 gm of SDS in 1 liter of deionized, distilled water. 
- Stir well before filtering. 
- Sterile filter through a 0.2 micron Nalgene unit rinsed with 20 ml 
deionized,distilled water. Store at room temperature. 
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42. Sodium hydroxide, 10 M: 
- Dissolve 200 gm of NaOH in 450 ml of distilled, deionized water. 
- Bring up to a volume of 500 ml. 
43. Southern transfer solution I : 
- Dissolve 877.0 gm of NaCI and 200.0 gm NaOH in 10 liters distilled tap 
water. 
- Store at room temperature. 
44. Southern transfer solution II : 
- Dissolve 1580 gm Tris HCI and 877.0 gm NaCI in 9.0 liters deionized, 
distilled water. 
- Adjust pH to 8.0 with 16 N NaOH. 
- Adjust the total volume to 10 liters with deionized, distilled water. 
- Store at room temperature. 
45. SSPE buffer, 20X : 
- Combine the following: 
NaCI 841.2 gm (3.6 M) 
NaHaPO^HjO 110.4 gm (0.2M) 
EDTA 160 ml (20 mM) 
distilled tap water 3.0 liters 
- Adjust pH to 7.4 with 16 N NaOH and bring volume up to 4.0 liters. 
- Aliquot in 1 liter bottles and autoclave to sterilize. 
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46. STET plasmid mini-prep buffer : 
- Combine the following: 
Sucrose 8.0 gm (8 %) 
Triton X-100 0.5 gm (0.5%) 
0.5 M EDTA 1.0 ml (50 mM) 
2.0 M Tris, pH 8.0 0.5 ml (10 mM) 
Sterile deionized distilled water to 100 ml total volume 
- Store at 4°C. 
47. TAE agarose electrophoresis buffer, 50X : 
- Combine the following: 
Tris base 242.0 gm {1.6 M) 
Na acetate SHgO 136.1 gm (0.8 M) 
EDTA 19.0 gm (40 mM) 
deionized distilled water 800 ml 
- Adjust pH to 7.2 with acetic acid then adjust total volume to 1.0 liter. 
- Sterile filter through a rinsed 0.2 micron Nalgene filter unit. 
- Aliquot in 100 ml volumes. 
- Dilute 1:50 for IX TAE running buffer. 
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48. 0.5 M Tris, pH 6.8 (for SDS-PAGE stacking gel): 
- Dissolve 6.0 gm Tris base in 60 ml of distilled, deionized water. 
- Adjust the pH to 6.8 with 1.0 N HCI and bring the solution up to a final 
volume of 100 ml with distilled, deionized water. Store at 4°C. 
49. 1.5 M Tris, pH 8.8 (for SDS-PAGE separating gel): 
- Dissolve 54.45 gm of Tris base in 150 ml of distilled, deionized water. 
- Adjust the pH to 8.8 with 1.0 N HCI and bring the solution up to a final 
volume of 300 ml with distilled, deionized water. 
- Store at 4®C. 
50. 2.0 M Tris, pH 7.4, 7.6, and 8.0 : 
- Dissolve 242.2 gm Tris base in 850 ml deionized, distilled water. 
- Adjust to the desired pH by slowly adding concentrated HCI. 
- Adjust total volume to 1 liter. 
- Autoclave to sterilize. 
- Store at room temperature. 
51. 10 mM Tris / 1.0 mM EDTA buffer (TE), pH 7.4, 7.6, and 8.0 : 
- Combine the following : 
2.0 M Tris 500 //I 
0.5 M EDTA 200 fj\ 
sterile deionized distilled water 99.3 ml 
- Store at room temperature. 
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52. Tris buffered saline (TBS): 
- Combine stock solutions to achieve buffer concentrations as follows: 
50 mM Tris, pH 7.4 25.0 ml of 2.0 M stock 
150 mM NaCI 30.0 ml of 5.0 M stock 
Distilled, deionized water 945 ml 
- Autoclave and store at room temperature. 
53. Tris-saturated phenol: 
- Tris-saturated phenol is stable for only 1 month, therefore only small 
amounts of tris-saturated phenol are made from the stock water-
saturated phenol. 
- Remove the lower yellow phase water-saturated phenol (10-20 ml) 
and place in a 50 ml polypropylene tube, add an equal volume of 
0.5 M Tris, pH 8.0. 
- Vortex vigorously for 30 seconds and separate the phases by low speed 
centrifugation. 
- Remove the aqueous phase and replace with the same volume of 0.1 M 
Tris, pH 8.0, vortex vigorously and separate the phases by low 
speed centrifugation. 
- Check the pH of the phenol phase to make sure it is near neutral, if not 
repeat the 0.1 M Tris step until the pH approaches neutral. 
- Store at 4°C. Tris-saturated phenol is stable for 1 month at 4°C. 
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54. Triton X-100, 10.0 % : 
- Combine 10.0 ml of Triton X-100 and 90 ml of sterile deionized, 
distilled water. 
- Mix completely and sterile filter through a 0.2 micron Nalgene unit 
rinsed with 20 ml deionized, distilled water. 
- Store at room temperature. 
55. X-gal (5-bromo-4-chloro-3-indoiyl-B-D-galactoside), 10% : 
- Dissolve 100 mg of X-gal in 1.0 ml of dimethylformamide. 
- Store at -20 °C in an amber bottle. 
